key: cord-0021559-4po01hcq
authors: nan
title: 32nd International Symposium on the Autonomic Nervous System
date: 2021-09-26
journal: Clin Auton Res
DOI: 10.1007/s10286-021-00822-5
sha: df25bd695580b451b0b3ade1ecc22c33dbc010b8
doc_id: 21559
cord_uid: 4po01hcq

nan

Parkinson disease (PD) is a neurodegenerative disease where both autonomic disturbances and mood symptoms commonly co-occur. Increasing evidence in affective neuroscience points to changes in autonomic nervous system as having an upstream causal effect on mood symptoms via interoception, but we do not yet know whether and how this relationship applies to Parkinson's disease patients. Using the Parkinson's Progressive Marker Initiative (PPMI) database, we examined whether measures of autonomic disturbances in PD patients predict depression and anxiety symptoms cross-sectionally and longitudinally. From the PPMI database, we extracted measures of autonomic disturbances (Scale for Outcomes in Parkinson's Disease-Autonomic-SCOPA-AUT), depression (Geriatric Depression Scale-GDS), anxiety (State Trait Anxiety Inventory-STAI) and daily life function (Modified Schwab and England Activities of Daily Living Score-MSEADL) for 1347 PD patients at the initial visit and 670 patients for the 4-year follow-up visit. We performed regression analyses with year-4 visit SCOPA-AUT score as predictor variable, and GDS and STAI scores at the 4-year visit as outcome variables. The 4-year visit MSEADL score was also included as a predictor variable in a stepwise fashion to ensure it was not a confounder. To then examine whether autonomic disturbances predict mood symptoms longitudinally, we performed a second set of regression analyses; this time substituting the year-4 visit SCOPA-AUT score with the initial visit SCOPA-AUT score. Higher SCOPA-AUT scores significantly predicted both higher GDS and STAI scores at the 4-year visit. Higher SCOPA-AUT scores at the initial visit significantly predicted higher GDS and STAI scores in PD patients at the 4-year visit. Both sets of findings suggest that increased autonomic disturbances lead to increased depression and anxiety symptoms in PD patients at a given point in time and in the future. Furthermore, this relationship remained significant despite inclusion of MSEADL scores in the regression analysis. Our findings suggest mood symptoms frequently occurring in PD patients may be partly attributed to autonomic disturbances, and that this relationship holds both crosssectionally and longitudinally. This may offer a stepping stone in improving treatment of mood symptoms in PD patients by developing novel therapies targeting autonomic disturbances.

Probable 'premotor' multiple system atrophy-cerebellar form R. Sakakibara 1 , J.N. Panicker 2 , Y. Aiba 1 , F. Tateno 1 , T. Yamamoto 3 , T. Uchiyama 3 , T. Yamanishi 3,4 , C Shibata 4 , S. Simeoni 2 during supine rest and active standing in OFF and ON-states. Fre-Background: Synucleinopathies are a group of neurodegenerative disorders that result from the deposition of phosphorylated a-synuclein within the central and peripheral nervous systems. Synucleinopathies include Parkinson disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF). Study Design: This is a multi-center, cross-sectional, observational study to evaluate phosphorylated a-synuclein pathology in cutaneous tissues in individuals with PD, DLB, MSA, PAF and healthy controls at a single study time point. Study Cohort: A total of 500 participants (300 with a clinically diagnosed synucleinopathy and 200 healthy controls without synucleinopathy) will be recruited to participate. The estimated breakdown of the 300 synuclein study participants will be 105 with PD, 40 with MSA, 95 with DLB and 60 with PAF. The 200 healthy control subjects will be recruited by sex and age as follows: 40 of each sex by decile from ages 40-49, 50-59, 60-69, 70-79 and 80 ? . Data Collection: Study subjects will meet consensus criteria for the clinical diagnosis of PD, MSA, DLB and PAF. Study participants will have standardized neurologic examinations, orthostatic vital signs, cognitive testing, quality of life measures and skin biopsies for quantitation of phosphorylated a-synuclein. Subject clinical diagnosis will be confirmed by a panel of blinded independent disease experts who will review the referring site records blinded to results of the skin biopsy. Pathological diagnosis will be determined by blinded independent pathological experts with confirmation at 2 independent laboratories. Results: Sensitivity, specificity, accuracy and precision of phosphorylated a-synuclein detection will be calculated against clinical diagnosis of synucleinopathy and by synucleinopathy subtypes. Inter and intra-rater reliability testing will be reported across laboratories. Discussion: The need for a validated, well characterized, simple, reproducible marker of synuclein pathology has never been greater. The number of individuals with neurodegenerative diseases continues to grow at an enormous rate and confusion between synuclein and non-synuclein pathologies continues to occur which may result in incorrect medication choices, iatrogenic complications, poor prognostication and patient frustration. We will test the clinical utility of skin biopsies to provide a low-cost insurance-friendly solution to support the challenging clinical diagnosis of the synucleinopathies. Funding: NIH R44 NS117214

Effect of automated mechanical peripheral stimulation on 24-h blood pressure in a non-dipper patient with Parkinson's disease: a case study Introduction: Patients with Parkinson disease (PD) may not present a nocturnal blood pressure (BP) fall (non-dipper) due autonomic dysfunction. Automatic mechanical peripheral stimulation (AMPS) promotes improvement of motor and cardiovascular parameters. However, its effect on 24-h BP in PD patients is unknown. Objective: To evaluate the effect of AMPS on 24-h BP in a nondipper patient with PD. Methods: The case study was approved by the UCM ethics committee (#125/2018). An 86-year-old male volunteer, diagnosed with PD, Hoen & Yhar stage III, and non-dipper (defined as having nocturnal decrease of mean systolic and diastolic blood pressure less than 10%) took part in the study. The participant was randomly assigned to 2 intervention sessions, with a two-week washout between assignments: (1) AMPS, which consisted of applying pressure until reaching the pain pressure threshold at 2 specific points in the plantar area of both feet; (2) Sham session followed the same AMPS methodology, but with a pressure reaching only the sensory threshold. Before and after each intervention, the 24-h BP was evaluated with a 24-h blood pressure monitor. Results: After the Sham intervention, the participant presented mean 24-h systolic BP (SBP) and diastolic BP (DBP) of 160 and 84 mmHg, respectively. Diurnal mean SBP and DBP of 166.1 and 87.1 mmHg, respectively; and nocturnal SBP and DBP of 151.5 and 79.6 mmHg, respectively. Nocturnal systolic and diastolic fall were 8.8% and 8.6%, respectively. After the AMPS intervention, mean 24 h SBP and DBP were 140.9 and 75.4 mmHg, respectively. Diurnal SBP and DBP were 143.8 and 77.5 mmHg, respectively, and nocturnal SBP and DBP were 128.2 and 66.5 mmHg, respectively. Nocturnal systolic and diastolic fall were 10.9% and 14.2%, respectively, interpreted as being within normal limits. associated total baroreflex areas and by prolonged pressure recovery times. The patients also all had low interventricular septal myocardial concentrations of 18F-DA-derived radioactivity. In contrast, the 3 PRKN patients had normal baroreflex-sympathoneural function and normal 18F-DA-derived radioactivity. Conclusions: Genetic forms of PD differ in the extents of baroreflexsympathoneural dysfunction and cardiac noradrenergic deficiency. PD from SNCA, LRRK2, or GBA mutations entails baroreflex-sympathoneural failure and cardiac noradrenergic deficiency. PD from PRKN mutations does not involve these abnormalities. These results suggest that synucleinopathy underlies chronic autonomic failure in genetic PD. Funding: The research reported here was supported by the Division of Intramural Research, NIH, NINDS.

Biomarkers of central and cardiac catecholamine deficiency predict Parkinson disease in at-risk individuals D.S. Goldstein, C. Holmes, J. Gelsomino, J. Cherup, G. Lopez, Y. Sharabi Autonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, MD, USA Background: In Parkinson disease (PD), by the time motor signs become manifest substantial loss of nigrostriatal dopaminergic neurons probably has already occurred. There is great interest in identifying biomarkers that can detect preclinical PD, when diseasemodifying treatments would most likely be effective. This prospective cohort study addressed whether neurochemical and neuroimaging evidence of central and cardiac catecholamine deficiency predicts PD among individuals with multiple PD risk factors. Methods: Participants in the intramural NIH PDRisk study provided information about family history of PD, olfactory dysfunction, dream enactment behavior, and orthostatic hypotension at a protocol-specific website. Twenty-six people with at least 3 confirmed risk factors underwent comprehensive testing including lumbar puncture for cerebrospinal fluid (CSF) catechols, cardiac 18 F-dopamine positron emission tomographic scanning, and brain 18 F-DOPA scanning and were followed for 7.5 years or until PD was diagnosed. CSF was assayed for the catecholamine precursor DOPA, 3,4-dihydroxyphenylacetic acid (DOPAC, the main neuronal metabolite of dopamine), and 3,4-dihydroxyphenylglycol (DHPG, the main intraneuronal metabolite of norepinephrine). Interventricular septal and left ventricular free wall concentrations of 18 F-dopamine-derived radioactivity were measured, as were the putamen/occipital cortex (PUT/OCC) ratio of 18 F-DOPA-derived radioactivity, the posterior/ anterior (P/A) ratio of radioactivity, and the washout percent of PUT 18 F-DOPA-derived radioactivity. Kaplan-Meier curves were constructed for these 8 catecholaminergic biomarkers. Results: Six participants (25%) were diagnosed with PD during follow-up (Preclinical group). Eighteen risk-matched participants remained disease-free (No-PD group; 2 participants censored). For all 8 catecholaminergic biomarkers the survival curves differed between the Preclinical and No-PD groups (p \ 0.0001 for septal 18 F-dopamine-derived radioactivity, p = 0.0001 for free wall radioactivity, p = 0.0014 for CSF DOPA, p = 0.040 for CSF DOPAC, p = 0.0096 for CSF DHPG, p \ 0.0001 for PUT/OCC ratios, p = 0.0008 for P/A ratios, and p \ 0.0001 for washout percents). Conclusions: In at-risk individuals followed for up to 7.5 years, biomarkers of central and cardiac catecholamine deficiency predict the development of symptomatic PD. Background: The synucleinopathies Parkinson disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) feature intra-cytoplasmic deposition of the protein alpha-synuclein and catecholamine depletion. PAF, which is diagnosed clinically by neurogenic orthostatic hypotension (nOH) with no motor signs of central neurodegeneration, can evolve into PD ? nOH. Levels of catecholamine metabolites in cerebrospinal fluid (CSF) may indicate central catecholamine deficiency in these synucleinopathies, but the literature is inconsistent and incomplete. Methods: We assayed CSF for catecholamines, the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and the norepinephrine metabolites 3,4dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) in samples from 36 patients with PD, 37 patients with MSA, and 19 patients with PAF and from 38 controls. Results: Compared to the control group, the PD, MSA, and PAF groups had decreased CSF MHPG (p \ 0.0001 each), DHPG (p = 0.004; p \ 0.0001; p \ 0.0001) and norepinephrine (p = 0.017; p = 0.0003; p = 0.044). CSF HVA and DOPAC were decreased in PD (p \ 0.0001 each) and MSA (p \ 0.0001 each) but not in PAF. Conclusions: The three synucleinopathies therefore have in common in vivo evidence of central noradrenergic deficiency but differ in the extent of central dopaminergic deficiency, which is prominent in PD and MSA and less apparent in PAF. Data from putamen 18 F-DOPA and cardiac 18 F-dopamine neuroimaging in the same patients, postmortem tissue catecholamines in largely separate cohorts, and review of the neuropathology literature fit with these distinctions. The results fit with a ''norepinephrine-first'' ascending pathogenetic sequence, with degeneration of pontine locus ceruleus noradrenergic neurons before the loss of midbrain substantia nigra dopaminergic neurons. Funding: Division of Intramural Research, NINDS, NIH.

Detection of the autotoxic catecholaldehyde DOPEGAL in pure autonomic failure D.S. Goldstein, R. Isonaka, P. Sullivan Autonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, MD, USA Background: Pure autonomic failure (PAF), defined clinically by neurogenic orthostatic hypotension without an identified cause and by no signs of a neurodegenerative movement disorder, is associated with low plasma concentrations of the catecholamine norepinephrine, neuroimaging evidence of cardiac noradrenergic deficiency, and Lewy bodies, intra-neuronal cytoplasmic inclusions that contain the protein alpha-synuclein (a-syn). Bases for the association between catecholamine deficiency and synucleinopathy in Lewy body diseases (LBDs) are poorly understood. According to the catecholaldehyde hypothesis, catecholaminergic neurons are susceptible because of harmful interactions between a-syn and catecholaldehydes. Catecholaldehydes are formed continuously in the cytoplasm of catecholaminergic neurons via enzymatic deamination catalyzed by monoamine oxidase. Previously we provided evidence for buildup of 3,4-dihydroxyphenylacetaldehyde (DOPAL), the catecholaldehyde of dopamine, in the putamen in patients with the LBD Parkinson disease; Clin Auton Res however, until now no LBD case has been described in which 3,4-Objective: To investigate the association between symptoms of depression and symptoms of autonomic dysfunction (AuD) in people with Parkinson's disease (PD). Background: Depression and AuD are common and disabling nonmotor symptoms of PD that portend a poor prognosis. Although the literature suggests an overlap in pathophysiology between these symptoms in PD, the examination of the relationship between these symptoms in clinical cohorts has remained rudimentary. Methods: Data were obtained from the Parkinson's Progression Markers Initiative (PPMI), a prospective longitudinal database of early PD participants who are followed over several years with regular clinical evaluations, symptom assessments, and collection of neuroimaging and biospecimens. We compared associations of depression, AuD, and other demographic and clinical variables among PD and control participants at baseline and at visit 6 (24 months after initial, or baseline, study visit). Spearman correlation and Mann-Whitney-U tests were used to assess associations between variables, and regression modeling was used to measure predictors of AuD while controlling for potential confounding covariates. Results: We show that symptoms of depression predict AuD in persons with PD but not in controls, and that this effect grows stronger with increasing disease duration. These findings are independent of severity of motor impairment, age, and use of depression or blood pressure medications. Conclusions: These data build on the existing literature by supporting an overlapping pathophysiology between depression and AuD in PD. This finding accentuates the importance of identifying therapies for PD non-motor symptoms that can work synergistically with, rather than independently of, therapies for other PD symptoms.

testing was reviewed when available. The study was reviewed and approved by the Mayo Clinic institutional review board. Results: Twenty-six patients with Ross syndrome were identified. The most common initial reported manifestation was an abnormal segmental sweating response in 16 patients (described as hyperhidrosis in 12 patients and anhidrosis in 4 patients) while a tonic pupil was the initial manifestation in 10 patients. Other commonly reported symptoms included fatigue, chronic cough, and increased urinary frequency. An associated autoimmune disorder was identified in one patient. Positive autoantibodies were found in a minority of patients often with unclear clinical significance. Distributions of anhidrosis encountered were segmental (n = 15), widespread (n = 7), and global (n = 4). Well-circumscribed small areas of preserved sweating within areas of anhidrosis were observed in the majority of patients (88.5%). Anhidrosis progressed slowly over time and sudomotor dysfunction was predominantly (post)ganglionic. Cardiovagal and adrenergic functions were preserved in most patients. Conclusions: The pattern of autonomic dysfunction in Ross syndrome is suggestive of a limited autonomic ganglioneuropathy. Sudomotor impairment is prominent and should be the focus of symptomatic management; however, clinicians should be aware of symptoms beyond the classic triad. Introduction: Sjögren syndrome (SS) is a common autoimmune disorder that characteristically affects lacrimal and salivary glands, resulting in sicca symptoms, but has a particular predilection for affecting the autonomic nervous system (ANS). ANS complications of SS may include autonomic neuropathy with or without orthostatic hypotension, gastrointestinal dysmotility, and phenotypically may resemble postural tachycardia syndrome (POTS). Purpose: We sought to: (1) report the clinical and diagnostic features of a large cohort of patients with SS who otherwise meet criteria for POTS; and 2) to determine whether any clinical or diagnostic features distinguish SS patients who otherwise met criteria for POTS, from POTS patients without SS. Methods: Clinical and diagnostic features of 60 patients diagnosed with SS patients with an excessive, symptomatic postural tachycardia were reviewed and compared with a cohort of 60 POTS patients without laboratory evidence or clinical features worrisome for SS. Results: Clinical and diagnostic features in this study that were predictive of SS included older age, presence of sicca symptoms, a diagnosis of laboratory supported or clinically suspected mast cell activation syndrome, worse CASS score, and an abnormal ANA. Interestingly, supine norepinephrine values were higher in patients with SS relative to the POTS cohort. Neuropathic or hyperadrenergic forms of ANS impairment and the frequency of gastrointestinal dysmotility did not differ between groups. All but 4 patients in this series were diagnosed with SS sometime after a diagnosis of POTS was made, or less commonly at the time of their autonomic evaluation at our institution. Minor salivary gland biopsy was necessary to make a SS diagnosis in 36 of the 60 patients in this series.

Conclusions: SS may result in ANS impairment that resembles POTS. Older age, sicca symptoms, and more severe ANS impairment should prompt consideration of SS in POTS patients. Minor salivary gland biopsy may be necessary to establish a diagnosis of SS in POTS patients.

Hereditary ATTR amyloidosis presenting with exercise-induced hypotension: a case report Case: 70-year-old man presented for exercise intolerance. He had a 30 year history of well controlled diabetes and was previously quite active. 6 years prior to presentation he had developed atrial fibrillation, leading to the discovery of asymptomatic coronary artery disease for which he underwent bypass grafting. He later developed bilateral carpal tunnel syndrome. 2 years prior to presentation he noticed exercise intolerance. Mild exertion such as walking up a small incline would provoke lightheadedness and fatigue, resolved with standing quietly. 8 months prior to presentation he started having syncope with exertion. He also had peripheral edema and orthopnea to 30 degrees. Workup: Evaluations for arrhythmia and cardiac ischemia were negative. Autonomic testing showed absent heart rate variability with deep breathing, and square-wave Valsalva blood pressure response with subsequent hypotension and prolonged pressure recovery time. He did not have orthostatic hypotension, but easy stair-stepping exercise provoked symptomatic hypotension. 99 M Technetium-Pyrophosphate imaging showed heart to contralateral lung activity ratio of 1.88, consistent with transthyretin cardiac amyloidosis. Transthyretin gene analysis revealed heterozygous pathogenic Pro44Ser mutation. Follow up: He started intravenous patisiran infusions every 3 weeks. Midodrine did not alleviate exercise induced hypotension. Atomoxetine 18 mg twice daily was effective. 4 months after starting infusions, he had diuresed 30 pounds, orthopnea resolved, and exercise capacity improved markedly, with the ability to hike a quarter of a mile. Discussion: Exercise-induced hypotension can be a symptom of autonomic failure, though unusual to present in isolation. The presumed mechanism is impaired sympathetically-mediated vasoconstriction in non-exercising muscles. Cardiac amyloidosis is an under-recognized cause of heart failure, but is important to identify in the context of effective emerging therapies. Patisiran was initially studied specifically for the effect on sensorimotor neuropathy in hereditary transthyretin amyloidosis, but beneficial effects on cardiac and autonomic parameters are also reported. by BES) were found to have small fiber peripheral neuropathy. All patients underwent neurologic history and examination, subsequently undergoing a variety of neurophysiologic testing including EMG, autonomic reflex screen (ARS) and quantitative sensory testing (QST). This report, approved by the Mayo Clinic Institutional Review Board, details results from this investigation. Results: Of the 1001 patients the mean age was 56.7 years and the gender distribution 44.5% female and 55.5% male. Some 532 (53.1%) were found to have peripheral neuropathy (PN) and 91 (9.1%) small fiber peripheral neuropathy (SFPN). Mean age and gender distribution were similar for the PN cohort and the SFPN cohort. For the PN cohort, 504 (94.7%) Introduction: Amyloidosis is a disorder characterized by extracellular deposition of amyloid, nonbranching protein fibrils derived from precursor proteins which organize into beta-pleated sheets. The precursor proteins can be derived from abnormal protein, such as in light chain amyloidosis and hereditary amyloidosis; or they can be associated with aging, such as in wild-type transthyretin amyloidosis (wtATTR). Amyloid protein can deposit in several organ systems, including the nervous system, resulting in varying clinical phenotypes. While there is much known about peripheral and autonomic neuropathies associated with systemic light chain amyloidosis and hereditary transthyretin amyloidosis (hATTR), less is described regarding peripheral nerve manifestations of wtATTR. Commonly described findings include carpal tunnel syndrome and radiculopathy. Autonomic manifestations have not been characterized. With recent advancements in treatment of transthyretin amyloidosis, early disease recognition is critical. We sought to describe peripheral and autonomic nervous system manifestations of wtATTR. Methods: Following IRB approval, we retrospectively reviewed records of 194 consecutive patients who were diagnosed with amyloidosis. WtATTR patients were identified with biopsy demonstrating TTR and negative genetic testing. Autonomic reflex screen and electromyography data were reviewed. Results: Sixty-nine patients were identified to have wtATTR. Median age at diagnosis was 78. Of those patients who underwent EMG testing (n = 28), the patterns of abnormality included: peripheral neuropathy, bilateral carpal tunnel syndrome, radiculopathy, unilateral carpal tunnel syndrome and myopathy. Only one patient in the cohort had a normal EMG. Autonomic reflex screen was performed on 13. Twelve had a pattern of abnormality consistent with autonomic neuropathy. The median Composite Autonomic Scoring Scale was 4 indicating moderate impairment. Sudomotor impairment was present in more than 50%, but not necessarily in a length-dependent distribution. Cardiovagal impairment was present in all where it could be assessed. With Valsalva maneuver, 8/13 had flat-top response, and impaired late phase II and/or phase IV was seen in 4. Orthostatic hypotension was seen in 5/13. Conclusions: Autonomic neuropathy is seen in wtATTR. Peripheral nervous system manifestations of wtATTR are more diverse than what has been previously described. When evaluating an older patient with autonomic and/or peripheral neuropathy, consideration should be given for wtATTR as a possible etiology.

Orthostatic intolerance after bariatric surgery: mechanistic insights S.Y. Paranjape, S. Takkouche, A. Diedrich, V. Ulriche, S. Scudder, C.A. Shibao Vanderbilt Autonomic Dysfunction Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Objective and Methods: Obesity is an epidemic in the US affecting over 78 million adults. Bariatric surgery is the only treatment modality that results in substantial and sustained weight loss. Every year, approximately 200,000 people undergo bariatric surgery, and this number is projected to increase over time. We previously reported cases of chronic orthostatic intolerance (OI) post-bariatric surgery with an estimated incidence of 4.2%. The main objective of this study was to determine the mechanisms underlying OI after bariatric surgery. For this purpose, we conducted a 3-month prospective observational study in morbidly obese subjects. All subjects were studied before (V1) and after bariatric surgery: first, after achieving 10% weight loss (V2) and then at 3-months post-surgery (V3). In each visit, the subjects underwent a 30-min head up tilt challenge where we measured continuous heart rate (HR) and blood pressure (BP) and plasma volume using DAXOR (I-131 albumin injection). Results: 17 subjects were enrolled, 10 completed the study (9 females and 1 male), age was 42 ± 9.3 years, weight 139 ± 14.5 kg, height 166 ± 8.6 cm, fat mass 73 ± 12.18 kg and BMI 51 ± 8.27 kg/m 2 . After the surgery, the subjects lost on average 17 ± 7.71 kg (V2) and 28 ± 14.2 kg (V3). Supine SBP and DBP were significantly decreased throughout V1 (125 ± 12), V2 (112 ± 14), V3 (108 ± 13), P \ 0.001; DBP V1 (78 ± 9), V2 (70 ± 8), V3 (68 ± 8), P \ 0.001. Of note, HR was similar between days (74 ± 13 vs. 67 ± 10 vs. 66 ± 12, P = 0.09). There were no significant hemodynamic changes during orthostatic stress in SBP (P = 0.438), DBP (0.356) and HR (P = 0.367) between visits. Further, there were no differences in plasma volume decreased across visits (P = 0.368). Conclusions: Despite a significant decline in supine blood pressure, orthostatic tolerance was not affected during periods of substantial weight loss after bariatric surgery. Funding: American Heart Association.

Autoimmune autonomic ganglionopathy (AAG) is a rare disorder affecting the synaptic transmission in autonomic ganglia. AAG is frequently caused by autoantibodies against ganglionic nicotinic acetylcholine receptors (nAChR). Previously, we presented evidence that an autoimmune response to ganglionic nAChR is influenced by HLA-DRB1*04:03 alleles in the Japanese population. Since the first report of an AAG experimental rabbit model with autoantibodies against nAChR, there have not been any major reports replicating the pathogenicity of nAChR antibodies. In the present study, the amino acid sequence of the mouse nAChRa3 protein was analysed using an epitope prediction tool to predict possible MHC class II binding mouse nAChRa3 peptides. Given the predicted epitope affinities for MHC class II molecules, we elected to focus on these two nAChRa3 peptides in the extracellular region. Here, we demonstrate that mice immunised with two different nAChRa3 recombinant peptides generated anti-nAChRa3 antibodies and exhibited autonomic dysfunction, including reduced heart rate, excessive fluctuations of systolic blood pressure (SBP), poor body weight gain, and intestinal transit slowing. Additionally, we observed skin lesions, such as alopecia and skin ulcers, in immunised mice. Neuronal cell density (NCD) in sympathetic cervical ganglia (SCG) in immunised mice was significantly lower than that in control mice at the light microscopic level. There was no inflammation in SCG and brain in immunised mice, therefore, we considered the pathogenesis in this new murine model of human AAG to be an antibody-mediated mechanism. Together, we concluded that active immunization of mice with nAChRa3 peptides causes autonomic dysfunction similar to human AAG induced by ganglionic nAChR antibodies. We suggested a mechanism by which different HLA class II molecules might preferentially affect the ganglionic nAChR-specific immune response, controlling diversification of the autoantibody response. Our new murine model mimics AAG in humans and provides a useful tool to investigate its pathomechanism. Further experimental and clinical studies are required to prove the pathogenicity of ganglionic nAChR antibodies in patients with AAG. Funding: This study was supported by JSPS KAKENHI (Grant Numbers 19K17012, 16K09695, and 19H03549) , and AMED under Grant Number 19dk0310099h0001.

The role played by ASIC1a in the exercise pressor reflex in rats with heart failure A.L.E. Butenas 1 , K.S. Rollins 1 , A.C. Williams 1 , S.K. Parr 1 , S.T. Stimulation of thin fiber skeletal muscle afferents during exercise activates a reflex, termed the exercise pressor reflex (EPR), which, in healthy subjects, contributes to appropriate increases in sympathetic nervous system activity (SNA) and concomitant cardiovascular adjustments. In patients with heart failure with reduced ejection fraction (HF-rEF) the EPR is exaggerated, and its activation contributes to aberrant increases in SNA and vasoconstriction thereby furthering exercise intolerance within this patient population. A subtype of acid sensing ion channels (ASIC), namely ASIC1a, is known to play a key role in evoking the EPR in healthy subjects, however, its role in HF-rEF is unknown. Accordingly, the purpose of this investigation was to determine the role of ASIC1a in the EPR in rats with HF-rEF. We hypothesized that injection of the ASIC1a antagonist psalmotoxin-1 (PcTx-1; 100 ng, 0.1 mL saline) into the arterial supply of the hindlimb would reduce the reflex increase in renal SNA (RSNA, stainless steel electrodes) and mean arterial pressure (MAP, arterial catheter) evoked during 30 s of electricallyinduced static hindlimb muscle contraction in HF-rEF rats. Experiments were performed on male Sprague-Dawley rats subjected to a coronary artery ligation surgery to produce myocardial infarction and HF-rEF. At least six weeks after the initial surgery, in decerebrate, unanesthetized rats with HF-rEF (n = 8; ejection fraction 45 ± 3%) we compared the EPR before and after ASIC1a blockade. We found that PcTx-1 reduced the RSNA response evoked during hindlimb muscle contraction (peak DRSNA pre: 138 ± 25; post: 81 ± 12%; p = 0.02; $DRSNA pre: 1462 ± 243; post: 973 ± 242 a.u.; p = 0.04). Interestingly, we found that PcTx-1 had no effect on the pressor response evoked during the contraction maneuver (peak DMAP pre: 33 ± 6; post: 31 ± 8 mmHg; p = 0.66). Our results suggest that ASIC1a contributes to increased SNA, at least to the kidney, but does not contribute importantly to blood pressure reactivity during hindlimb skeletal muscle contractions in rats with HF-rEF. Background: Renal sensory nerves contribute to hypertension and renal dysfunction in chronic kidney disease. Selective chemokines (e.g., bradykinin or capsaicin) activate renal sensory nerves and produce reflexive efferent sympathetic nerve activity (SNA) and arterial blood pressure (ABP) responses. SNA, ABP, and renal function exhibit circadian patterns; yet the impact of circadian cycle on chemosensitive responses is unknown. Methods and Results: Using inactin anesthetized Sprague-Dawley rats (250-400 g), we hypothesized that SNA and hemodynamic responses would be greater during nighttime (N; 20:00-04:00; n = 12 M, 10 F) versus daytime (D; 09:00-16:00; n = 8 M, 8 F). Simultaneous renal and splanchnic SNA and ABP were measured during intrarenal arterial capsaicin or bradykinin infusion (0.1 lM-30.0 lM; 50 ll over 15 s). No significant differences were observed for renal or splanchnic SNA between time periods. Baseline mean ABP was significantly elevated during nighttime (N: 104 ± 2 mmHg; D: 97 ± 2 mmHg, p = 0.04). Intrarenal capsaicin infusion produced concentration-dependent increases in renal and splanchnic SNA. A greater increase occurred for renal SNA with 10 lM (N: 723 ± 136 vs. D: 409 ± 79%; p = 0.03) and 30 lM (N: 826 ± 181 vs. D: 509 ± 80%; p = 0.03) during nighttime. Splanchnic SNA was greater using 10 lM (N: 501 ± 117 vs. D: 204 ± 53%, p = 0.03) and 30 lM (N: 537 ± 101 vs. D: 295 ± 68%; p = 0.03) concentrations during the nighttime. However, ABP responses were similar between nighttime (7 ± 1 mmHg; 30 lM) and daytime (6 ± 1 mmHg; 30 lM). Intrarenal infusion of bradykinin produced concentrationdependent increases in renal and splanchnic SNA. A greater increase occurred for renal SNA using 10 lM (D: 1773 ± 216 vs. L: 1249 ± 112%; p = 0.01) and 30 uM (D: 2605 ± 263 vs. L: 1783 ± 163%; p = 0.001) during nighttime. Similarly, splanchnic SNA was exaggerated using 0.1 lM (D: 163 ± 65 vs. L: 0 ± 0%; p = 0.02), 1.0 lM (D: 566 ± 114 vs. L: 184 ± 52%; p = 0.005), 10 lM (D: 1110 ± 193 vs. L: 583 ± 87%; p = 0.006) and 30 lM (D: 2008 ± 193 vs. L: 1044 ± 162%; p \ 0.001) during the nighttime. ABP responses were similar between nighttime (10 ± 2 mmHg; 30 lM) and daytime (6 ± 1 mmHg; 30 lM). Conclusion: Circadian cycle exaggerates sympathoexcitatory responses produced by chemosensitive renal sensory nerve activation. Funding: NIDDK F32 DK123994, NHLBI R01 HL145875, NHLBI R01 HL152680. Prolonged periods of bed rest and inactivity lead to cardiovascular deconditioning (CVD), which is associated with orthostatic intolerance, impaired cardiovascular reflexes and autonomic imbalance. The Hindlimb Unloading (HU) rat model mimics many of the alterations seen in CVD. The autonomic alterations in CVD and HU are related to plasticity within the central nervous system. The nucleus tractus solitarii (nTS) is a critical integrative central region for autonomic and cardiovascular control. Glutamate and GABA are the major excitatory and inhibitory neurotransmitters within this nucleus. We have shown that HU increases nTS glutamatergic neurotransmission yet hyperpolarizes neurons and decreases their excitability. The role for GABA in counter-balancing glutamatergic signaling and decreasing excitability is unknown. This study tested the hypothesis that HU increases GABA synaptic modulation of nTS neurons, which contributes to impaired autonomic and cardiovascular control. HU was induced by placing stainless wire rings in the tail of male Sprague-Dawley rats (3 weeks old), and after one week of recovery suspending rats at an angle of 30°-35°for two weeks with free access to food and water. Control animals were maintained in normal postural conditions. After HU or the control period, coronal brainstem slices were generated and whole-cell patch clamp was performed to evaluate synaptic neurotransmission and electrophysiological properties of nTS neurons. Block of GABA A receptors (Gabazine 20 lM and Bicuculline 20 lM) depolarized membrane potential in HU but not in Control, suggesting greater tonic GABA inhibition in HU. Compared to control rats, HU increased the amplitude and area of inhibitory postsynaptic currents (IPSCs) evoked by nTS GABA interneuron stimulation (nTS-IPSC). HU also elevated the frequency of spontaneous miniature IPSCs but not their amplitude. Puffer application of GABA (100 lM, 50 ms) produced similar postsynaptic current response in nTS neurons of HU and Control. These results indicate that HU increases GABAergic signaling in the nTS likely via augmented presynaptic release. Together, this synaptic plasticity may contribute to impaired autonomic and cardiovascular control following CVD. ACUC number: 9906. Observational cohort studies suggest that salt restriction increases cardiovascular morbidity/mortality, and the relationship between cardiovascular morbidity and dietary salt intake resembles a J-shaped curve. Our laboratory has reported a high salt diet exaggerates sympathetic nerve activity (SNA) and arterial blood pressure (ABP) responses to several cardiovascular reflexes in salt-resistant animals. The purpose of the present study was to assess whether salt restriction exaggerates cardiovascular reflex responses and sensitizes central autonomic networks. To test this hypothesis, male Sprague-Dawley rats were fed low (0.01% NaCl), normal (0.1% NaCl), and high (4.0% NaCl) salt diet for 14-21 days. Baseline mean ABP was not different across groups (low: 104 ± 4, normal: 107 ± 4, high: 107 ± 4 mmHg; P [ 0.5 ANOVA). Activation of sciatic afferents (1 ms pulse, 500 uA, 5 s duration, 2-20 Hz) produced significantly greater increases in renal SNA (5 Hz; low: 196 ± 12, normal: 136 ± 9, high: 177 ± 8%, n = 8, P \ 0.05) and ABP (5 Hz; low: 29 ± 3, normal: 16 ± 1, high: 24 ± 2 mmHg, n = 8, P \ 0.05) of rats fed low and high versus normal NaCl diets. Activation of the aortic depressor nerve (2 ms pulse, 500 uA, 15 s duration, 2-20 Hz) produced significantly greater decreases in renal SNA (renal SNA (5 Hz; low: -55 ± 9, normal: -34 ± 8, high: -63 ± 13%, n = 7-8, P \ 0.05) and ABP (5 Hz; low: -31 ± 3, normal: -15 ± 5, high: -32 ± 5 mmHg, n = 7-8, P \ 0.05) of rats fed low and high versus normal NaCl diets. To test whether dietary salt intake sensitized central sympathetic circuits, microinjection of L-glutamate in the rostral ventrolateral medulla (0.1-1 nmol, 30nL) produced significantly greater increases in renal SNA (0.1 nmol; low: 212 ± 15, normal: 149 ± 8, high: 183 ± 17%, n = 7-8, P \ 0.05) and ABP (0.1 Hz; low: 20 ± 2, normal: 12 ± 2, high: 22 ± 2 mmHg, n = 7-8, P \ 0.05) of rats fed low and high versus normal NaCl diets. Low and high NaCl diets also exaggerated sympathoinhibitory responses to GABA injection. Finally, rats fed low or high NaCl versus normal NaCl diets displayed exaggerated cardiovascular responses to cage switch or mild restraint and increased 24-h blood pressure variability. The present findings showed that both severe salt restriction and excess dietary salt intake exaggerates sympathetic and cardiovascular responses and may be explained by a parallel change in the sensitivity of central autonomic networks to resemble a J-shaped curve.

Funding: Supported by NIH HL14575 (SDS) and HL128388 (SDS, WBF).

Exposure to a high-fat diet rich in linoleic acid exaggerates viscerosensory-sympathetic reflexes in spinalized animals via a TRPV1-dependent mechanism individuals to a considerable degree, its role in the development of severe hypertensive episodes in patients living with spinal cord injury (SCI) is irrefutable. Eicosanoids are a class of lipid mediators derived from polyunsaturated fatty acids (PUFAs) that modulate nociceptive processing through their interactions with multiple members of the family of transient receptor potential (TRP) cation channels, which are widely expressed on small unmyelinated C fibers and lightly myelinated Ad fibers. Our laboratory seeks to determine whether dietary PUFA content and diet-derived eicosanoids modulate viscerosensory-sympathetic reflex reactivity using the spinalized rat model. In the current study, quantification of sympathetic/pressor responses to colorectal distension (CRD) following SCI was achieved using a decerebrate preparation, which enables anesthesia to be discontinued prior to electrophysiological recording. Our results indicate that exposure to a high-fat diet rich in the omega-6 PUFA, linoleic acid, significantly exaggerates sympathetic/pressor responses to CRD in spinalized rats and is associated with the accumulation of linoleic acid-derived TRP eicosanoid agonists within the GI lumen and serum. Spinalized rats exposed to a high-fat diet rich in saturated fat displayed similar responses to those maintained on the standard chow diet. We also observed that enema administration of endogenous (linoleic acid-derived) and exogenous TRP agonists potentiates sympathetic/pressor responses to CRD, while TRP antagonists have the opposite effect. Our findings suggest that dietary fat composition may modulate the severity of hypertensive episodes in individuals living with SCI by influencing the accumulation of eicosanoid TRP ligands. Ongoing studies will evaluate the specific role of dietary linoleic acid in modulating viscerosensory-sympathetic reflex reactivity following SCI. *All animal protocols and surgical procedures employed in this study were reviewed and approved by the Wayne State University Institutional Animal Care and Use Committee (IACUC). Funding: NIH-5R01DK121812.

Orthostatic tolerance before and after 60 days of strict head down tilt bedrest with and without daily artificial gravity training Background: Orthostatic intolerance occurs after space flight, after immobilization, and in patients with autonomic nervous system disease and there is a need for more effective countermeasures. We hypothesized that daily artificial gravity elicited through short-arm centrifugation attenuates orthostatic intolerance following 60 days of strict head-down tilt bedrest, which models cardiovascular responses to weightlessness. Methods: We studied 24 healthy persons (8 women, 33.4 ± 9.3 years, 24.3 ± 2.1 kg/m 2 ) who were exposed to 60 days head-down tilt bedrest. Subjects were assigned to 30 min/day continuous short arm centrifugation, 6 9 5 min short arm centrifugation, or a control group (no countermeasures). We measured heart rate and finger blood pressure during 15 min of 80°head-up tilt testing with incremental lower body negative pressure until presyncope before and at the end of 60 days HDTBR. Two subjects were excluded from analysis due to immediate presyncope after tilting following bedrest. Results: Time to presyncope decreased in all three groups following bedrest (control: 22:56 min before and 9:35 min after, continuous centrifugation 15:34 min before and 10:11 min after; intermittent centrifugation 14:56 min before and 10:00 min after, p \ 0.001). The significant interaction (p = 0.025) between bedrest and intervention was explained by greater baseline orthostatic tolerance time in the control group. Early into head-up tilting, heart rate increased more after bedrest (pooled data, n = 22, 22 ± 11 bpm before and 49 ± 16 bpm after, p = 0.0001) while mean finger blood pressure and low frequency systolic blood pressure variability responses did not change. With continued orthostatic stress, heart rate increased more and blood pressure showed a steeper decrease following bedrest. Conclusions: Thirty minutes daily artificial gravity training did not prevent a reduction in orthostatic tolerance following 60 days headdown tilt bedrest. Whether numerically smaller reductions in orthostatic tolerance in the artificial gravity groups indicate efficacy or result from baseline differences cannot be ascertained. Possibly, a stronger artificial gravity stimulus or combination with other countermeasures is required to maintain orthostatic tolerance. Background: Circadian disruption is increasingly recognized as a precursor of adverse cardiovascular outcomes. Emerging evidence suggests that social jetlag, namely the misalignment between biological and social rhythms, is associated with increased cardiometabolic risk in the general population. Whether this relationship is manifest in individuals with hypertension is unclear and the potential underlying mechanisms remain unknown. Here we assessed whether social jetlag is associated with elevated blood pressure in hypertensive patients and if this effect is mediated by sympathetic hyperactivation. Methods: Fifty-six patients (27 women, age 48 ± 12 years, body mass index [BMI] 28 ± 4 kg/m 2 ) with essential hypertension and no other cardiovascular or metabolic diseases were recruited. Attended polysomnography was conducted to rule out sleep disorders. Resting systolic and diastolic blood pressure (SBP/DBP) was measured. Participants completed two weeks of wrist actigraphy to objectively estimate social jetlag, defined as the difference of the midpoint of sleep time between workdays and weekends/free days. Patients were classified into two groups based on social jetlag C 1 or \ 1 h. 24-h urinary catecholamine excretion was obtained in a subset of participants (n = 31). Results: Social jetlag C 1 h was noted in twenty-five patients (45%; average social jetlag 99 ± 32 min). Participants exhibiting social jetlag C 1 h had similar age (P = 0.512), BMI (P = 0.132) and sex distribution (P = 0.977) compared to those with social jetlag \ 1 h (average social jetlag 30 ± 16 min). Total sleep time across the 2-week actigraphy was also similar between groups (P = 0.553). Participants with social jetlag C 1 h had significantly higher resting SBP than those with social jetlag \ 1 h (136 ± 10 vs. 130 ± 9 mmHg, P = 0.017), while the between-group difference in DBP approached significance (88 ± 7 vs. 84 ± 8 mmHg, P = 0.07). There were no differences in 24-h urinary norepinephrine (42 ± 15 vs. 40 ± 17 ng/dL, P = 0.693), epinephrine (4 ± 3 vs. 5 ± 3 ng/dL, P = 0.268), or dopamine excretion (242 ± 90 vs. 250 ± 86 ng/dL, P = 0.825). Conclusions: Social jetlag is prevalent in patients with hypertension and is associated with higher BP levels, independently of demographic characteristics and total sleep duration. As urinary catecholamines were similar between groups, mechanisms other than sympatho-excitation are likely implicated in these findings and warrant further investigation. Funding: National Institute of Health HL 134,808, American Heart Association 16SDG27250156, Mayo Clinic Marie Ingalls Research Career Development Fund.

Augmented T cell mitochondrial reactive oxygen species in adults with major depressive disorder: potential neural-immune interaction Background: Major depressive disorder (MDD) is associated with an increased risk of cardiovascular disease; however, the underlying mechanism(s) are incompletely understood. Evidence supports sympathetic overactivity and chronic systemic inflammation as contributing factors. Notably, recent animal studies implicate norepinephrine (NE) as an important modulator of pro-inflammatory cytokine release via direct stimulation of T cell mitochondrial reactive oxygen species (mitoROS). This led us to test the hypothesis that adults with MDD exhibit augmented resting muscle sympathetic nerve activity (MSNA) and T cell mitoROS. We further hypothesized that NE would augment T cell mitoROS in vitro. Methods: All participants underwent a structured diagnostic clinical interview to determine the presence or absence of MDD. Resting MSNA (peroneal microneurography) and T cell mitoROS were measured in seven healthy non-depressed adults (Control; 22 ± 1 years) and five otherwise healthy adults with MDD of mildto-moderate severity (24 ± 3 years). Immune cells were isolated from whole blood by red blood cell lysis. For culture experiments, T cells were isolated using negative selection (EasySep) and cultured over four days with supplementation of NE (1 lM) alone and NE plus the mitoROS scavenger MitoTempol (1 lM) every 24 h. T cell mitoROS was measured by labeling with antibodies against CD3 ? (total T cells) and mitoROS targeted fluorogenic dye (Mi-toSoxRED) and analyzed by flow cytometry. All data are expressed as mean ± SE. Results: MSNA burst incidence (Controls: 21 ± 5; MDD: 31 ± 4 burst/100 heartbeats), was higher in MDD than in Controls, but did not reach statistical significance (p = 0.07). Total T cell mitoROS (Controls: 4936 ± 4193, MDD: 51,167 ± 235 a.u., p = 0.02) was significantly augmented in MDD compared with Controls. In vitro experiments show that NE augmented T cell mitoROS (D16223 ± 19,610) compared to control condition, which was blunted by Mito Tempol (D-19,437 ± 2297). Conclusion: These preliminary findings suggest that elevated resting MSNA may be linked to increased T cell mitoROS in adults with MDD, contributing to a pro-inflammatory phenotype. In vitro studies further support that the sympathetic nervous system can promote inflammation via modulating T cell mitoROS in humans. Background: Evidence of autonomic dysfunction after menopause suggests greater sympathetic activity and parasympathetic withdrawal. Heart rate variability (HRV) is an important measure of parasympathetic function, and low HRV has been shown in menopausal females and is associated with greater rates of mortality. It is unknown whether the age at which a woman completes menopause influences HRV. Therefore, the purpose of this study was to determine if menopausal age influences HRV. We hypothesize that we will observe a reduced HRV in women who completed menopause at an earlier age. Methods: Twenty-two postmenopausal females (62 ± 3 year old; menopause age range: 40-57 year) attended two study visits. Visit 1: Written informed consent and completion of the Menopause-Specific Quality of Life (MENQOL), which asks participants to rate how bothered they feel in four areas of symptoms: psychosocial, vasomotor (VMS), physical, and sexual. Participants ranked the symptoms on a scale of 1-8, with 1 indicating 'not at all bothered' and 8 indicating 'extremely bothersome'. The second visit was conducted in the morning after an overnight fast and abstinence of alcohol, caffeine, and exercise for a minimum of 12 h and included measurements of heart rate via 3-lead electrocardiography (ADInstruments, Colorado Springs, CO) during 10 min of quiet rest and a blood draw to measure sex hormones. HRV (percent [%] high-frequency (HF) power and total power) was calculated from the resting ECG using LabChart software (ADInstruments). Results: Body mass index was 24 ± 3 kg/m 2 . Sex hormone levels were 18.9 ± 5.8 pg/ml for estrone and 4.4 ± 1.7 pg/ml for estradiol. MENQOL scores were-psychosocial: 1.6 ± 0.6; VMS: 1.6 ± 1.1; physical: 1.8 ± 0.6; and sexual: 2.1 ± 1.6. Menopause age, but not current age (p [ 0.05), was significantly correlated with %HF power (r = 0.44, p = 0.046). Psychosocial score was significantly correlated with total power (r = -0.46, p = 0.047). Conclusions: These findings suggest that females who experience menopause at an earlier age, as well as those who experience more severe menopausal symptoms, particularly psychosocial symptoms, demonstrate lower HRV. This likely indicates reduced parasympathetic function, which may contribute to autonomic dysregulation and cardiovascular risk in these women. Acute exacerbation of heart failure (HF) occurs without significant weight gain in a significant proportion of patients, possibly due to redistribution of blood from capacitance vessels to the central circulation. It has been proposed that acute sympathetically-mediated venoconstriction (i.e., reduced capacitance) of the splanchnic vasculature, the largest blood volume reservoir of the human body, is the underlying mechanism. Thus, interventions that increase splanchnic capacitance or decrease sympathetic activity may improve cardiac function. In a proof-of-concept study in subjects without HF, we evaluated whether venodilation with nitroglycerin (NTG) (Protocol 1) or sympathetic withdrawal with trimethaphan (Protocol 2) would increase splanchnic capacitance and reduce cardiac and stroke volumes. In Protocol 1 (n = 10, 36 ± 4 years, BMI 26.1 ± 1.7, 6 females), abdominal and chest scintigrams, to measure relative regional blood volumes, were obtained before and after 0.6 mg sublingual NTG. Splanchnic capacitance (volume-pressure relationships, VPR) and compliance (VPR slope) were estimated by recording abdominal scintigrams during progressive escalation of intrathoracic pressure using continuous positive airway pressure (CPAP) at 0, 4, 8, 12, and 16 cm H 2 O, each for B 2 min. We found that NTG increased splanchnic blood volume at rest (4%, ; P \ 0.01) resulting in a rightward parallel shift in splanchnic VPR (P slope = 0.460 and P intercept = 0.01), signifying an increase in splanchnic capacitance. This was associated with a decrease in cardiac blood volume (-9%, IQR 2.2-10.3; P \ 0.01). In Protocol 2, blood pressure (BP) and stroke volume, as a surrogate of venous return, were measured during the same CPAP protocol before and during autonomic blockade with trimethaphan in 12 hypertensive subjects (49 ± 2 years, BMI 29.9 ± 1.7, 7 females), a condition associated with sympathetic overactivity. Indeed, sympathetic withdrawal decreased systolic BP by 27 ± 14 mmHg and produced a leftward parallel shift in splanchnic VPR (i.e., reduced stroke volume; P slope = 0.126 and P intercept \ 0.01), indicating a reduction in venous return likely due to an increase in splanchnic capacitance. In conclusion, pharmacologic venodilation with NTG increased splanchnic capacitance coupled with a decrease in cardiac volume. Sympathetic withdrawal produced similar hemodynamic effects. These findings highlight the importance of splanchnic capacitance in cardiovascular regulation. Funding: National Institutes of Health (NIH) grants R01 HL144568, P01 HL56693, U54 NS065736, R01 HL122847, and UL1 TR000445 (National Center for Advancing Translational Sciences). Additional support was provided by American Heart Association grant 14CRP20380211 (Okamoto).

Reduced baroreflex sensitivity in men with low testosterone: insight from the Valsalva maneuver Introduction: Men with low testosterone are more likely to develop hypertension compared to men with normal testosterone, however, mechanisms contributing to hypertension in men with low testosterone have yet to be elucidated. Purpose: Determine if middle-age and old (MA/O) men with low testosterone have reduced baroreflex sensitivity (BRS) compared to men with normal testosterone. Methods: Young (18-40 years) and MA/O (50-75 years) men participated in this study. MA/O men were divided into groups based on testosterone concentrations (low testosterone \ 300 ng/dL; higher testosterone C 400 ng/dL). Beat-by-beat blood pressure (BP, finger photoplethysmography) and R-R interval (single-lead EKG) were recorded during 10 min of supine rest and two 20-s Valsalva maneuvers. Cardiovagal BRS was assessed by assessing the relation between R-R interval and systolic BP. BRS was assessed during decreasing BP using Phase II of the Valsalva and during increasing BP using Phase IV of the Valsalva. Results: Three young men (age: 34 ± 2 years, BMI: 22.2 ± 3.7 kg/ m 3 , systolic BP: 107 ± 11 mmHg, diastolic BP: 69 ± 3 mmHg, testosterone: 565 ± 161 ng/dL), eight MA/O men with higher testosterone (age: 56 ± 4 years, BMI: 28.4 ± 3.8 kg/m 3 , systolic BP: 127 ± 8 mmHg, diastolic BP: 80 ± 8 mmHg, testosterone: 501 ± 99 ng/dL), and seven MA/O men with low testosterone (age: 57 ± 8 years, BMI: 30.7 ± 5.7 kg/m 3 , systolic BP: 132 ± 9 mmHg, diastolic BP: 80 ± 7 mmHg, testosterone: 268 ± 32 ng/dL) participated. Overall BRS was higher in young men (18.6 ± 1.4 ms/mmHg) compared to MA/O men with higher (13.9 ± 3.4 ms/mmHg; p = 0.03) and low (7.4 ± 2.6 ms/mmHg; p \ 0.001) testosterone, and men with higher testosterone had higher BRS compared to men with low testosterone (p \ 0.001). BRS assessed using Phase II of the Valsalva maneuver was similar between groups (young: 5.7 ± 0.5; higher testosterone: 4.5 ± 1.9; low testosterone: 3.6 ± 0.8 ms/ mmHg; p = 0.134). However, BRS during Phase IV of the Valsalva maneuver was lower in MA/O men and in men with low testosterone compared to men with higher testosterone (young: 14.9 ± 2.8; higher testosterone: 9.3 ± 2.3; lower testosterone: 5.3 ± 2.4 ms/mmHg; p \ 0.001). Conclusions: These data suggest that MA/O men with low testosterone have reduced cardiovagal BRS compared to MA/O men with higher testosterone. However, examination using the Valsalva maneuver indicates that these differences are occur during increasing but not decreasing BP. Funding: NIH T32 AG000279, NIH R01 AG049762, NIH P30 DK048520, NIH UL1 TR001082, Eastern Colorado VA GRECC.

Morning cardiovascular reactivity after evening binge alcohol consumption: sex differences I.M. Greenlund 1,2,3 , J.A. Bigalke 1,2,3 , A.L. Tikkanen 1,3 , J.R. Nicevski 1,3 , C.A. Smoot 3 , J.J. Durocher 3,4 , J.R. Carter 1, 2, 3 and was consumed two hours prior to lights out. Polysomnography was recorded during an 8-h sleep opportunity. Following lights on, participants were instrumented with continuous blood pressure and electrocardiogram (Finapres NOVA, Netherlands) for a cold pressor test (CPT) that included a 3-min baseline, 2-min CPT, and 3-min recovery period. Statistical analysis utilized repeated measures ANOVA with condition and time as within subject factors and sex as a between factor (a = 0.05). Results: Breath alcohol content (BrAC) increased to a peak of 0.093 ± 0.004 in the alcohol group, but returned to normal by the morning (0.000 ± 0.000). During CPT, changes in mean arterial pressure (MAP) were augmented the morning after binge alcohol consumption when compared to fluid control in women (D21 ± 4 to D29 ± 6), but not men (D33 ± 2 to D29 ± 2; condition 9 time 9 sex: p = 0.012). The augmented MAP in women persisted into recovery following evening binge alcohol consumption (condition 9 time 9 sex: p = 0.036). Heart rate reactivity and recovery to CPT were not different between sexes (condition 9 time 9 sex: p [ 0.05 for both). Conclusions: In conclusion, evening binge alcohol consumption increased cardiovascular reactivity more dramatically in women, a finding that might have cardiovascular risk implications. Funding: Support is provided by the National Institutes of Health (AA-024892; U54GM115371; P20GM103474).

Exaggerated sympathetic neural responses to the cold pressor test in heart failure with preserved ejection fraction R. Takeda 1,2 , S.L. Hissen 1,2 , S.W. Holwerda 3 , J.P. MacNamara 1,2 , S. Background: Heart failure with preserved ejection fraction (HFpEF) may be associated with autonomic dysfunction. However, there is no information available on sympathetic neural responses to physiological stimuli in patients with HFpEF. The cold pressor test (CPT), which evokes a sympathoexcitatory response, is often performed in the clinical evaluation of autonomic function to ensure the integrity of central vasomotor processes and their efferent pathways. We hypothesized that sympathetic activation during the CPT would be exaggerated in HFpEF. Methods: Fourteen HFpEF patients [age 69 ± 6 (SD) years; body mass index (BMI) 39 ± 7 kg/m 2 ; 6 men/8 women] and 16 healthy controls (68 ± 7 years; BMI 28 ± 3 kg/m 2 ; 7 men/9 women) were studied. Blood pressure (BP, SunTech/Nexfin/Finometer), heart rate (HR, lead II of the electrocardiogram), and muscle sympathetic nerve activity (MSNA, microneurography) were measured during 10-min supine rest and the 2-min CPT with the hand immersed up to the wrist in an ice-water mixed bath (50% ice and 50% water, about 4°C). Results: HFpEF patients had higher resting systolic BP with no differences in diastolic BP, HR, and MSNA burst frequency (45 ± 11 vs. 41 ± 10 bursts/min) and burst incidence (67 ± 18 vs. 66 ± 15 bursts/100 heartbeats) between the groups during supine rest (all, p [ 0.05). HFpEF patients had greater increases in MSNA burst frequency (DMSNA, 18 ± 11 vs. 9 ± 10 bursts/min, p = 0.018) and burst incidence (18 ± 15 vs. 6 ± 13 bursts/100 heartbeats, p = 0.036) in response to the CPT compared with controls. The increase in diastolic BP during the CPT was lower in HFpEF patients (3 ± 8 vs. 12 ± 10 mmHg, p = 0.014), but there were no differences in the systolic BP and HR responses between groups (both, p [ 0.05).

Conclusions: Patients with HFpEF have exaggerated sympathetic activation but reduced diastolic pressor responses to the CPT compared with healthy individuals. Alterations in the central neural mechanism(s) and/or peripheral vascular regulation (i.e., sympathetic transduction) may be responsible for the augmented sympathetic activation and blunted diastolic BP reactivity in HFpEF. Purpose: Post-COVID-19 syndrome is a poorly understood aspect of the current pandemic, with clinical features that overlap with symptoms of autonomic/small fiber dysfunction. An early systematic analysis of autonomic dysfunction following COVID-19 is lacking and may provide initial insights into the spectrum of this condition. Methods: We conducted a retrospective review of all patients with confirmed history of COVID-19 infection referred for autonomic testing for symptoms concerning for para-/postinfectious autonomic dysfunction at Mayo Clinic Rochester or Jacksonville between March 2020 and January 2021. Results: We identified 27 patients fulfilling the search criteria. Symptoms developed between 0 and 122 days following the acute infection and included lightheadedness (93%), orthostatic headache (22%), syncope (11%), hyperhidrosis (11%), and burning pain (11%). Sudomotor function was abnormal in 36%, cardiovagal function in 27%, and cardiovascular adrenergic function in 7%. The most common clinical scenario was orthostatic symptoms without tachycardia or hypotension (41%); 22% of patients fulfilled the criteria for postural tachycardia syndrome (POTS), and 11% had borderline findings to support orthostatic intolerance. One patient each was diagnosed with autoimmune autonomic ganglionopathy, inappropriate sinus tachycardia, vasodepressor syncope, cough/vasovagal syncope, exacerbation of preexisting orthostatic hypotension, exacerbation of sensory and autonomic neuropathy, and exacerbation of small fiber neuropathy. Conclusion: Abnormalities on autonomic testing were seen in the majority of patients but were mild in most cases. The most common finding was orthostatic intolerance, often without objective hemodynamic abnormalities on testing. Unmasking/exacerbation of preexisting conditions was seen. The temporal association between infection and autonomic symptoms implies a causal relationship, which however cannot be proven by this study.

(POTS) or orthostatic intolerance (OI). There were also rare reports of autonomic neuropathy involving the sympathetic adrenergic, sympathetic cholinergic, or cardiovagal functions. Case description: A 47-year-old-female who developed upper respiratory symptoms of congestion, fever, and anosmia. RT-PCR from nasopharyngeal swab was positive for SARS-CoV2. Within days, she noticed tremors, palpitations, hands and feet tingling, hyperhidrosis, and lightheadedness. For eight months, she had ongoing OI symptoms. Two years prior, she had on and off burning pain in her anterior legs and muscle cramps, which worsened with the infection. Neurological exam was unremarkable except for hyperalgesia below bilateral mid-shins. Results: Laboratory work-up for acquired causes of neuropathy including blood counts with differential, comprehensive metabolic panel, A1C, thyroid function tests, Vitamin B1, B12, serum protein electrophoresis, serum and urine immunofixation, and inflammatory markers were normal. Bilateral lower limb nerve conduction and electromyography studies were normal. Autonomic reflex screen showed absent late phase II and reduced phase IV of the blood pressure response to Valsalva maneuver. The heart rate responses to deep breathing and Valsalva maneuver were normal. Quantitative Sudomotor Axonal Reflex Testing showed reduced sweat outputs on the forearm (0.08 lL/CM 2 , normal = 0.13 lL/CM 2 ) and foot (0.04 lL/CM 2 , normal = 0.14 lL/CM 2 ) sites. She developed palpitations and worsening headache during the 10-min head-up tilt table test. Her heart rate went up from 81 bpm at baseline to 103 bpm on average during the period of tilt. She was diagnosed with sympathetic adrenergic and cholinergic impairment and OI. Skin punch biopsy showed normal epidermal nerve fiber density for age and sex at the ankle (12.2/mm, normal = 5.7/mm) and thigh (12.6/mm) sites. There was a single small perivascular mononuclear cellular infiltrate surrounding a dermal arteriole at the thigh site. Conclusion: This case adds to the rare reported cases of post acute-COVID-19 autonomic neuropathy. In addition to OI, it features sympathetic cholinergic and adrenergic dysfunction that has continued for at least eight months after COVID-19 infection. This emphasizes on the need for increased awareness of the varied autonomic manifestations seen after COVID-19 infections.

Moderate to severe autonomic dysfunction is common in postacute COVID syndrome Background: Up to 50% of COVID-19 patients experience persistent symptoms six months after the onset of their infection, referred to as post-acute COVID syndrome (PACS). Numerous case series have identified autonomic dysfunction in PACS patients. We aimed to identify the severity and distribution of autonomic symptoms in an international cohort of PACS patients using the Abbreviated Composite Autonomic Symptom Score (COMPASS-31). Methods: Adults aged 18-65 with COVID-19 were invited to complete an online REDCap survey. Recruiting occurred through COVID-19 social media groups between September and December 2020. The survey received IRB approval from Stanford University and Stony Brook University and electronic informed consent was obtained. Individuals reporting pre-existing autonomic disorders, those who had not experienced symptoms C 30 days after onset of COVID-19, and those without test confirmed SARS-CoV-2 were excluded from the final cohort. Results: 707 participants met final inclusion criteria. Most were young (45 ± 11 years) and female (85%). Mean duration of symptoms was 146 ± 76 days. 81% had not been hospitalized, suggesting the initial infection was mild to moderate for most. Median COMPASS-31 score was 22.9. 57% had COMPASS-31 scores C 20, and 37% had COMPASS-31 scores C 30. There was no significant difference in median total COMPASS-31 scores between hospitalized and nonhospitalized patients (25.75 [14.20, 39.98] vs. 22.70 [11.50,37 .80], p value = 0.12). Discussion: COMPASS-31 scores for healthy individuals typically range from 0 to 15, and in our clinical experience a COMPASS-31 score C 20 is consistent with moderate to severe autonomic dysfunction. Our findings suggest that a majority (57%) of PACS patients are experiencing moderate to severe autonomic dysfunction. This is consistent with findings of post-viral autonomic dysfunction in 50% of patients during the 2002 SARS outbreak. Clinicians should be trained to recognize and treat post-viral autonomic dysfunction given the large number of PACS cases with autonomic dysfunction likely to be seen. COMPASS-31 surveys and clinician-administered bedside orthostatic stand testing may be helpful screening tools to identify PACS patients with autonomic dysfunction. Further research on the autonomic manifestations of PACS is urgently needed. Background: Preliminary data suggest that about 10% of patients who have been tested as positive for SARS-CoV2, still remain unwell beyond three weeks. Post-acute sequelae of COVID-19 may affect the autonomic nervous system (ANS) functioning, thus resulting in related symptoms. However, prevalence and time course of autonomic symptoms experienced by COVID-19 survivors after discharge from hospital are currently unknown. Aims: To evaluate the prevalence of dysautonomia symptoms in patients discharged from hospital after COVID-19 and the symptoms intensity at 1-month follow-up. Methods: 95 patients (40 M; age 64 ± 13 years; BMI 28 ± 6 kg/m 2 ) admitted to hospital for COVID-19 during the second and third outbreaks in Italy were consecutively enrolled at time of hospital discharge (T0). Dysautonomia symptoms were assessed by COM-PASS31 questionnaire at T0 and after 1 month (T1) from negativization of nucleic acid amplification test for SARS-CoV2. At enrollment, patients were asked to answer retrospectively to an additional COMPASS31 questionnaire to assess their potential symptoms intensity before COVID-19 (PRE). Based on literature data (Greco C, Diabet Med. 2017) a COMPASS31 total score (0-100; CTS) [ 16.4 was considered reflecting an initial autonomic dysfunction (DYS). The investigation was approved by the Internal Review Board (#2742/2020). A written consent was signed by all participants.

Results: At T0, DYS was reported by 55.8% of patients compared to PRE (24.4%; p \ 0.01). DYS was still present at T1 in 45.2% of patients (p \ 0.01). At T0, a significant increase in the CTS and orthostatic intolerance domain (OI, 0-40) was observed compared to PRE (N = 74; TS: D 6.9 ± 1.3 from 12.0 ± 1.3 p \ 0.01; OI: D 3.68 ± 1.0 from 4.9 ± 0.9, p \ 0.01). At T1, the CTS and OI were still unmodified compared to T0 (N = 69; CTS: D -0.49 ± 1.7; OI 0.29 ± 1.5). Conclusion: At hospital discharge, symptoms were reported in a significant number of COVID-19 patients. Orthostatic intolerance is the main domain affected. Moreover, a significant increase of COMPASS31 total symptoms intensity was observed compared to their condition before hospital admission. Finally, symptoms were still present one month after hospital discharge. Funding: Partially funded by CardioCalm, Montichiari, Brescia, Italy.

Sympathoadrenal imbalance associated with tilt-evoked sudden hypotension in post-acute SARS-CoV2

A. Lenka, P. Sullivan, D.S. Goldstein; and the NINDS PASC study group Autonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, MD, USA Background: After recovery from COVID-19, a substantial proportion of individuals with post-acute SARS-CoV2 (PASC) have persistent neurological problems that may include (1) fatigue, (2) ''brain fog,'' and (3) cardiovascular dysautonomia, manifested by excessive orthostatic tachycardia, lightheadedness, or a tendency to faint. We conducted comprehensive autonomic function testing including provocative tilt table testing with serial blood sampling for levels of catecholamines in people with PASC. We wished to determine whether individuals with tilt-evoked sudden hypotension (TESH) have an increase in plasma epinephrine (EPI) without a corresponding increase in plasma norepinephrine (NE) (sympathoadrenal imbalance, SAI, PMID 12505571) before or at the time of TESH. Methods: Four PASC participants underwent provocative tilt table testing at the NIH Clinical Center. Antecubital venous blood samples were obtained through an indwelling intravenous catheter during supine rest and during 70 degrees head-up tilting every 4 min for up to 40 min or until TESH became evident. A blood sample was also obtained at the time of TESH. Results: Two PASC participants had TESH and two did not. Both individuals with TESH had the SAI pattern. One TESH-negative participant had an immediate increase in plasma EPI that was not sustained. The other TESH-negative participant had a progressive increase in plasma EPI until about 24 min, with a subsequent decline. Because of the continuous monitoring of blood pressure, no patient had actual loss of consciousness. Conclusions: PASC patients who have TESH have large increases in plasma EPI without concurrent increases in plasma NE (SAI). Because of obvious inter-individual variability, data from a larger cohort are necessary in order to draw inferences about the frequency and autonomic correlates of TESH in PASC. Purpose: Post COVID-19 cardiovascular symptoms are a growing concern noted in as many as one-fourth of patients hospitalized with the virus accounting for up to as much as 40% of all COVID-19 deaths. Symptoms expressed include dizziness up to and including syncope, palpitations, irregular heartbeat, shortness of breath and chest pain. Cause has been linked to post viral inflammation in as many as 60% of these patients. The goal of this paper is to describe autonomic measurements in patients who after surviving COVID-19 are presenting to Stem Cardiovascular Foundation for evaluation of symptoms mentioned above. Methods: Forty-seven patients presenting for cardiac and then autonomic evaluation due to persistent symptoms following recovery from COVID-19 are described. Average age was 40.96 years. Patient intake included symptom inventory assessed using COMPASS questionnaire and patient report. Evaluations presented include orthostatic assessments. Symptom inventories and evaluations were then compared between initial and first follow up visit. Results: Symptoms at initial visit in order of prevalence included fatigue (95.7%), dizziness (93.6%) and gastric symptoms (91.5%). Syncope/pre-syncope (76.6%), palpitations/tachycardia (63.8%) and dry eyes/mouth (55.3%). Chest pain or discomfort was reported by (29.8%) of patients at initial visit. Average initial COMPASS score 26.5. Orthostatic assessment demonstrated an increase in SBP or DBP at initial visit in ([ 50%) of patients in upright positions. Average HRV was 9.857 lying to sitting. Average HRV sit to stand 4.857. Treatment with cholinergic support was initiated ± antioxidant therapy ? H2 blockade Follow-up visit (30 days ± 1-14 days) Symptom inventories demonstrated description of dizziness in 93.8%, a slight increase (0.21%) from initial visit. Fatigue (90.9%), gastric symptoms (77.4%) and dry eyes/mouth (45.2%) were all decreased by 5.14%, 16.7% and 20.1%, respectively. Complaints of palpitations/tachycardia (54.8%) and chest pain (21.9%) were also reduced (15.7% and 30.56%) following cholinergic support. Average COM-PASS score at second visit 24.9. Average HRV lying to sitting 11.333 an increase from initial visit (13.93%). However, HRV declined when measured sit to stand at follow up. Lying to sitting SBP and DBP were decreased (13.8% and 4.04%) when compared to initial visit and increased when measured sit to stand SBP (8.43%) and DBP (25.2%). Conclusion: Autonomic evaluation post COVID-19 demonstrated decline in measures of parasympathetic activity as noted in symptom inventory and assessment. Some improvements were noted in a relatively short period of time following cholinergic ± antioxidant and H2 blockade therapies. Our intention is to continue to follow these patients and update our findings over the next few months. Methods: IRB approval was obtained for retrospective and prospective review of patients with CoV-2 infection referred for suspected autonomic dysfunction. Results: We identified 19 patients with COVID-19 disease associated dysautonomia. Median age was 45 years old (range 22-66), and 16 were women. Presenting infectious symptoms included fever, headache, cough, chest pressure, dyspnea, myalgias, and anosmia; 2 also reported dizziness. Five of the 16 who underwent chest imaging had confirmed pneumonia and 1 additionally had myocarditis. Six patients were hospitalized, 4 of those at a later time post-COVID infection. Two patients had a history of autoimmunity. Onset of autonomic symptoms developed at time of respiratory infection in at least 9 patients, versus post-infection in 7 patients with a range of 2 weeks to 3 months later. Reported symptoms included orthostatic intolerance: postural lightheadedness (n = 19; 100%), near-syncope (n = 17), heart racing/palpitations (n = 18), and syncope (n = 6). Sixteen of 19 (84%) had new/different headaches and 6 (32%) had dysesthesias (primarily in hands and feet, 1 thoracic). Thirteen patients had GI symptoms including diarrhea and/or constipation. Autonomic testing was performed on all patients, ranging 2 weeks to 7 months postinfection. Testing revealed cardiovagal dysfunction in 3 patients, abnormal blood pressure response to Valsalva in 3 (flat-top response in additional 2), and impaired sudomotor function in 4. Tilttable testing was notable for hypertension in 7, orthostatic hypotension in 2, and excessive heart rate increment in 13 (elevation from baseline 33-50 bpm). EMG was normal in the 7 patients who completed testing. Conclusions: COVID-19 disease associated dysautonomia is associated with typical features of orthostatic intolerance although autonomic testing shows heterogenous findings on tilt-table testing and variable cardiovagal and sudomotor involvement. Given that some symptoms were already present at the time of infection, deconditioning is unlikely to be the sole explanation, though whether autonomic dysfunction is due to direct viral effect on autonomic pathways, or to para-/post-infectious immune-mediated mechanisms remains to be determined.

Autonomic dysfunction following acute COVID-19: a series of 3 cases M.E. Brisen˜o-Godı´nez, R.X. Domínguez-Vega, K. Cárdenas-Soto, A. González-Duarte Autonomic and Small Fiber Neuropathy Department, Instituto Nacional de Ciencias Medicas y Nutrición ''Salvador Zubirán'', Mexico City, Mexico

Introduction: The incidence of autonomic dysfunction as a neurological complication during acute phase of Sars-CoV-2 infection is established. However, now the pandemic has evolved, we are witnessing the persistence or emergence of autonomic dysfunction after the acute respiratory period due to a virus cytokine storm response or immune-mediated disruption to the autonomic nervous system. Objective: To report a case series of autonomic dysfunction after acute infection of COVID-19. Methods: This is a prospective review of patients evaluated in the autonomic clinic at our institution from December 2020 to date, for persistent symptoms suggestive of autonomic dysfunction that started in the acute or post-acute COVID-19 infection. They underwent formal autonomic testing. Case reports: Three middle age females, ranged from 31 to 44 years old, were identified, all of them tested positive for SARS-CoV-2 with mild respiratory symptoms. Only one patient reported the onset of autonomic complains concomitant with COVID-19 infection, the other two 4 and 6 weeks later. Two of them debuted with repetitive hypertensive crisis that required management in the emergency room, the other with postural lightheadedness and syncope. Autonomic testing demonstrated baroreflex failure (BF), orthostatic hypertension (OH) and vasovagal syncope (VS), respectively. Noradrenaline levels were high only in the case with OH. Sudomotor impairment was reported in BF and OH. The patient with BF was treated with intravenous immunoglobulin (IVIG) with partial recovery. The VS improved only with general recommendations and the OH with clonidine. We plan to follow these patients monthly to evaluate progress. Conclusions: We present the clinical features and initial autonomic assessment in 3 patients with history COVID-19 infection. The partial recovery of one patient after IVIG could support the autoimmune theory, but we would need more time in the follow-up of this patients to determine the causality and outcomes of autonomic disorders triggered by of Sars-CoV-2 infection.

Post-COVID POTS: experience in a single tertiary care center Introduction: The COVID-19 pandemic has impacted the world's health and economy and has been a major source of morbidity and mortality over the past year and a half. Of patients who survive infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), a subset of patients continue to experience a constellation of chronic symptoms. These cases have been termed ''long-COVID'', ''post-COVID syndrome'' or ''long-haul COVID''. Reported symptoms often include autonomic symptoms like syncope, lightheadedness, fatigue and orthostatic intolerance. There are many unanswered questions surrounding cases of post-COVID syndrome such as natural history, pathophysiology, and best treatments. Our aim was to better characterize the autonomic symptoms, severity and involvement of the autonomic nervous system pathology in patients with post-COVID syndrome. Methods: We are conducting a retrospective analysis of patients with confirmed COVID-19 infection referred to the UT Southwestern autonomic laboratory from the post-COVID clinic. During initial evaluation in the clinic, patient completed COMPASS 31 questionnaires and complete supine and standing orthostatic vitals. A subset was referred for standardized autonomic function testing plus evaluation by an autonomic disorder specialist. Results: On preliminary evaluation, we identified 12 patients referred from the UT Southwestern post-COVID clinic to the autonomic laboratory, 3 met heart rate criteria for POTS (either during tilt test or active stand test), 1 had delayed orthostatic hypotension with appropriate heart rate increment suggestive of hypovolemia, and 8 had normal autonomic function testing and orthostatic vitals. 2 of the 8 with normal testing had orthostatic tachycardia, but did not meet the heart rate increment criteria for POTS. The mean COMPASS-31 score was 45.3, indicating moderately severe symptoms associated with autonomic function. This COMPASS 31 score was similar to a previous POTS cohort (COMPASS-31 46.01, n = 205). Conclusion: The clinical autonomic features of post-COVID syndrome are still being defined. Although all patients included in our cohort had autonomic symptoms, the majority of patients had normal autonomic function tests and only 25% had findings consistent with POTS. Analysis is still ongoing, and we will have a larger cohort to review in the future.

Teaching autonomic disorders to neurology trainees: a singlecenter experience E. Coon, R. Mustafa, D. Abarbanel, P. Sandroni, L.K. Jones Jr., J.K. Cutsforth-Gregory Department of Neurology, Mayo Clinic, Rochester, MN, USA Background: There is significant demand for autonomic specialists, yet the number of neurology trainees who choose to complete a United Council for Neurologic Subspecialties-accredited Autonomic Disorders fellowship remains low. Lack of exposure to autonomic disorders during medical school and residency may contribute to low fellowship interest; however, best practices regarding integration of autonomic education into residency and the ideal amount of autonomic education during training are unknown. Aims: We sought to create graduated, complementary autonomic didactic lectures and perform a qualitative assessment of resident feedback on the autonomic curriculum. Methods: This is a descriptive study of an autonomic didactic curriculum at a single neurology residency program. All neurology trainees (N = 33) were surveyed anonymously at the end of the 2020-2021 academic year to qualitatively assess their experiences with the autonomic curriculum. Results: A total of 3 h of formal autonomic didactics was curated for the first and second years of neurology training (postgraduate year, N-1 and N-2). The N-1 lectures are part of a Neuroanatomy course (highlighting structures) and an Advanced Clinical Neurology course (primarily clinical and case-based). For N-2 trainees, a laboratorybased session with case studies and lab demonstration occurs during Clinical Neurophysiology. These are supplemented with a yearly autonomic journal club and quarterly departmental conferences by autonomic faculty. Residents are invited to participate in a 2-or 4-week elective rotation in Autonomic Disorders that combines clinic and laboratory experiences. All 33 adult and child neurology residents were invited to participate in an anonymous survey. Survey response rate was highest for the N-2 residents (63%), followed by N-3 (55%) and N-1 (27%). The majority of residents felt that the amount of autonomic didactics was just right (69%), while 31% felt that it was not enough. No respondents reported too much time spent on autonomic didactics. Additionally, the majority of respondents (66%) reported no exposure to formal autonomic didactics prior to residency training. Conclusions: Institution of an autonomic didactic curriculum during neurology residency was well-received by trainees. While this is a single-center experience, sharing of best practices to increase trainee exposure may foster interest in autonomic disorders and subspecialty fellowship selection.

Online case-based medical education program identifies differential practice gaps among neurologists and cardiologists in assessment and management of neurogenic orthostatic hypotension T. Finnegan 1 , J. Maeglin 1 L. Arnaud-Hevi 1 , S.R. Raj 2 1 Medscape, LLC, New York, NY, USA; 2 University of Calgary, Calgary, Alberta, Canada Introduction: Neurogenic orthostatic hypotension (NOH) is a consequence of disease states associated with autonomic failure, such as Parkinson's disease (PD). NOH manifests as a significant drop in blood pressure. Evidence indicates that neurologists and cardiologists would benefit from education on the timely recognition and appropriate management of NOH. An online medical education program was developed to improve the ability of neurologists and cardiologists to recognize and manage NOH in patients with PD. Methods: An educational intervention comprising 2 patient case scenarios was developed and delivered online in an interactive, textbased format. Using a ''test and teach'' approach, clinicians were presented with multiple-choice questions to evaluate their application of evidence-based recommendations. Each response was followed by detailed, referenced, feedback to teach. A paired 2-tailed t-test evaluated whether the mean pre-and post-assessment scores significantly differed from one another and McNemar's test measured changes in paired responses to individual questions. Cohen's d was used to calculate the effect size of the intervention. Data were collected between February 3, 2021 and May 10, 2021. Results: Exposure to the program resulted in a large educational effect size for both cardiologists (n = 252; d = 0.456; P \ 0.05) and neurologists (n = 191; d = 0.88; P \ 0.05). Prior to the education, [ 85% of cardiologists and neurologists correctly identified the assessment of orthostatic vital signs to identify and factors that can exacerbate NOH. Following education, a significant (P \ 0.05) improvement in the awareness of both concepts among neurologists and cardiologists was found. When asked a question about selecting a second-line therapy for the management of NOH, * 40% of neurologists and cardiologists selected the correct answer prior to education. Following education, * 90% of both groups selected the correct treatment option. 23% of cardiologists and 21% of neurologists reported increased confidence in their ability to optimize therapy for NOH in patients with PD following exposure to the education. Conclusion: This study demonstrated the success of an online, interactive, case-based educational intervention on improving the knowledge and competence of both cardiologists and neurologists regarding the care of patients with NOH. Future education should focus on the selection of pharmacotherapies for the management of NOH.

Funding: This educational program and associated outcomes analysis were funded by an independent educational grant from Lundbeck.

Poster #47 Anhidrosis due to topiramate contributing to persistent fever in a critically ill patient P. Millar Vernetti, H. Kaufmann Dysautonomia Center, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA Background: Topiramate can cause asymptomatic anhidrosis or be accompanied by fever or hyperthermia, especially in pediatric patients. Objectives: To report a case of anhidrosis as an adverse effect of topiramate in an ICU patient admitted for refractory status epilepticus. Methods: Case report. Repeated-samples T-test was used to assess differences in temperature before and after discontinuing topiramate. Results: A 17-year-old male with morbid obesity and recent onset focal motor seizures was admitted due to refractory status epilepticus requiring treatment with midazolam, clobazam, phenobarbital and topiramate. Topiramate, was titrated up to 900 mg BID. Admission was complicated by persistent fever, in spite of empirical treatment with antibiotics and antifungals. He was not receiving medications with anticholinergic properties. Extensive workup for infectious and rheumatological causes was unrevealing. He remained hemodynamically stable, with no signs of organ failure. The patient's family reported that, at home, the patient used to sweat profusely and would often noticeably dampen his clothes. Nevertheless, after admission, and in spite of persistent fever, his sweating had ceased completely. Topiramate blood levels were in therapeutic range at 6.4 lg/mL (reference range: 5-20 lg/mL). Subsequently, topiramate was tapered and eventually discontinued over 13 days. Continuous EEG monitoring showed he remained seizure-free. After 12 days of topiramate tapering, the patient started sweating in his face. After 13 days, he was sweating over his back and skin folds. Daily average temperature 30 days prior to discontinuing topiramate was 38.8 C ± 0.8 C, and 30 days after 38.0 C ± 0.9 C (repeated samples T-test p \ 0.05). Conclusions: Topiramate-induced anhidrosis should be considered as a cause of, or a contributing factor to sustained fever when infectious causes have been appropriately ruled out and treated, even when the topiramate is within therapeutic range.

Effects of a cool classroom microclimate on cognitive performances and cardiac autonomic control in undergraduate students Background: Uncomfortable indoor microclimate conditions may affect subjective thermal comfort, working and learning performance. An inverted U-shape relationship between cognitive performance and indoor temperature with best performance peaking at 21.6°was described. The autonomic nervous system plays a key role on both thermoregulatory function and cognitive performance that has been described to take advantage in the presence of a cardiac vagal predominance. Aim: To evaluate the effects of a mild indoor temperature reduction on cognitive performances and cardiac autonomic profile during the cold season. Methods: Fifteen undergraduate heathy students (8 M, age 20 ± 2 years, BMI 23 ± 2 kg/m 2 ) underwent a continuous electrocardiogram recording during a 2-h lecture in two days in December when the classroom temperatures were set as neutral (NEUTRAL, 20-22°C) and cool (COOL, 16-18°C). Cognitive performance (memory, verbal ability, reasoning, and overall cognitive C-score) was assessed in all students at the end of each lecture by the Cambridge Brain Science cognitive evaluation tool. Forty minutes after the beginning of the lecture, cardiac autonomic control and thermal comfort were assessed in all students. Power spectral and symbolic analysis of spontaneous fluctuations of heart period provided the indexes of cardiac sympathetic (LF RR ; 0 V%) and vagal (HF RR ; 2 V%) modulation. Sympathovagal interaction was assessed by LF to HF ratio (LF/HF). The investigation was approved by the Internal Review Board (#2153). A written consent was signed by all participants. Results: Classroom temperatures were 21.5 ± 0.8°C and 18.4 ± 0.4°C during NEUTRAL and COOL. Memory, verbal ability, C-Score were greater during COOL (13.01 ± 3.43, 12.32 ± 2.58, 14.29 ± 2.90, respectively) compared to NEUTRAL (9.98 ± 2.26, p = 0.002; 8.57 ± 1.07, p = 0.001 and 10.35 ± 3.20, p = 0.001; respectively). During COOL, 2 V% was greater (30.5 ± 10.9%) compared to NEUTRAL (26.2 ± 11.3, p = 0.047) while LF/HF (2.4 ± 1.7) and 0 V% (23.2 ± 11.1%) were lower during COOL compared to NEUTRAL (3.7 ± 2.8, p = 0.042; 28.1 ± 12.2.1%, p = 0.031). Conclusion: During winter, the COOL indoor microclimate was associated with an improved students' cognitive performance in the presence of a shift towards enhanced vagal and reduced sympathetic modulations to the heart. In addition, the potential energy saving during the COOL lecture may bear important ecological implications. Background: Readily available techniques to measure cerebrovascular changes at altitude (e.g., transcranial Doppler and near-infrared spectroscopy) provide little insight into the cerebral microvasculature. Similar to the brain, blood supply to the retina is almost exclusively controlled by myogenic and metabolic mechanisms. Consequently, changes in the retinal microvasculature likely relate closely to that of the brain. Therefore, we evaluated changes in the retinal microvasculature using functional optical coherence tomography (fOCT) following rapid ascent and acclimatization to high altitude. Methods: This study was approved by the UCalgary and MRU REB. Eighteen volunteers (age: 29 ± 8 years; F, n = 7; BMI = 25 ± 3.6 kg/m 2 ) participated in a research expedition to Barcroft Research Station (3800 m) in the Sierra Nevada mountains, California, USA. Retinal vascular perfusion density (rVPD) (an index of blood volume), retinal thickness (RT) and arterial blood gases (aBGs) were measured during steady-state rest prior to ascent (Day 0 [D0]; 1130 m), within 24-h of ascent (Day 2 [D2]) and following acclimatization to altitude (Day 9 [D9]). One-way repeated measures ANOVAs with Bonferroni tests were used to assess changes in rVPD and RT across days. Linear regressions were used to assess the relationship between aBGs, rVPD and RT. Results: Retinal perfusion (rVPD) increased significantly following ascent (D2: 5.05% ± 0.5 vs. D0: 4.4% ± 0.6; p = 0.0003) and was inversely related to PaO 2 (R 2 = 0.24; p = 0.007). Following acclimatization, rVPD decreased and was no longer different from D0 (D0: 4.4% ± 0.6 vs. D9: 4.6% ± 0.8; p = 0.12). Retinal Thickness (RT) was not affected by initial ascent (D0: 300.1 lm ± 13.3 vs. D2: 299.6 lm ± 13.1; p [ 0.99). However, RT was significantly reduced following acclimatization (D9: 297.4 lm ± 12.9) compared to D0 (300.1 lm ± 13.3; p = 0.001) and D2 (D2: 299.6 lm ± 13.1; p \ 0.001). RT changes relative to D0 were strongly related to changes in PaO 2 (D2: R 2 = 0.6; p = 0.001; D9: R 2 = 0.4; p = 0.02) and stimulus index (PaCO 2 /PaO 2 ) (D2: R 2 = 0.4; p = 0.001; D9: R 2 = 0.4; p = 0.02). Conclusion: These data suggest differential metabolic regulation of the retina via arterial O 2 , with rapid but adapting (rVPD), and slow but sustained (RT) responses to altitude. The ability to measure cerebral microvasculature is critical during normal physiological stress and in chronic pathological conditions. The current study supports the use of fOCT to assess retinal microvascular changes to acute and chronic stressors. Background: Repeated, acute exposures to low oxygen (intermittent hypoxia, IH), similar to that observed in sleep apnea, elicit an increase in efferent sympathetic nervous system activity and a rise in arterial blood pressure (BP) in men. Endothelin (ET) receptor antagonists can attenuate the sympathetic and BP response to IH in rodents, highlighting their therapeutic potential for sleep apnea-induced hypertension. However, whether these data translate to humans is unclear. We sought to assess a role for the ET receptor in mediating the increase in muscle sympathetic nerve activity (MSNA) and arterial BP associated with acute IH in humans. We hypothesized ET receptor antagonism with oral bosentan would attenuate any rise in MSNA and BP following acute IH in healthy young men. Methods: Twelve men (31 ± 4 years) completed two study visits (control, bosentan) separated by a minimum of 1 week. Bosentan (62.5 mg) was taken by mouth daily for 3 days prior to the study visit. On each visit, MSNA, beat-by-beat BP, and baroreflex sensitivity (modified Oxford) were assessed during normoxic rest prior to and following 30-min of experimental IH. The midpoint (T50) for each individual's baroreflex curve was calculated. Results: Acute IH increased plasma ET-1 (p \ 0.01), MSNA burst frequency (p = 0.03), and mean arterial BP (p \ 0.01). There was no effect of IH on baroreflex sensitivity (p = 0.46), although an increase in the T50 was observed following IH exposure (p \ 0.01). MSNA burst frequency was higher and mean arterial BP was lower following 3 days of oral bosentan treatment compared to control (p = 0.04 and p \ 0.01, respectively). There was no effect of bosentan on baroreflex sensitivity (p = 0.53), although a lower T50 was observed on the bosentan visit (p \ 0.01). There was no effect of bosentan on the increase in MSNA or mean arterial BP following acute IH (p = 0.81 and p = 0.12, respectively). Conclusions: Acute IH results in an increase in ET-1, MSNA and BP in healthy young men. The effect of IH on MSNA and BP was not attenuated following ET receptor inhibition with oral bosentan. Present data suggest acute IH does not increase MSNA or arterial BP through activation of the ET receptor in healthy young men. Funding: NIH HL130339 (JKL), Mayo Clinic Center for Biomedical Discovery (JKL).

An automated non-invasive approach to investigating the intrinsic vascular regulation using functional optical coherence tomography (fOCT)

Objective: Impaired cerebral microvascular responses are a hallmark of prominent metabolic and cerebrovascular diseases. The human retina is a developmental outcrop of the brain and like the brain, the retina's blood supply is regulated almost entirely by myogenic and metabolic mechanisms. Moreover, this neuronal tissue bed is accessible to non-invasive high-resolution 3D-optical coherence tomography (OCT) imaging through the eye. To automate functional assessment of the retinal cerebrovasculature, we introduced a robust image processing pipeline to measure retinal thickness and vascular perfusion density (VPD) from 4D OCT images. Methods: First, image artifacts were corrected by applying Robust Principal Component Analysis. Then, output images were registered (Rigid Body approach) to assess the same area of retina across different tests within participant. Anisotropic diffusion was applied to remove the noise, followed by contrast enhancement. The resulting image was fed through a Frangi's algorithm that segments any tubular form. The segmented area (vessels) was divided by the total number of pixels to calculate the retina vasculature density as an index to retina perfusion (VPD). The distances between internal limiting membrane and retinal pigment epithelial layers were also mapped to yield retina thickness (RT). Here, the utility of this pipeline is illustrated by applying it to a database of 9 participants exposed to acute hypoxia. A minimum of two images were collected following steadystate exposure to normoxia (ETO 2 : 86 mmHg) and hypoxia (ETO2: 44 mmHg). Test-retest reliability was calculated using a Model 3 intra-class correlation coefficient (ICC) between repeated scans. Results: The accuracy of the pipeline was qualitatively investigated by inspecting random images across the entire database. The ICC yielded a Cronbach's alpha of 0.8 for VPD and 0.99 for RT, demonstrating that the pipeline produces reliable measures. Additionally, we obtained OCT images during acute eucapnic hypoxia, a cerebrovascular vasodilator stimulus, and observed that VPD is increased with end-tidal O 2 (R 2 = 0.2, p value = 0.03). RT also showed a significant increase with acute hypoxia.

Significance: Recent OCT machines have unrealized potential to uncover functional cerebrovascular responses. Development of this analytical pipeline accelerates the assessment of intrinsic vascular regulation, and these findings confirm the effectiveness of the proposed pipeline. Background: Exercise pressor reflex or metaboreflex plays a significant role in regulating the cardiovascular response to exercise. In humans, metaboreflex evoking sympathetic vasoconstriction is well established but its role in cardio-accelaration is not very clear. Objective: The aim of this study is to evaluate changes in hemodynamics occurring during metaboreflex activation obtained by postexercise muscle ischemia (PEMI) after two different exercise intensities. Material and Methods: Twenty healthy male volunteers after a supine rest for 15 min baseline parameters were recorded. Subjects performed two sets of exercise protocols after determination of maximum voluntary contraction (MVC) using handgrip dynamometer from which grade I 30% (moderate) and grade II 45% (High) was calculated. Protocol 1 (free flow recovery) and protocol 2 (isolation of metaboreflex) was performed. Continuous heart rate and respiration were recorded. Blood pressure was recorded during baseline, at the end of exercise, at the end of PEMI, at recovery 1 min, 2 min, 3 min and 5 min. Data was statistically analysed using SPSS. Results: During metaboreflex, exercise conducted against the grade II caused a more pronounced blood pressure rise than the strain conducted against the grade I (p = 0.002). Heart rate responses during post-exercise muscle metaboreflex were not significantly different from that of control. Conclusion: During PEMI 45%, blood pressure response was mainly achieved through enhancement of myocardial contractility that increased in cardiac output, whereas during PEMI 30%, blood pressure response was reached predominantly by means of vasoconstriction. The parasympathetic cardiac tone is enhanced during activation of the metaboreflex and balances enhanced cardiac sympathetic activity to result in heart rate an unchanged. Objective: Evaluate long-term change in neurofilament light chain (NfL) levels in response to patisiran in patients enrolled in the Global Open-Label Extension (OLE) study. Background: Hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, is a rare, rapidly progressing, fatal disease; majority of patients develop a mixed phenotype of polyneuropathy and cardiomyopathy. Patisiran is approved for the treatment of hATTR amyloidosis with polyneuropathy and its longterm efficacy/safety is being studied in a Global OLE. Plasma biomarkers, such as NfL, are being investigated for utility in facilitating earlier diagnosis of ATTRv amyloidosis and monitoring disease/treatment response. Methods: NfL plasma levels were measured in duplicate in healthy controls and patients with ATTRv amyloidosis with polyneuropathy using the Quanterix Simoa platform. Patient samples were analyzed from the APOLLO study at baseline and 18 months in placebo and patisiran groups. NfL levels were also measured at 12 and 24 months following APOLLO in patients who rolled into the Global OLE. Results: NfL levels at APOLLO baseline were 63.2 (placebo) and 72.1 pg/mL (patisiran). NfL increased during APOLLO in the placebo group (99.5 pg/mL), whereas a significant decrease was observed at 18 months following patisiran (48.8 pg/mL). Reduced NfL levels were maintained in the APOLLO-patisiran group through 24 months of additional patisiran treatment in the Global OLE (44.0 pg/mL), consistent with maintained improvement in mNIS ? 7. Upon initiation of patisiran in the Global OLE, the APOLLO-placebo group experienced a reduction in NfL levels through 24 months (44.2 pg/mL), reaching a similar level to the APOLLO-patisiran group.

Conclusions: NfL may serve as a biomarker of active nerve damage and polyneuropathy due to TTR amyloid deposition, making it useful as a potential biomarker of disease progression and treatment response. NfL levels may be useful for earlier diagnosis of polyneuropathy in patients with ATTRv amyloidosis and monitoring disease and treatment response over time. Funding: Alnylam Pharmaceuticals, Inc.

Autonomic and quality of life assessments in patients with TTR mutations after treatment with patisiran vs. placebo Clin Auton Res extracellular deposition of amyloid fibrils in multiple organs. The most common mutation around the world is Val30Met. Patisiran is a small interfering RNA and is indicated for the treatment of the polyneuropathy of hATTR. Methods: 15 patients with TTR pathogenic mutations and symptoms were screened and followed up for 30 months after initiating with patisiran 3 mg/kg vs. placebo every 3 weeks for 18 months. The patients were assessed before and after with EQ-5D-5L, Norfolk QOL-DN and COMPASS-31 questionnaires. Results: 15 patients were analyzed at the screening. Twelve (80%) patients had the mutation Ser50Arg, 1 (6.7%) Gly47Ala, 1 (6.7%) Ser52Pro, 1 (6.7%) Val30Met. Nine (60%) were men and the mean age was 46 years (36-62 years old). 11 (73.3%) patients were on the Patisiran arm and 4 (26.7%) on the placebo arm. At the screening, the mean total EQ VAS in a scale from 0 to 100 points in patients with patisiran vs. placebo was 68 vs. 60 and after the 30 month follow-up was 69 vs. 57. The COMPASS-31 score was for the screening 30 vs. 38 and after 30 months was 30 vs. 42. In the Norfolk QOL-DN questionnaire, the patisiran group reported self-care activities as ''very mild problem'', while the placebo group reported as ''moderate problem''. 3/4 patients from the placebo arm died while all the patisiran are still alive. Conclusion: Patients who received patisiran during the study maintained their EQ VAS and COMPASS-31 score after 30 months. Background: 16p11.2 duplications have an incidence of * 3/10,000. 16p11.2 duplications carry an autosomal dominant inheritance pattern or can occur via de novo mutation. Phenotypic expression includes low weight, microcephaly, developmental delay, and seizures; while others have no identified physical or behavioral abnormalities. * 80% of individuals with 16p11.2 duplications have speech/ language dysfunction, 33% have delayed motor milestones, and 20% are diagnosed with autism. A PubMed search consisting of ''16p11.2 duplication'' ? ''autonomic'' yields zero results. Methods: Siblings, a 22-year-old woman (S1) and 21-year-old man (S2), share a phenotype of constipation, orthostatic intolerance (OI), intellectual disability, autism, and attention deficit hyperactivity disorder. Their father, a 16p11.2 duplication carrier, has lifelong OI and fainting. Multimodal testing results are described. Results: S1 demonstrated exam findings of a small fiber sensory neuropathy, absent post-ganglionic sudomotor responses, and decreased heart rate response to deep breathing (HRDB) compared to norms. Valsalva maneuver demonstrated absent reflexive late phase II response, variably present blunted phase IV overshoot, and a prolonged pressure recovery time with normal heart rate ratio. There was orthostatic hypotension (OH) on tilt table test (TTT). Gastric motility studies (GES) revealed severely prolonged gastric emptying. Epidermal nerve fiber density was decreased at the calf and normal in the thigh. S2 had hyperesthesia to pinprick in the distal extremities. Sudomotor responses were reduced at all sites with progression from 2017 to 2020. HRDB was normal. Valsalva maneuver demonstrated an absent phase IV overshoot, blunted late phase II response, and prolonged pressure recovery time. There was no OH on TTT but mildly exaggerated orthostatic tachycardia. GES revealed delayed gastric emptying at 2 and 4 h. Whole exome, mitochondrial DNA sequencing, and gene microarray assays were completed for the siblings and their parents demonstrating a paternally-inherited 16p11.2 duplication and a maternally-inherited variant of uncertain significance (VUS) in SCN9A (c.1675G [ A, p.G559S). Conclusions: 16p11.2 duplications may be associated with autonomic neuropathies resulting in AF. The VUS in SCN9A shared by the siblings and mother is reported in 23 alleles in the gnomAD database, and is predicted benign/tolerated in Polyphen and SIFT. Introduction: Sri Lanka, a middle-income country in South Asia, has seen a rapid expansion in motor vehicles and, associated with this, an increase in demand for fuel. The dispensing of fuel at fuel stations is performed manually by male fuel handlers, who have long working hours. Such workers are exposed to hydrocarbon fuels which are associated with multiple health effects. This study was performed to determine cardiovascular autonomic functions among fuel handlers in a densely populated district of Sri Lanka. Methods: Fuel handlers (n = 50) from the Gampaha district of Sri Lanka, aged between 19 and 65 years, were identified for the study from seven selected fuel stations. Age and gender-matched controls (n = 46) without occupational exposure to fuel were used as controls. All participants were male (females were not employed as fuel handlers). After obtaining written informed consent, demographic data were collected, and general physical examination performed before autonomic function assessment. Non-parametric methods were used for data analysis. Ethical approval was granted by the ethics review committee of the Faculty of Medicine, University of Kelaniya, Sri Lanka.

Results: There were no significant differences in weight, height or BMI among the study and the control populations (p [ 0.05). Both the systolic (SBP) and diastolic (DBP) blood pressures were significantly higher among the fuel handlers compared to controls (SBP, Mann Whitney U = 743.5, p = 0.003) and (DBP, Mann Whitney U = 686.5, p = 0.001). Valsalva ratio was significantly higher among the fuel handlers (Mann Whitney U-874.00, p = 0.043). The rise in DBP during sustained handgrip, a sympathetic parameter, was significantly higher among the controls (Mann Whitney U = 863.00, p = 0.049).

Conclusions: Altered sympathetic:parasympathetic balance was observed among the fuel handlers. Monitoring of the health, using personal protective equipment, and curtailing hours of employment per week is recommended for those employed at fuel stations. Funding: University of Kelaniya research grant (RP/03/04/03/01/ 2017).

Heart rate variability among gas station attendants exposed to benzene, toluene, and xylenes (BTX) in Sri Lanka Introduction: Benzene, toluene, and xylenes (BTX) exposure among gas station attendants in Sri Lanka is high. Cardiovascular morbidity and mortality are reported to be higher among those exposed to BTX. A hypothesis is based on alterations in the autonomic nervous system, especially disruption of autonomic regulation of the heart. Autonomic regulation of cardiac functions can be assessed by short-term heart rate variability (HRV), which measures the fluctuations in the interval between sequential sinus heartbeats. Objective: To determine whether BTX exposure affects the heart rate variability (HRV) among gas station attendants. Methods: Forty-nine gas station attendants from the Gampaha district of Sri Lanka, aged between 19 and 65 years, were recruited for the study. Age and gender-matched controls (n = 46) without occupational exposure to fuel were used as controls. Ethical approval for the study was granted by the Ethics Review Committee of the Faculty of Medicine, University of Kelaniya, Sri Lanka. Informed written consent was obtained from each participant. Demographic data were collected, and a physical examination was performed before the HRV assessment. We measured SDNN, RMSSD, pNN50, HF, LF, and LF: HF ratio as HRV indices. Pre-and post-shift samples of end-exhaled air were collected and analyzed for BTX using a thermal desorption gas chromatography-mass spectrometry system (TD-GC-MS) among 24 gas station attendants and 14 controls. As a proxy of shift exposure, we calculated the increase from pre-shift (as a baseline) to postshift and reported this as 'delta'. Results and discussion: For gas station attendants (n = 24) median pre-/post-shift exhaled air concentrations (ng/L) were: benzene 10.47/ 19.00; toluene 10.41/21.86; m/p-xylene 1.63/2.14; o-xylene 0.93/1.42. For controls (n = 14) these values were 9.40/11.05, 3.19/3.91, 1.23/ 1.43 and 0.47/0.47. The heart rate variability (HRV) analysis showed significantly higher SDNN and SD2 among the gas station attendants (n = 49) than controls (n = 46) (Mann Whitney U = 842.00, p = 0.034 and Mann Whitney U = 843.50, p = 0.035, respectively). RMSSD, pNN50, Total power, HF, and SD1 among gas station attendants negatively correlated at a significant level with the mean increment in exposure to BTX (p \ 0.05). Conclusions: Exposure to BTX alters the HRV indices, indicating an effect on autonomic cardiac regulation. Heart rate variability (HRV) has become a common measure in both research and clinical applications. Many turnkey systems as well as mobile device apps now routinely report indices of HRV. Therefore, a better understanding of the properties of these indices is needed. Lewis and colleagues (2012) investigated the properties of several HRV indices but did not examine common time domain indices. Importantly, they concluded that when the various indices met certain criteria they each could provide valid indices of vagally-mediated HRV largely free from the effects of respiration and lack of stationarity. The two criteria were (1) normal distribution, and (2) higherorder detrending with higher order detrending being essential to minimize the effects of respiration. Tarvainen and colleagues (2002) demonstrated the effects of detrending on both time and frequency domain indices of HRV and showed that the root mean squared successive difference (RMSSD) and the percentage of IBI differences greater than 50 ms (pNN50) were both robust to detrending compared to the standard deviation of the IBI series (SDNN). However, they only had four participants and no statistical analyses were performed. In the present study 147 participants were recorded during a fiveminute resting baseline and the three time-domain indices of RMSSD, pNN50 and SDNN with and without smoothness priors detrending examined. Results indicated statistically significant differences with large effect sizes between the SDNN values with and without detrending (mean difference = 21.88 ms). For both RMSSD and pNN50, the effect of detrending was minimal (mean diffs \ 0.33 ms and \ 0.20% for RMSSD and pNN50, respectively). These results support the use of RMSSD without additional detrending as an index of vagally-mediated HRV largely free of the effects of respiration rate and non-stationarity. In addition, it shows that RMSSD acts as a locally stationary high-pass filter that minimizes the effects of slower trends reflecting respiration rate and other non-periodic influences.

Cardiac and respiratory-related activity recorded from the human vagus nerve All visceral organs receive dual innervation from the sympathetic and parasympathetic divisions of the autonomic nervous system, which play important roles in the homeostatic adjustments in organ function essential for life. The vagus nerve belongs to the parasympathetic division, but it primarily conveys sensory information from the heart, lungs, airways and gastrointestinal tract, as well as providing motor control to these and other visceral organs. We recently described a method for recording from the human cervical vagus nerve, using ultrasound-guided insertion of tungsten microelectrodes that allows us to penetrate fascicles of the nerve without impaling the carotid artery or internal jugular vein (Ottaviani et al., J Physiol, 2020). Here we Clin Auton Res report on further recordings we have obtained from 14 of 17 healthy individuals, aimed at quantifying cardiac and respiratory modulation within the vagus nerve. Multi-unit recordings were obtained at rest from a total of 36 intraneural sites, via tungsten microelectrodes inserted percutaneously into the left (n = 7) and right (n = 7) cervical vagus nerves. Neural activity was amplified (20,0000 9, 0.3-5.0 kHz) and sampled at 10 kHz (NeuroAmpEX, ADInstruments) and recorded with ECG and respiration using LabChart 8 software and PowerLab hardware (ADInstruments). Cross-correlation histograms were constructed between neural spikes and the R-waves or the inspiratory peaks of chest expansion. Modulation [ 15% was considered physiologically significant. Cardiac modulation, ranging from 15.33 to 93.25% (mean ± SD 28.98 ± 19.32%) was found in 15 sites, while respiratory modulation (15.02-93.95%; 46.35 ± 23.28%) was found in 30 sites; 14 sites exhibited both respiratory and cardiac modulation [ 15%. Cardiac modulation could reflect the sensory activity of atrial, ventricular or aortic-arch stretch receptors, or of parasympathetic axons directed to the sinoatrial node, atrioventricular node or to the ventricles themselves. Respiratory modulation could reflect the sensory activity of stretch receptors within the airways, motor axons directed to the larynx or parasympathetic axons supplying the bronchioles. We conclude that cardiac and respiratory modulation of vagal nerve traffic can be identified through invasive recordings in awake humans, with respiratory modulation being more prevalent. As the nerve is intact, the identification of neural activity as being sensory or motor (including parasympathetic) will require quantification of the firing properties of single-unit recordings obtained at rest and during specific cardiovascular and respiratory maneuvers. Many individuals with spinal cord injury (SCI) experience autonomic dysfunction, including profound impairment to bowel and cardiovascular function that substantially impacts day-to-day living. Indeed, the burden of bowel dysfunction is reported to exceed other autonomic and motor deficits; bowel management emerges as a potential determinant of quality of life (QoL). Notably, for individuals with high level lesions (T6 and above), stool impaction and bowel management are common triggers of autonomic dysreflexia (AD; profound hypertension secondary to sensory stimuli below the lesion) that further complicates bowel care. To date, bowel-related QoL has been studied using a variety of methods, making comparisons difficult, and few studies address the impact of bowel care-induced AD. We conducted a literature review to examine current evidence regarding the impact of bowel dysfunction and (bowel care-induced) AD on the QoL of individuals with SCI. In this systematic review, five databases (Pubmed, Web of Science, CINAHL, PsychINFO, and EMBase; March 2021) were searched to identify peer-reviewed articles assessing the influence of neurogenic bowel dysfunction or AD on QoL after SCI. Two independent reviewers screened titles, abstracts, and then full-text articles, for inclusion. QoL data were extracted and QoL measures classified as validated or unvalidated. Our search identified 1,375 unique titles, of which 65 met inclusion criteria after review of the titles/abstract/full text. Of the studies included, 44 used validated QoL measures while 21 used unvalidated measures. The Neurogenic Bowel Dysfunction (NBD) Score measures the severity of bowel dysfunction and bowel care-associated QoL for individuals with SCI, and was used by 3 papers. The weighted average of the NBD score from 454 individuals was 9.4 ± 5.1 (mean ± standard deviation) or ''Minor-Moderate'' severity. Twelve studies measuring the influence of AD on QoL were identified, revealing an adverse impact of AD on QoL, and highlighting that the impact of AD on QoL is not well represented in the literature. Our results provide an aggregate view into the complex relationships between bowel dysfunction, AD, and QoL. Ultimately, these insights will enable better identification of lynchpin concerns in bowel management to improve QoL for those living with these devastating secondary complications of SCI.

Effects of chronic pelvic pain on ambulatory heart rate variability in women Background: Chronic pelvic pain (CPP) is associated with decreased cardio-vagal modulation. Specifically, our prior research showed a healthy control (HC) group had greater HF-HRV (i.e., vagal mediated HRV) compared to the interstitial cystitis/bladder pain syndrome (IC/ BPS) group during both supine and upright positions in a laboratory environment. In contrast, women with myofascial pelvic pain (MPP) did not demonstrate the same reduction in HF-HRV as in IC/BPS. Objective: The present study utilizes ambulatory physiological methods to determine if individuals with CPP show diminished vagal activity, marked by lower HRV, in home environments similar to our laboratory observations. Methods: Our preliminary analysis includes a total of 26 female subjects (9 MPP, 3 HC, 14 IC/BPS). High frequency HRV (0.15-0.4 Hz) was derived by autoregressive spectral analysis of the Faros' continuous ECG recording of heart rate while subjects were in their home. First, participants completed supine rest for 10 min (supine 1), followed by another supine rest of 5 min (supine 2), followed by an upright position (standing) for 5 min. Results: Pre-planned t tests showed higher resting HF-HRV in the HC group relative to both the MPP and IC/BPS group during supine 1 (MPP vs. HC: t (10) = -1.98, p = 0.038; HC vs. IC/BPS: t (10) = -2.51, p = 0.012) and supine 2 (MPP vs. HC: t (10) = -2.14, p = 0.029; HC vs. IC/BPS: t (10) = -2.28, p = 0.019) positions. Differences in HF-HRV were slightly attenuated in the upright position (MPP vs. HC: t (10) = -2.14, p = 0.168; HC vs. IC/BPS: t (10) = -1.85, p = 0.042) positions. Conclusion: This preliminary analysis replicates our prior study and extends diminished vagal activity in individuals with CPP to everyday life. In contrast with our prior study, these data do not demonstrate a difference between IC/BPS and MPP groups, however, the sample size in the current analysis is significantly smaller. Overall, this preliminary analysis highlights parasympathetic activity as key mechanism in understanding abnormal self-regulatory function in CPP. Background: Hypothalamic and brainstem pathways, particularly the leptin melanocortin system, regulate energy balance through adjustments in autonomic efferent activity. Disordered regulation of the system predisposes to obesity and obesity-associated arterial hypertension. We applied high-resolution subcortical functional magnetic resonance imaging (fMRI) to test whether short-term increase in energy intake elicits functional connectivity changes between and within hypothalamus and brainstem nuclei in human beings. Methods: We submitted 20 subjects (7 women, 26.7 ± 8 years; 22.6 ± 2 kg/m 2 ) to 5 days hypercaloric (25% increase of energy intake by fat) or normocaloric diets in a randomized crossover fashion with a washout period between interventions. We obtained high resolution brainstem and hypothalamus fMRI (3 T PET/MRI, Siemens mMR Biograph). Then, we applied masked independent component analysis for resting state measurements and defined functional connectivity changes using dual regression between and within relevant regions. Results: We observed significantly decreased functional connectivity after hypercaloric compared to normocaloric diet. In particularly, connectivity decreased between hypothalamic regions involved in metabolic regulation such as ventromedial and arcuate nuclei, mamillary bodies, and lateral and posterior hypothalamic areas. In the brainstem, functional connectivity decreased between rostral ventrolateral medulla and the inferior olive; two regions involved in sympathetic regulation. Moreover, connectivity decreased between hypothalamus and brainstem involving several nuclei: ventromedial, arcuate and supraoptic nuclei in the hypothalamus; as well as the solitary, raphe and inferior olivary nuclei in the brainstem. Conclusion: We conclude that several days hypercaloric dieting produces significant resting state functional connectivity changes within and between hypothalamus and brainstem areas known to regulate efferent autonomic activity. The methodology may have utility in elucidating how metabolic and cardiovascular autonomic control are integrated in human beings and how perturbed regulation contributes to cardiometabolic disease.

The effect of low dose morphine on cardiovascular responses during simulated hemorrhage in humans Hemorrhage is a leading cause of preventable death in pre-hospital settings. Morphine is recommended as an analgesic in such a setting. While morphine reduces hemorrhagic tolerance in anesthetized animals, it is unknown whether morphine impairs hemorrhagic tolerance in humans. Purpose: The purpose of this investigation was to test the hypothesis that morphine administration in conscious humans impairs hemorrhagic tolerance. Methods: Sixteen adults (7 females/9 males; age: 30 ± 6 years; body mass index: 27 ± 3 kg m -2 ; BP: systolic 122 ± 9, diastolic 75 ± 9 mmHg) completed this randomized, crossover, placebo-controlled trial during two visits to the laboratory (IRB approval identifier: STU-092017-070). We administered morphine (5 mg; based on US Army guidelines) or placebo (saline) intravenously one minute before eliciting progressive central hypovolemia via lower-body negative pressure (LBNP)-a validated model of human hemorrhage. The LBNP protocol started at 40 mmHg and increased by 10 mmHg every three minutes until the participant reached pre-syncope. We compared tolerance to simulated hemorrhage, quantified as the cumulative stress index (LBNP [mmHg] Á time [minutes]), between trials using a Wilcoxon matched-pairs signed-rank test and present data as median with interquartile range. We measured brachial artery blood pressure (BP) via automated auscultatory analysis, heart rate (HR) via ECG, and muscle sympathetic nerve activity via radial microneurography throughout both trials. To compare the resultant data, we used twoway repeated-measures ANOVAs with main factors of time (pre-infusion, post-infusion, LBNP 40, 50, and 60) and trial. Conclusions: These preliminary data suggest that morphine administration reduces tolerance to simulated hemorrhage in conscious humans. These results suggest that 5 mg of morphine reduces an individual's capability to tolerate a hemorrhagic insult and, therefore, should be carefully considered when used for pre-hospital trauma care. Rapid changes in heart rate (HR) at the onset of volitional exercise reflect changes in cardiovagal influence. Neuroimaging data suggest that this response involves changes in activation patterns within a network of sites located in the brainstem and supramedullary regions, particularly reduced activity in the medial prefrontal cortex (MPFC). However, a specific role of this region in cardiovagal activity remains difficult to validate in humans. The present study investigated the effect of direct electrical stimulation of the MPFC and orbital frontal Clin Auton Res cortex (OFC) on the transient HR response to brief bouts of isometric handgrip (IHG) task, testing the hypothesis that stimulation of the MPFC and OFC (i.e., preventing the normal reduction in activity) diminishes the cardiac response to voluntary IHG exercise. We studied seven patients with refractory epilepsy (3 female) aged 38 ± 12 years, who were implanted with intracranial electrodes for seizure onset localization. Patients remained seated for the duration of the study, and were monitored for respiration, HR, and continuous stereo electrocorticography. After calibration of maximal voluntary contraction (MVC) strength, each patient completed a series of 2-s IHG contractions at 50% MVC during simultaneous electrical stimulation (50 Hz, 300 ls pulse duration, 4-5 mAMP). Stimulated electrodes varied by hemisphere implanted (4 left, 3 right), and the number of electrodes stimulated for clinical study. HR responses were compared to either: (1) sham-stim IHG trials randomized with stim trials, or (2) baseline IHG trials performed before and following the stimulation period. HR data were obtained immediately before, and for two-seconds following each contraction. We found that sham-stim and baseline IHG contractions increased HR by D4.8 ± 2.9 bpm (80.4 ± 8 to 85.2 ± 11), compared to an attenuated HR response of D1.4 ± 2.9 bpm (81.7 ± 11 to 83.3 ± 11) during stimulation (P \ 0.01). These findings support previous neuroimaging and animal studies implicating the OFC/mPFC regions in the cortical autonomic network and further suggest that retention of high activity of these prefrontal regions attenuates the transient cardiovagal withdrawal response to IHG exercise. The main role of the dorsolateral prefrontal cortex (dlPFC) is to perform executive functions, with lateralisation occurring between the right and left sides. Moreover, through its interactions with the ventromedial prefrontal cortex (vmPFC), the dlPFC is known to regulate emotions. Indeed, brain imaging studies have revealed a link between the vmPFC and the generation of SSNA, which is elevated in states of emotional arousal or anxiety. However, no studies have been conducted to explore how the dlPFC influences SSNA. Thus, we sought to examine the effect of stimulating the right or left dlPFC on the generation of SSNA in healthy participants (age range 21-38 years). SSNA was recorded from cutaneous fascicles of the common peroneal nerve using microneurography. To investigate how the dlPFC modulates SSNA, transcranial alternating current stimulation was utilized. This involved applying low-frequency sinusoidal stimuli (-2 to 2 mA, 0.08 Hz, 100 cycles) to the left or right dlPFC, and nasion. Subsequently, SSNA modulation was evaluated by calculating the modulation index for each stimulation paradigm, by extracting negative-going spikes of the raw nerve recordings and constructing crosscorrelation histograms between the spikes and the sinusoidal stimulus. This study was approved by the Human Research Ethics Committee of Western Sydney University (research protocol H11010) and conformed to the Declaration of Helsinki. The results revealed statistically significant modulation of the dlPFC on SSNA (p \ 0.01). However, there was no significant difference in the median modulation index when comparing stimulation of the left (n = 12) and right (n = 21) dlPFC, 14.0% and 9.2%, respectively (p = 0.34). Primary and secondary peaks were observed within a sinusoidal cycle in crosscorrelation histograms depicting dlPFC stimulation and SSNA. Moreover, left dlPFC stimulation displayed clearer distinction between the primary and secondary peaks than the right side (83% vs. 43%, respectively, p = 0.03). Overall, the results revealed that SSNA was modulated by dlPFC simulation. However, there were no significant differences between stimulating the left or right dlPFC on SSNA modulation. This modulation may have occurred through dlPFC's connectivity to the vmPFC, which is implicated in emotion regulation. Epworth score for diurnal somnolence, sweating: 1. Hyperhidrosis disease severity scale (HDSS) for interference with daily activities (score 1 = never, 2 = sometimes, 3 = frequently, 4 = always). Patients were allocated in a group of mild/moderate (score 1, 2) and a group of severe sweating (score 3, 4). 2. The basic Nordic Sleep questionnaire for frequency scale of nocturnal sweating (score 1 = never or seldom, 2 = less than 1 a week, 3 = once or twice a week, 4 = 3-5 times a week, 5 = every day. Patients were allocated in a group with infrequent sweating (score 1, 2, 3) and a group of frequent sweating C 3 times a week (score 4, 5). Results: 1. HDSS: 17 patients (28.3%) reported severe sweating interference, this group showed a higher Epworth score compared with the group of 43 patients with mild/moderate sweating interference. 2. Nordic Sleep: 8 patients (13.3%) reported frequent night sweating and showed higher BMI and Epworth score compared with the group of 52 patients with infrequently sweating. In the group of infrequent night sweating, the mild-moderate and severe grading OSA were 48.8% and 51.2% respectively, while in the group of frequent nocturnal sweating the mild-moderate and severe OSA were 41.2% and 58.8%, respectively (p [ 0.05 Chi-square). Polysomnography: AHI and minimal O 2 saturation did not show relationship with increased sweating scores (HDSS and Nordic sleep evaluations). Arousal index was higher in patients with frequent compared with seldom night sweating group (Nordic sleep). Conclusion: Severe interference with daily activities due to hyperhidrosis and frequent night sweating in men OSA patients, were associated with excessive diurnal somnolence. BMI and arousal index were higher in patients with frequent night sweating. OSA severity was not associated with sweating complaints. Introduction: Chronic use of hormonal contraceptives (HCs) is associated with increased resting blood pressure without alterations in muscle sympathetic nerve activity (MSNA). Whether this is secondary to increased sympathetic transduction to blood pressure (BP) has not been examined. Purpose: We tested the hypothesis that young women using HCs would display augmented increases in BP following spontaneous bursts of muscle sympathetic nerve activity (MSNA) at rest compared to naturally cycling women (NAT). Methods: Women were tested during the placebo phase (HC; n = 7, 22 ± 3 year, 21 ± 2 kg/m 2 , 109 ± 9/68 ± 7 mmHg) or the early follicular phase (NAT; n = 5, 21 ± 2 yr, 23 ± 4 kg/m 2 , 106 ± 11/ 66 ± 12 mmHg) to minimize the potential impact of changes in sex hormones on sympathetic regulation of BP. R-R interval (electrocardiography), beat-by-beat BP (finger photoplethysmography) and MSNA (peroneal microneurography) were measured during 10 min of supine rest. Signal averaging was used to characterize changes in BP for the 10 cardiac cycles following spontaneous MSNA bursts. Data are presented as mean ± SD. Results: Neither resting mean arterial pressure (MAP; HC: 82 ± 7 vs. NAT: 80 ± 11 mmHg, P = 0.71), heart rate (HC: 69 ± 7 vs. NAT: 77 ± 13 bpm, P = 0.24), nor MSNA at rest (HC: 5 ± 2 vs. NAT: 7 ± 4 bursts/min, P = 0.48; HC: 8 ± 3 vs. NAT: 9 ± 5 bursts/100 heart beats, P = 0.67) were different between groups. Following spontaneous MSNA bursts, MAP increased over the subsequent 10 cardiac cycles in both groups (Time: P \ 0.001, Group: P = 0.10, Interaction: P = 0.99). However, the peak increase in MAP was not different between groups (HC: D 3.0 ± 0.5 vs. NAT: D 3.5 ± 1.6 mmHg, p = 0.44). Conclusions: These preliminary data indicate that spontaneous bursts of MSNA do not elicit greater increases in BP in young women using hormonal contraceptives, suggesting that heightened sympathetic transduction to BP may not contribute to the association between hormonal contraceptive use and future hypertension. Background and objective: After heart transplantation, the neurogenic regulation of the heart rhythm disappears, whereas the vasomotor regulation in the postoperative period has been insufficiently studied. Occlusal plethysmography (OP) allows assessing vascular neurogenic response but its technical implementation is rather complicated. Contactless approach to the reactivity evaluation using imaging plethysmography (IPPG) may facilitate wider adoption of this technique in clinical and scientific practice. The aim of our study was assessing musculocutaneous blood-flow reactivity in response to cold stress and deactivation of cardiopulmonary baroreceptors (CPBR) by OP using two techniques: classical air-plethysmograph and IPPG. Materials and methods: We examined 13 patients with terminal heart failure (THF) aged 45.5 ± 15.2 years at the time of inclusion and 12 healthy volunteers of comparable age of the control group. Before and during 12 months after the surgery, the blood-flow response to cold stress and deactivation of cardiopulmonary baroreceptors (CPBR) was assessed in a forearm using a low body negative pressure chamber (LBNP -20 mmHg). Registration of blood flow dynamics was performed by occlusion plethysmography (OP) using airplethysmograph by Dohn and contactless IPPG. Results: Significant decrease in blood flow response to cold vasoconstriction was observed in patients with THF compared to the control group: 0.02 ± 0.33 vs. 0.35 ± 0.12 rel.un., P \ 0.01. Similarly, a decrease in CPBR deactivation was also found: 0.09 ± 0.08 vs. 0.31 ± 0.08 rel.un., P \ 0.001. After heart transplantation, bloodflow reactivity was increased in response to cold stress up to 0.22 ± 0.12, P \ 0.01, whereas there was no increase in response to LBNP: 0.16 ± 0.12; P = 0.54. It is worth noting that the blood flow reactivity measured by air plethysmography and IPPG correlated with each other: r = 0.68, p = 0.02 in the cold test and r = 0.57, p = 0.05 with CPBR deactivation. Conclusion: Patients with THF show a significant decrease in vasomotor reactivity in response to cold stress and deactivation of CPBR, which is partially restored after heart transplantation. Vascular reactivity can also be assessed using the simple, contactless, and easy-touse IPPG method. Background: Lewy body diseases (LBDs) are aging-related neurodegenerative disorders characterized by intra-neuronal deposition of the protein alpha-synuclein and by deficiencies of the catecholamines dopamine and norepinephrine in the brain and heart. Previously, computational analysis of a model consisting of a system of 9 coupled first-order parametrized linear ordinary differential equations (ODEs), accounting for 17 reactions, revealed abnormalities of catecholamine synthesis, vesicular storage, and neuronal recycling in LBDs. Methods: To investigate the progression of catecholamine depletion in LBDs we constructed a substantially updated model with a system of 11 coupled first-order parameterized nonlinear ODEs and 25 reactions. The model incorporates autotoxicity from the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). DOPAL augments vesicular leakage and inhibits tyrosine hydroxylase (TH), Laromatic-amino-acid decarboxylase, and vesicular uptake of cytosolic catecholamines. We investigated the model using the numerical continuation and bifurcation methods. Model predictions were compared with longitudinal trends in myocardial 18 F-dopamine-and putamen 18 F-DOPA-derived radioactivity (respective biomarkers of cardiac norepinephrine and striatal dopamine stores), post-mortem myocardial catecholamine contents, and effects of hypofunctional genetic mutations in preclinical studies. Results: The model generated a triphasic curve for the loss of vesicular intra-neuronal norepinephrine stores. Longitudinal neuroimaging data in the heart and putamen of LBD patients fit this pattern. Post-mortem myocardial norepinephrine was drastically decreased (by 91% from control), as predicted. The model also predicted correctly that genetically decreased ALDH or VMAT2 activity would hasten the decline in catecholamine stores, while decreased MAO activity would retard the decline, in line with empirical data from animal studies. Conclusion: We present a computational model that predicts a triphasic progression pattern of catecholamine deficiency in LBDs and accounts for modulatory effects of specific genetic predispositions. Combining computational modeling with clinical laboratory data to detect preclinical disease may enable individualized predictions about disease progression and target specific intra-neuronal dysfunctions for disease-modifying interventions in LBDs. Introduction: Our laboratory has reported that experimental, 24-h sleep deprivation elicits sympathoexcitation in women when compared to men. However, the role of habitual total sleep time (TST) on muscle sympathetic nerve activity (MSNA) has not been adequately examined. In the present study, we hypothesized that a reduction in objective, actigraphy-based TST would be associated with increased MSNA in both men and women, and that this relationship would be stronger in women compared to men. Methods: TST was determined via at-home wristwatch actigraphy (Actiwatch Spectrum Pro, Philips Respironics) recorded for a minimum of seven days in 48 healthy participants (23 male, 25 female, 35 ± 3 years, 27 ± 1 kg/m 2 ). Additionally, participants completed an in-laboratory morning autonomic function test that assessed MSNA via intraneural recording (microneurography) during a 10-min resting supine baseline. Partial correlations were utilized to determine the association between TST and MSNA burst frequency, burst incidence, and sympathetic baroreflex sensitivity (sBRS). All partial correlations included age and BMI as covariates. Results: Contrary to our initial hypothesis, actigraphy-based TST was not associated with MSNA burst frequency (r = -0.128, p [ 0.05), or burst incidence (r = -0.197, p [ 0.05). Furthermore, actigraphybased TST was not associated with sBRS (r = 0.057, p [ 0.05). When evaluating the role of biological sex, women had a higher actigraphy-based TST compared to men (433 ± 6 vs. 407 ± 8 min, p = 0.008). However, sex did not appear to influence the relationship between TST and either baseline MSNA or sBRS (all p [ 0.05). Conclusion: In summary, habitual TST does not appear to be significantly related to MSNA in healthy adults. Funding: National Institutes of Health (AA-024892; HL098676; HL122919).

Autonomic dysfunction in Ehlers-Danlos syndrome: how do microcirculatory and sensory profiles contribute?

J. Gierthmu¨hlen, J. Forstenpointner, R. Baron Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital of Schleswig-Holstein, Kiel, Germany Introduction: Hypermobile Ehlers-Danlos syndrome (EDS) is characterized by joint hypermobility and skin hyperextensibility, somatosensory and autonomic dysfunction. Pain is a frequent symptom and it is still discussed whether small-fiber dysfunction or central sensitization as a consequence of persistent nociceptive input caused by excessive joint stress is the major mechanism of pain. Since autonomic nerve fibers belong to the small-nerve fibers, the aim was to explore senso-vascular profiles by autonomic, microcirculatory and sensory testing. Methods: Five female patients with hypermobile Ehlers-Danlos syndrome (mean age 29.2 ± 22.1, years, range 12-60 years, three generations] were investigated with 30 min tilt table, heart rate variability (HRV), cutaneous vasoconstrictor test (CVC), thermal sensory testing and C-fiber/endothelial microcirculation using functional laser speckle contrast analysis (LASCA, PeriScan PIM 3, Sweden). Results: Autonomic testing revealed a severe postural tachycardia syndrome (POTS) in the 12-year old and marginal findings for POTS in one 16-year old (both are hereafter referred to as POTS patients), but otherwise normal findings at tilt table testing. HRV and CVC were normal in all five patients. fLDF showed concordant with tilt table testing a microcirculatory perfusion enhancement in the two patients with POTS (n = 2, 380% [± 42%]) as compared to patients with no POTS (n = 3, 134% [± 29%]). QST revealed a dysfunctional processing of somatosensory information in 4/5 patients with no characteristic sensory profile, although the patients with POTS showed loss of function for A-delta-fibers or central pathways. Conclusion: Since even the young patients (12, 16 and 16 years) had abnormalities upon thermal testing who did not complain of joint pain so far, results suggest that an underlying small-fiber dysfunction due to e.g. an impaired supply of vasa nervorum rather than central sensitization as a consequence of persistent nociceptive input plays a major role in pain in EDS. The loss of somatosensory function in both patients with POTS might point towards an additional dysfunction of autonomic nerve fibers. Indeed, results indicate an increased elasticity of vascular terminals in patients with POTS. The evidence of a functional microcirculatory impairment, with respect to the underlying pathophysiological mechanism in POTS, may be an explanation for the autonomic dysfunction. Neuromodulation provides a whole range of alternative approaches to anti-hypertensive medications. However, the potential of non-invasive vagus nerve stimulation remains largely untapped, despite evidence that it activates cardiovascular centres in the brain and improves autonomic blood pressure control in healthy populations. Anatomical evidence suggests the cymba concha region of the ear is 100% innervated by the vagus nerve and yet the tragus region (45% innervation) continues to be targeted in most vagus nerve stimulation trials. In this study, we aimed to determine the optimal stimulation site for modulating the autonomic nervous system in healthy individuals, in order to inform future clinical studies in hypertensive patients. We measured blood pressure, ECG, respiration, and muscle sympathetic nerve activity (MSNA) in healthy males and females during transcutaneous vagus nerve stimulation (30 Hz) at the ear. Using stimulation periods of 15 min, we compared three sites: cymba concha, tragus and earlobe (sham). Our preliminary results (n = 5) indicate that the cymba concha region is more effective than the tragus because it is associated with greater reductions in heart rate (-Clin Auton Res 5 ± 2 vs. -2 ± 2 beats/min) and larger increases in heart rate variability (DRMSSD 11 ± 6 vs. 8 ± 7) indicative of greater vagal outflow. Blood pressure remained relatively constant because of a compensatory 18 ± 2% rise in MSNA, which increases peripheral resistance. However, we hypothesise that in individuals with very high resting sympathetic nerve activity, such as hypertensive patients, there is a ceiling effect that prevents a rise in MSNA. Without this mechanism to counteract it, the drop in heart rate should drive a fall in blood pressure in these patients. This study provides initial indications that the cymba concha region may be more effective in improving autonomic function. Further work will be done to test this hypothesis in a larger group in which bilateral vagus nerve stimulation will be explored.

Insomnia symptom severity is associated with increased muscle sympathetic nerve activity in chronic insomnia Introduction: Chronic insomnia is a highly prevalent sleep disorder associated with numerous comorbidities including cardiovascular disease and hypertension. We have previously reported that individuals with chronic insomnia experience reduced sympathetic baroreflex sensitivity (sBRS) and augmented muscle sympathetic nerve activity (MSNA) reactivity to cold pressor test. However, the impact of symptom severity on sympathetic dysfunction remains unknown. The purpose of the present study was to examine the association between subjective symptom severity and baseline MSNA in individuals with chronic insomnia. We hypothesized that more severe insomnia symptoms would be associated with elevated baseline MSNA, and greater reductions in sBRS and cardiovagal baroreflex sensitivity (cBRS). Methods: Symptom severity was assessed using the validated Insomnia Severity Index (ISI) in 18 participants with clinically diagnosed chronic insomnia (4 male, 14 female; 40 ± 4 years; 24 ± 1 kg/m 2 ). Participants underwent a morning autonomic function test consisting of simultaneous recording of muscle sympathetic nerve activity (MSNA, microneurography), beat-to-beat blood pressure (finger plethysmography and sphygmomanometer), and heart rate (electrocardiogram) during a 10-min supine baseline. Partial correlations were used to assess the association between ISI and neurohemodynamic parameters while controlling for age, which strongly influences MSNA. Results: Insomnia symptom severity was positively associated with baseline MSNA burst frequency (r = 0.597, p = 0.01) and burst incidence (r = 0.519, p = 0.03). In contrast, ISI was not associated with systolic arterial pressure (r = -0.042, p [ 0.05), diastolic arterial pressure (r = 0.182, p [ 0.05), sBRS (r = -0.319, p [ 0.05), or cBRS (up-up sequence, r = 0.212, p [ 0.05; down-down sequence, r = 0.263, p [ 0.05). Conclusion: In summary, clinically diagnosed insomnia participants with more severe insomnia symptoms exhibit augmented baseline sympathetic activation compared to those with moderate insomnia. Sympathetic hyperactivity may act as a key mechanistic underpinning behind the relationship between insomnia and cardiovascular dysfunction, with insomnia symptom severity acting as a mediator of this relationship. Funding: Support is provided by Merck Investigator Initiated Studies Program (MISP).

Autonomic testing in paragangliomas of the head and neck R.X. Domı´nguez-Vega, M.E. Briseño-Godínez, K. Cárdenas-Soto, S. Mier y Terán, A. González-Duarte Neurology Department, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico Introduction: Paragangliomas of the head and neck have an incidence of 1:30,000, accounting for 3% of all paragangliomas. Common localizations are carotid body, jugular, tympanic and vagal and are more common in women of 40-50 years. The clinical presentations depend on the tumor location, generally presents as a painless, slowly enlarging cervical mass and can be unilateral or bilateral. Neurologic deficits of cranial nerves VII, IX, X, XI, and XII can be presented. Complete tumor excision is considered the treatment of choice, complication rates vary significantly based on tumor size, localization, and vessel involvement. Normal cardiac rhythmicity of muscle sympathetic nerve activity is lost following baroreceptor denervation. The clinical syndrome of baroreflex failure is characterized by recurrent episodes of unrestrained sympathetic excitation manifesting severe hypertension, headache, and diaphoresis. This complication is common in bilateral carotid body tumor resection. There are not studies that assess the autonomic findings before resection of a paraganglioma in the head and neck. Methods: This is a prospective study of patients that evaluated autonomic testing at our institution from November 2020 to date, for paraganglioma of head and neck. They underwent to formal autonomic testing before and after unilateral resection. Results: We followed six women, age 44-64 years, three with bilateral paragangliomas and three with unilateral paragangliomas. Presurgical autonomic testing: all had alteration in at least one test; two in parasympathetic cardiovagal regulation, three in sympathetic adrenergic vascular regulation and one patient dysfunction in both areas. In the assessment within the first month after surgery; one patient had a normal test, one patient had failure in cardiovagal regulation, four had dysfunction in sympathetic adrenergic vascular regulation. These patients are following and will be evaluated at 3, 6 and 12 months after surgery. Conclusion: Autonomic alterations before resection of paraganglioma may be associated with mechanic compression of the baroreceptor due to the tumor. Therefore, it is essential to know the basal autonomic state and evaluate function after surgery due to possible complications in patients with unilateral resection, because this could be an important cause of morbidity in these patients.

Human dorsal root ganglion stimulation reduces sympathetic outflow and long-term blood pressure We demonstrated previously that deep brain stimulation (DBS) can modulate sympathetic nerve activity and hemodynamic variables in humans. To investigate whether stimulating the dorsal root ganglion (DRG), an accepted treatment for chronic pain, with lower risk than DBS, would alter sympathetic nerve activity and hemodynamic variables, we directly recorded sympathetic nerve activity (MSNA) during ON and OFF stimulation of the DRG whilst evaluating pain and measuring blood pressure (BP) and heart rate (HR). DRG stimulation significantly reduced the firing frequency of sympathetic nerves, with greater reductions evident when DRG stimulation was left-sided. MSNA burst frequency was reduced by 13.3% (n = 14, p \ 0.0001). The decrease in sympathetic nerve traffic occurred independently of reduction in pain scores. Acute-and chronic BP measurements demonstrated that left-sided DRG stimulation significantly reduced BP but not right-sided stimulation, despite both leading to significant pain relief. The reduction in blood pressure was maintained at 2 years after implantation, and also improved the blood pressure in patients that were hypertensive prior to surgery. Heart rate remained unchanged. These findings raise the potential of DRG stimulation being used to treat de novo autonomic disorders such as hypertension or heart failure. (TTR) that accumulates as amyloid fibrils in multiple tissues and organs. Vutrisiran is an RNAi therapeutic in development for the treatment of ATTR amyloidosis by targeting liver-expressed variant and wild type TTR. Vutrisiran utilizes the Enhanced Stabilization Chemistry (ESC)-GalNAc platform designed to provide increased potency and high metabolic stability. In a Phase 1 study of healthy volunteers, a single dose of vutrisiran 25 mg subcutaneously (SC) resulted in 80% mean maximum reduction in serum TTR maintained for 90 days. Design/methods: HELIOS-A is a Phase 3, global, open-label study of vutrisiran 25 mg SC once every 3 months in patients with ATTRv amyloidosis with polyneuropathy (NCT03759379). Patients were randomized (3:1) to vutrisiran or patisiran, a reference comparator RNAi therapeutic approved for hATTR amyloidosis with polyneuropathy based on the APOLLO study. Randomization was stratified by TTR genotype (V30M vs. non-V30M) and baseline NIS score (\ 50 vs. C 50). The APOLLO placebo group (N = 77) serves as an external control for the primary and most secondary endpoints. Month 9 efficacy analyses include change from baseline in mNIS ? 7 (primary endpoint), Norfolk QOL-DN (secondary), and 10-m walk test (secondary), compared to APOLLO placebo group. Results: HELIOS-A enrolled 164 patients (122 [74.4%] vutrisiran, 42 [25.6%] patisiran) across 57 sites in 22 countries. Baseline demographics, the 9-month primary endpoint, secondary endpoints, and safety results will be presented. Conclusions: Vutrisiran has the potential to address a significant unmet need for patients with ATTRv amyloidosis with polyneuropathy by offering an additional treatment option. HELIOS-A will continue to investigate the efficacy and safety of vutrisiran through an 18-month treatment period and 18-month extension period. Introduction: Hereditary transthyretin-mediated (hATTR) amyloidosis, a rare, multi-systemic, life-threatening disease, causes neurologic and cardiac dysfunction, leading to impaired functional status and declining ability to perform activities of daily living (ADLs). Analysis of the impact of patisiran on ADLs and functional status in the Phase 3 APOLLO study are presented here. Methods: APOLLO was a randomized, placebo-controlled study of patisiran in patients with hATTR amyloidosis with polyneuropathy (NCT01960348). ADL/functional status assessments included: Rasch-built Overall Disability Scale (R-ODS), Karnofsky Performance Status (KPS), the ADL subdomain of Norfolk QOL-DN (Norfolk ADL). Post-hoc analyses quantified patients with no change/ improvement in these assessments at 18 months.

Objectives: To describe how the ongoing phase 3 ampreloxetine program was adapted during the global COVID-19 pandemic. Background: The pivotal ampreloxetine phase 3 program (NCT03750552, NCT03829657, NCT04095793) is designed to evaluate the safety, efficacy and durability of a novel, once-daily norepinephrine transporter inhibitor in patients with symptomatic neurogenic orthostatic hypotension. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic impacted patient safety and the ability to recruit and retain patients across studies due to restrictions about in-person visits. Here we describe the steps taken to adapt the trial to ensure the safety of this vulnerable population while maintaining data integrity and aligning with regulatory expectations. Methods: Interviews were conducted with investigators, key medical experts, and patient advocacy organizations to determine the best approach toward implementation of decentralization mid-study, taking into account emerging regulatory guidance. Feedback was also sought from FDA regarding decentralizing the studies. The protocol was amended to reflect the global infrastructure to support decentralization, including shipping the investigational product to the patient's home, a telemedicine platform for visits with the site staff, in-home healthcare for collection of safety measures, other in-person assessments, and a dedicated hand-held electronic tablet for patient-reported outcomes. The intention of decentralization was to replicate the in-clinic experience in the home setting. The same dedicated hand-held electronic tablets used in the clinic setting were taken into the patient home by the local home health nurses to standardize the collection of all patient reported outcomes. Local home health nurses were trained to acquire blood pressure during an orthostatic standing test, collect safety bloods/electrocardiogram, and assist the clinical investigators with administering the neurological and physical examinations. Clinical investigators underwent training to implement changes in the protocol procedures and local ethics and regulatory approvals were obtained. Conclusions: In response to the pandemic, the protocol was adapted to ensure patient safety and study integrity. The decentralized ampreloxetine program is an example of how a clinical trial can be designed (or adapted) to put patient well-being at the forefront while also facilitating enrollment and retention. Objective: Evaluate the cardiovascular safety, tolerability, and pharmacokinetics of ATH434. Background: ATH434 is a novel, brain penetrant small molecule inhibitor of a-synuclein aggregation. In transgenic mouse models of Parkinson's disease (PD; A53T) and Multiple System Atrophy (MSA; PLP-a-Syn), ATH434 reduced a-synuclein aggregation and markers of oxidative stress, preserved neurons, and improved motor function. ATH434 reduced glial cell inclusions (PLP-a-Syn). ATH434 is thought to act by redistributing labile iron across neuronal membranes. The affinity of ATH434 for iron is lower than for transferrin and ferritin. Design/methods: In this randomized, double-blind, placebo-controlled study, adults received single oral doses of ATH434 (8/cohort) at 50, 100, 300 or 600 mg or 8 days dosing (10/cohort) at 100, 200 or 250 mg bid. Older adults (C 65 years) received 250 mg bid for 8 days. Serial blood samples were collected post-dose and cerebrospinal fluid (CSF) was sampled at 200-250 mg bid at steady state. Safety was assessed with orthostatic vital signs, physical examination, adverse events (AEs), laboratory tests and 12-lead electrocardiograms. A concentration-effect analysis was performed to estimate the effect of ATH434 on the QT interval. Results: ATH434 was readily absorbed with a Tmax of 0.5-2 h and demonstrated dose-dependent pharmacokinetics after single and multiple doses. Mean elimination half-life up to 9.3 h was observed. CSF concentrations of ATH434 correlated with free plasma concentrations (r 2 = 0.72). AE rates were similar for ATH434 and placebo. All AEs were mild to moderate in severity (no serious AEs or AEs leading to discontinuation). The AE profile was similar for adults and older adults. There was no evidence of drug-induced orthostasis after single-or repeated-dose administration and no clinically significant vital sign, laboratory, or 12-lead electrocardiogram findings. A linear mixed-effects model predicted the DDQTcF to be \ 2 ms (90% UCL \ 4 ms) at the anticipated steady state Cmax. Conclusions: CSF concentrations of ATH434 strongly correlated with plasma levels and exceeded those associated with efficacy in animal models of PD and MSA. ATH434 was safe at all doses and did not promote orthostasis or QT prolongation. ATH434 is an orally bioavailable, brain penetrant, small molecule inhibitor of a-synuclein aggregation with potential to treat PD and MSA. Funding: Alterity Therapeutics Ltd.

Clinician perceptions on the design of a randomized controlled trial on cardioneuroablation for recurrent vasovagal syncope: results from an international clinician survey Background: Cardioneuroablation (CNA) for vasovagal syncope (VVS) targets the intrinsic cardiac autonomic nervous system sites located in the peri-atrial epicardial fat. There is increasing interest in CNA as treatment for VVS, despite no randomized clinical trial (RCT) data. Our aim was to gauge the support for an RCT among physicians who treat VVS. Methods: A REDCap Survey was administered to international physicians (from Europe, South/Central America and North America) who treat VVS patients to assess their opinions regarding CNA, patient selection criteria, the ablation approach, design of a RCT and most appropriate endpoints for CNA procedures. The study was approved by the Calgary Conjoint Health Research Ethics Board (REB20-1248). Results: The survey was completed by 188 physicians, of whom 86% were cardiac electrophysiologists. The majority of respondents (79%) would consider referring a refractory VVS patient for CNA, and 27% have performed CNA for VVS themselves. The median minimal clinical benefit that a RCT should show to refer a patient with VVS for CNA was 50% . A cardio-inhibitory response on head-up tilt testing was the preferred patient selection criterion (67%). Physicians with CNA experience would prefer to only refer patients for CNA if a cardioinhibitory response was present on HUT testing (84% vs. 58%, P = 0.02). The minimum median age to consider CNA was 18 years with a median of 3 (IQR 2-5) episodes in the past year, whereas the maximum median age was 60 years. The majority felt that the ablation strategy should include both atria (70%) with an anatomical approach in combination with autonomic stimulation (85%). Due to a possible placebo-effect, 56% of respondents suggested a sham procedure in the RCT control arm. The primary sham intervention of choice was an electrophysiological study or venous access with or without sedation (71%). The preferred primary outcome was freedom from syncope with 1 year follow-up (88%); only 46% would also include presyncope as outcome.

Conclusion: There is widespread support for properly designed RCTs to confirm the hypothesized clinical benefit of CNA, provide data to guide the risk-benefit equations during patient selection, and determine the placebo-effect size. 

Chewing-induced pressor response in acquired afferent baroreflex failure: a useful therapeutic intervention P. Millar Vernetti, H. Kaufmann Dysautonomia Center, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA Background: Patients with congenital afferent baroreflex failure (ABF) due to familial dysautonomia (HSAN-III) present chewinginduced hypertension. This pressor effect has not been reported in patients with acquired ABF (aABF) and could help alleviate symptomatic orthostatic hypotension. Objectives: To evaluate blood pressure (BP) and heart rate (HR) response to chewing in patients with acquired aABF. Methods: Two patients with aABF had their blood pressure (BP) and heart rate (HR) evaluated every 1 min during supine rest, head-up tilt/ active standing, while and after chewing. Results: Patient 1 is a 68-year-old man with a 4 year history of aABF, with an onset 3 years after receiving right-sided neck radiotherapy. Average blood pressure in the supine position was 142/85 mmHg with a HR of 74 beats per minute (bpm). After 10 min of upright tilt, BP was 83/38 mmHg with HR of 82 bpm, asymptomatic. After 5 min of chewing gum, his BP rose to 141/71 mmHg with a HR of 96 bpm, reflecting a 70% increase in systolic BP. After stopping chewing, BP dropped to 96/45 mmHg, with a HR of 90 bpm. Patient 2 is a 74-year-old man with a 3 year history of aABF, manifesting after 9 years of neck radiotherapy. During supine rest, his average BP was 173/87 mmHg with a HR of 52 bpm. After 5 min of active standing, BP dropped to 125/69 mmHg with a HR of 50 bpm. While chewing gum, blood pressure increased to 139/77 mmHg, with a HR of 51 bpm, reflecting an 11% increase in systolic BP. After stopping chewing, BP dropped to 107/70 mmHg and HR 50 bpm. Conclusions: Chewing can help alleviate orthostatic hypotension in patients with aABF. Chewing prevented further reduction in blood pressure during orthostatic stress by inducing a progressive and sustained increase in BP and HR in both patients. The effect was transient and reverted after stopping chewing. Further clinical trials are required to assess the efficacy of this intervention in symptomatic orthostatic hypotension in patients with aABF.

Nociceptor-mediated impairment in spontaneous sympathetic baroreflex sensitivity and the potential for improvement via epidural spinal cord stimulation in chronic low back pain Methods: Sympathetic BRS was determined as the slope of the weighted linear regression between spontaneous changes in MSNA (peroneal microneurography) and beat-to-beat diastolic BP (finger photoplethysmography) at rest and during stimuli. Study 1: Sympathetic BRS was compared between patients with CLBP that previously underwent thoracic SCS implantation (n = 3) and controls without CLBP matched for age, sex, and BMI. In CLBP patients, SCS was activated for 60 min following resting baseline measures. Study 2: To examine the extent to which nociceptor activation impairs sympathetic BRS, a 2-min cold pressor test was performed in 18 healthy adults without CLBP. Results: Study 1: As expected, sympathetic BRS was significantly reduced in CLBP patients compared with matched controls (-1.0 ± 0.2 vs. -2.2 ± 0.2 bursts•100hb -1 •mmHg -1 , P \ 0.01). In CLBP patients, an increase in sympathetic BRS was observed within 15 min of SCS compared with baseline (-1.9 ± 0.6 bursts•100hb -1 •mmHg -1 , P = 0.06), but then declined (60 min: -0.4 ± 0.1 bursts•100hb -1 •mmHg -1 , P = 0.07 compared with baseline). Changes in sympathetic BRS during SCS were unrelated to ratings of pain (0-10 visual analog scale). Study 2: Nociceptor activation via 2-min cold pressor test in healthy adults significantly reduced sympathetic BRS (Baseline: -4.3 ± 2.3 vs. CPT: -1.2 ± 2.1 bursts•100hb -1 •mmHg -1 , P \ 0.001). Conclusion: These preliminary findings suggest that CLBP impairs sympathetic BRS similar to nociceptor activation in healthy adults without CLBP. Importantly, SCS may improve sympathetic BRS in CLBP, although increases in sympathetic BRS appear transient (* 15 min). These findings provide important insight to blood pressure regulation in states of chronic pain. Methods: We performed a retrospective chart review of all patients with a diagnosis of ABF who underwent standardized autonomic reflex testing between 2000 and 2020 at Mayo Clinic Rochester. Variables included demographic, all-cause mortality, medications, ABF manifestations, comorbidities, and laboratory (autonomic testing, thermoregulatory sweat test, blood pressure monitoring, echocardiogram, brain imaging, plasma catecholamines, serum sodium level and kidney function tests). The study was reviewed and approved by the Mayo Clinic institutional review board. Results: A total of 104 patients with ABF were identified. Head and neck radiation was the most common etiology (86.5%), followed by neck surgery (5.8%) and other causes (7.7%). The most common findings were hypertension (87.5%), fluctuating blood pressure (78.8%), orthostatic hypotension (91.3%), syncope (58.6%), headache (22.1%) and tachycardia (20.2%). Patients commonly received antihypertensives (66.3%), pressor agents (41.3%) or a combination of both (19.2%). The median latency from completion of radiation to ABF was longer compared to the latency in the surgery group (p \ 0.0001). Comorbidities, including complication from neck radiation, were frequently seen and all-cause mortality was 39.4% over a 20-year period. Autonomic profile was investigated in 90 patients with radiation-induced ABF. Median total composite autonomic severity score was 7 . Adrenergic impairment was seen in 85 patients (94.4%); increased blood pressure recovery time was seen in 71 patients (78.9%; median 17.4 s); neurogenic orthostatic hypotension was seen in 68 patients (75.6%). Cardiovagal impairment was demonstrated by abnormal heart rate responses to deep breathing (79.5%), Valsalva ratio (87.2%), and vagal baroreflex sensitivity (57.9%). Plasma norepinephrine was elevated and rose appropriately upon standing (722-1207 pg/mL). Blood pressure lability correlated with impaired vagal baroreflex function. Postganglionic sympathetic sudomotor function was normal in most cases, whereas the most frequent TST finding was focal neck anhidrosis (78.9%). Conclusions: ABF should be suspected in patients with prior head and neck cancer treated by radiation and/or surgery who present with labile hypertension and orthostatic hypotension. The morbidity and mortality in ABF patients are high. There is prominent adrenergic failure and paradoxically elevated plasma norepinephrine. Background: Vasovagal syncope (VVS) is the most common type of syncope and is usually considered a benign disorder, but the likelihood and severity of injuries due to a syncopal spell is unknown. We aim to determine the frequency, severity, and predictors of injuries due to syncope in cohorts of VVS patients. Methods: Participants were enrolled in the POST2 (fludrocortisone) and POST4 (midodrine) VVS randomized trials. Injury was defined as minor (bruising, abrasions), moderate (lacerations), and severe (fractures, burns, joint pain), and documented up to 1 year after enrollment. Results: A total of 344 patients (median 35 years) were analysed. A total of 673 faints occurred in 165 patients during a 1-year follow-up. Fully 47/165 (28%) of patients were injured with syncope (14% of overall group). There were 92 injuries associated with the 673 faints (14%), of which 16% were moderate or severe injuries. Females with syncope were more likely to be injured (Relative Risk 2.8, p = 0.008). Patients with C 4 faints in the prior year had more injuries than those with fewer faints (RR 3.7, p = 0.0001), but this was due to more frequent syncope, and not more injuries per faint. Pharmacological therapy significantly reduced the likelihood of an injury due to a syncopal spell (RR 0.64, p = 0.015). Injury severity did not associate with age, sex or prior year syncope frequency. Conclusion: Injuries are more frequent in VVS patients than previously thought. Clinicians should be aware of the risk of injuries when providing care and advice to VVS patients, injury avoidance should be emphasized with all patients. The predictors of injury in VVS, and how to reduce them still lack a thorough investigation. Funding: CIHR.

Evaluating the impact of syncope and presyncope on quality of life: a systematic review and meta-analysis Background: Syncope (transient loss of consciousness and postural tone) and presyncope are common manifestations of autonomic dysfunction that are usually triggered by orthostasis. While it is widely considered that quality of life (QoL) is impaired in patients with syncope and presyncope, there is a paucity of research evaluating the impact of these disorders on overall QoL and specific QoL domains. The availability of multiple QoL instruments to quantify impairment also makes it difficult to compare results across different studies. Methods: We conducted a systematic review and meta-analysis to assess the impact of orthostatic syncope/presyncope on QoL domains, identify literature gaps, and highlight future research needs. A comprehensive literature search of academic databases (MEDLINE (PubMed), Web of Science, CINAHL, PsycINFO, and Embase) was conducted (February 2021) to identify peer-reviewed publications that evaluated the impact of vasovagal syncope (VVS), postural tachycardia syndrome (POTS), or orthostatic hypotension (OH) on QoL. Two team members independently screened records for inclusion and extracted data. Results: From 12,258 unique records identified by the search, 35 studies met inclusion criteria (VVS: n = 19; POTS: n = 13; VVS and POTS: n = 1; OH: n = 2); across these studies, 12 distinct QoL instruments were used. QoL scores were compared between patients with syncope/presyncope and a control group in 16 studies; all reported significant QoL impairments in patients with syncope/ presyncope. Increased syncopal event frequency, increased autonomic symptom severity, and the presence of mental health disorders and/or comorbidities were associated with reduced QoL. The SF-36 (version 1) was the most frequently used instrument (14 studies). Physical (PCS) and mental (MCS) component summary scores for the SF-36 were available in 10 studies (5 VVS; 5 POTS). Patients with VVS (n = 939; PCS: 45.4 ± 9.8; MCS: 44.3 ± 12.9) and POTS (n = 524; PCS: 34.3 ± 10.5; MCS: 44.8 ± 10.6) exhibited significant reductions in PCS and MCS scores relative to US normative data (n = 2474; PCS: 50.0 ± 10.0; MCS: 50.0 ± 10.0; p \ 0.001) (mean ± standard deviation). PCS scores were significantly lower in patients with POTS than patients with VVS (p B 0.001). Conclusion: QoL is impaired in patients with orthostatic syncope/ presyncope across physical and mental health domains. This review synthesizes the impact of syncope/presyncope on QoL and identifies research priorities to reduce the burden of these debilitating disorders and improve patient QoL. Background: Autonomic neuropathy (AN) patients frequently experience multi-systemic symptoms, ranging from cardiovascular, urinary, secretory, and gastrointestinal (GI). Further, there is marked heterogeneity among patients, often limiting the yield of conventional diagnostic evaluations. The aim of this study was to describe our single-institution experience with wireless motility capsule (WMC) testing to quantitatively evaluate segmental dysfunction in AN patients with GI symptoms. Methods: We utilized an IRB-approved database to identify cases that presented to the University of Utah with undiagnosed GI and autonomic symptoms (2015-2019; n = 102). Inclusion criteria: AN diagnosis based on autonomic testing. Of the initial cohort, 29 subjects met inclusion criteria and were included in this analysis. WMC results were analyzed to identify abnormalities in gastric emptying, small bowel/colonic/global transit times, and contractions. Results: Subjects were predominately female (25/29); aged 17-62 years (median 29). Mean COMPASS-31 score was 54.4, with a mean GI domain score of 15.6. Overall, 25/29 subjects had dysmotility in at least one segment of the GI tract, with a mean of 2.0 segments affected. Of the 14/27 with one or more slow segments on WMC, 13 reported symptoms of constipation, while 8/8 of those with one or more rapid segments reported symptoms of diarrhea. Of subjects with abnormal sudomotor function, 11/20 (55%) showed corresponding anatomical segmental dysfunction in the GI tract on WMC testing. Conclusions: In this cohort of AN patients with prominent undiagnosed GI symptoms, 86% had abnormal WMC testing, and 55% reported symptoms that corresponded with their quantitatively documented motility pattern. These findings establish GI dysmotility as a quantifiable feature of AN with GI symptoms, and merit future studies to evaluate underlying pathophysiology. 

Background: Recurrent vasovagal syncope is common, responds poorly to treatment, and causes physical trauma and poor quality of life. Midodrine prevents hypotension and syncope during tilt tests in patients with vasovagal syncope. Objective: To determine whether midodrine can prevent vasovagal syncope in usual clinical conditions. Methods: This was a randomized, double-blind, placebo-controlled clinical trial conducted in 25 university hospitals in Canada, the United States, Mexico, and the United Kingdom. The patients had recurrent vasovagal syncope diagnosed by a structured history and no serious co-morbidities. Patients were randomized 1:1 to placebo or midodrine and followed for 12 months. The primary outcome measure was the proportion of patients with at least 1 syncope during follow-up. Results: The study included 133 patients who had a median of 6 syncopes in the prior year (median age 32 years, 73% female). When compared with patients taking placebo, fewer patients taking midodrine had at least 1 syncope (28 of 66 [42%] vs. 41 of 67 [61%]). The relative risk was 0.69 (95% confidence interval [CI] 0.49-0.97, p = 0.035). The absolute risk reduction was 19% (CI 2-36%) and the number needed to treat to prevent one patient from having syncope was 5.3 (CI 2.8-47.6). The time to first syncope was longer with midodrine (hazard ratio 0.59 (95% CI 0.37-0.96, p = 0.035, log rank p = 0.031). Side effects were similar in both groups. Conclusion: Midodrine can reduce the recurrence of syncope in healthy, younger patients with a high syncope burden. Background: Syncope is a common and challenging clinical condition. The high incidence of syncope that sometimes results in mortality incites for numerous high-cost extensive multidisciplinary investigations. The aim of this study is to investigate the difference between nine internal medicine wards in the use of diagnostic tests. This study looks into the amount of tests a patient undergoes whilst admitted and their correlation to mortality and readmission rates. Methods: The study was performed in a single center at Tel Aviv ''Sourasky'' Medical Center, and designed as a retrospective-observational study. The data was collected from electronic medical records, from January 2010 through December 2020. We identified 24,045 patients with a diagnosis of syncope (ICD-9-CM code 780.2) in admission or upon discharge from the ED (Emergency Department), selected using restringing criteria by applying in-text artificial linguistic program. We studied 7,435 patients that were only admitted to internal medicine departments. The relationship between the number of used diagnostic tests and their clinical outcomes was evaluated by applying logistic regression models for short term mortality and readmission rates. For statistical purposes, the nine internal medicine departments were divided into 3 groups (Tertiles), as high, medium or low testers based on the average tests performed per patient. Results: Both Logistic regression models demonstrated statistical significance (p \ 0.001). There was no difference found in odds for 30-day mortality between the different departments, i.e., tertiles.

Similarly, no difference in odds for readmission was found between High and Medium testing departments. However, odds for 30-day readmission rate in low testing departments was significantly higher than the medium testing departments (OR = 1.32, p \ 0.01). Importantly, no difference in odds of 30-day mortality was found between different departments. Conclusion: This is a further proof that the diagnosis of syncope requires a logistic personalized approach, that focuses on medical history and a few tailored diagnostic tests, with no need for multiple high-cost testing. This suggests that minimalistic personalized approach is associated with unaffected mortality and low costinvestigation.

Exaggerated postural sway improves orthostatic cardiovascular and cerebrovascular control Background: Syncope (fainting) is commonly provoked by motionless standing, whereby gravity redistributes blood away from the head and into the lower limbs, with associated venous pooling and capillary filtration that compromise effective circulating volume. Healthy nonfainting individuals with poor cardiovascular control adopt an innate strategy of increased leg movement in the form of postural sway that may serve to augment venous return; however, the direct effect of sway on cardiovascular hemodynamics and cerebral perfusion is unknown. Accordingly, we aimed to evaluate the impact of augmented sway on cardiovascular control. Methods: We tested twenty healthy adults (11 males) aged 25 ± 2 years. Following supine rest, participants performed a baseline stand (BL) on a force platform, followed by three trials of exaggerated sway (anterior-posterior, AP; mediolateral, ML; square, SQ) in a randomized order. Non-invasive beat-to-beat blood pressure (Finometer Pro), heart rate (electrocardiogram), and cerebral blood flow velocity (CBFv; transcranial Doppler) were measured continuously. Total peripheral resistance (TPR) was calculated as mean arterial pressure/cardiac output (Modelflow). Echocardiography (trans-thoracic view of left ventricular outflow tract) was performed in the last minute of each condition. Results: Exaggerated postural sway blunted orthostatic reductions in stroke volume (BL: -22.8 ± 3.1 ml; AP: -8.3 ± 2.9 ml; ML: -9.7 ± 3.0 ml; SQ: -8.5 ± 3.6 ml; p \ 0.01), maximum transvalvular flow velocity (BL: -1.4 ± 4.9 ms; AP: ? 6 ± 5.7 ms; ML: ? 11.1 ± 4.8 ms; SQ: ? 15 ± 4.6 ms; p \ 0.001) and CBFv (BL: -24.6 ± 2.9%; AP: -16.5 ± 2.1%; ML -15.9 ± 3.1%; SQ -16.6 ± 2.7%; p \ 0.05) compared to BL. Exaggerated sway also increased systolic arterial pressure (BL: ? 3.6 ± 2.5 mmHg; AP: ? 14.1 ± 2.6 mmHg; ML: ? 12.4 ± 2.9 mmHg; SQ: ? 17.1 ± 2.8 mmHg; p = 0.01) while reducing LF SAP (BL: ? 48.5 ± 4.2%, AP: ? 33.8 ± 3.7%, ML: ? 35.3 ± 4.0%, SQ: ? 32.6 ± 3.6%) and TPR (BL: ? 2.6 ± 0.7 mmHg min L -1 ; AP: ? 0.5 ± 0.9 mmHg min L -1 ; ML: ? 0.7 ± 0.6 mmHg min L -1 ; SQ: ? 0.9 ± 0.9 mmHg min L -1 ; p \ 0.05). We evaluated the net contribution of sway to cardiovascular control by quantifying the gain of the cardiovascular responses to sway using cross spectral analysis, multiplied by the total sway path length. The sway contribution to the maintenance of SAP (p \ 0.001), SV (p = 0.003) and CBFv (p = 0.03) increased in enhanced sway conditions compared to BL.

Conclusion: Exaggerated sway improved cardiovascular and cerebrovascular control compared to quiet standing. Sway may provide a simple means to boost orthostatic cardiovascular control for individuals with syncope, or those with occupations that require prolonged motionless standing. Funding: This work is supported by a grant from the Natural Sciences and Engineering Research Council of Canada.

Effects of short-term hypercaloric nutrition on orthostatic tolerance in healthy individuals: a randomized controlled crossover study Background: Reduced caloric intake lowers blood pressure through sympathetic inhibition and worsens orthostatic tolerance within days. Conversely, hypercaloric nutrition augments sympathetic activity and blood pressure. Because dietary interventions could be applied in patients with syncope, we tested the hypothesis that short-term hypercaloric diet improves orthostatic tolerance. Methods: In a randomized crossover trial, 20 healthy individuals (7 women, 26.7 ± 8 years; 22.6 ± 2 kg/m 2 ) followed a four-day hypercaloric (25% increase of energy intake by fat) or normocaloric standardized nutritional plan with an at least 23-day washout period between interventions. We then performed head-up tilt table testing with incremental lower body negative pressure while recording beatby-beat blood pressure and heart rate. The primary endpoint was orthostatic tolerance defined as time to presyncope. The study had [ 80% power to detect a 3-min improvement in orthostatic tolerance. Results: Time to presyncope during combined head-up tilt and lower body negative pressure did not differ between hypercaloric and normocaloric diet (median 1399 s vs. 1384 s, ratio of median 1.01, 95% CI of ratio 0.5439-1.879). Heart rate, blood pressure, heart rate variability, and blood pressure variability in the supine position and during orthostatic testing did not differ between interventions. Conclusion: We conclude that four days of moderate hypercaloric nutrition does not significantly improve orthostatic tolerance in healthy individuals. Nevertheless, given the important interaction between energy balance and cardiovascular autonomic control, caloric intake deserves more attention as potential contributor and treatment target for orthostatic intolerance.

One-none-done: is the autonomic nervous system involved in cardiac arrest in the young? Background: In approximately 50% of cardiac arrests in the young, no etiology is identified despite a thorough investigation, and the heart appears to be both structurally and electrically normal. During syncope, cardiovascular autonomic control switches from sympathetic activity (fight or flight response) to parasympathetic activity (resting conditions). This switch is not always seamless, and sometimes the body can utilize both pathways simultaneously (autonomic conflict). This phenomenon, which can potentially lead to cardiac arrest, has not been considered in the context of fainting. Methods: We aimed to investigate whether cardiac arrest survivors with known and unknown cause experienced syncope symptoms or known autonomic triggers immediately prior to their event. We conducted a case review of a national registry (CASPER) on cardiac arrest survivors \ 25 years of age, who only had one cardiac arrest, who had no abnormality despite comprehensive clinical testing, and who had no recurrent events. We compared the autonomic symptoms and situational triggers of their arrest to those in young adults who had a known genetic, structural or electrical cause for their cardiac arrest. Results: Our inclusion criteria yielded a sample size of 69 individuals, 22 (11 males) of whom had an identified cause of cardiac arrest, and 47 (31 males) of whom did not. Causes for explained cardiac arrest were long QT syndrome (n = 5), early repolarization syndrome (n = 4), Brugada syndrome (n = 2), cardiomyopathies (n = 5), and other (n = 6). Exercise was the main circumstance preceding the event for both those with explained (45.5%) and unexplained (36.2%, p = 0.79) cardiac arrest. There were similar associations with sleeping (explained, 4.5%; unexplained, 6.4%, p = 1.0) and quietly resting (22.7% and 21.2%, p = 1.0) at the time of the event. Significantly more individuals with explained cardiac arrest (31.8%) were able to identify a syncopal or presyncopal prodrome than with unexplained cardiac arrest (10.6%; p = 0.043). Conclusion: These preliminary results will improve understanding of the mechanisms and physiologic triggers of cardiac arrest in young people. Evaluation of the relationships between syncope, autonomic conflict, the autonomic nervous system, and cardiac arrest has yet to be considered and could provide insight into the mechanisms and triggers of previously unexplained cardiac events in the young.

Autonomic dysfunction in the setting of Moyamoya syndrome C. Nguma, E.P. Golden, S. Vernino Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA Case: A 44-year-old woman presented for evaluation of pre-syncope and syncope. She had presented to the inpatient neurosurgical service two years prior with intraventricular hemorrhage and bilateral watershed infarcts due to Moyamoya syndrome. She underwent right superficial temporal artery to middle cerebral artery bypass for revascularization. Subsequently she developed episodes of presyncope with standing, as well as frank syncopal episodes in the hospital. Orthostatic vital signs documented orthostatic hypotension. Workup: She underwent autonomic testing which showed severely impaired blood pressure response to Valsalva, supine hypertension with orthostatic hypotension (systolic 171-113 mmHg at 5 min of head up tilt) with preserved heart rate increment, and appropriate blood pressure response to cold pressor testing, a pattern suggestive of baroreceptor impairment. She was started on midodrine but had hypertension requiring dose reduction. Carbidopa was added for nausea and blood pressure lability (suspected hyperadrenergic mechanism) with good symptomatic response. Discussion: ''Moyamoya syndrome'' describes progressive narrowing of large intracranial arteries with the development of abundant small vessel collaterals. Autonomic dysfunction, including orthostatic hypotension and paroxysmal sympathetic activity, has occasionally been reported in Moyamoya syndrome, but the mechanism is not well understood. Labile blood pressure can be a particularly dangerous symptom in patients with this vascular pathology, as they are particularly susceptible to intracerebral hemorrhage, and to symptoms of cerebral ischemia in the setting of hypotension (due to inefficient collateral vasculature). We hypothesize the mechanism of labile blood pressure in this patient to be afferent baroreceptor impairment. We will review our experience with Moyamoya patients and autonomic impairment.

Factors affecting rehabilitation outcomes in a rehabilitation hospital: the effect of orthostatic hypotension Inpatient acute rehabilitation is crucial in the management of patients after injuries, surgery, or those with debilitating or neurological conditions. Orthostatic hypotension (OH) is commonly associated with these conditions and can negatively impact their recovery. Indeed, we previously found in a cohort of 8350 patients at Vanderbilt Stallworth Rehabilitation Hospital that OH was present in 4% of these patients (60 ± 17 years, 28% women vs. 60 ± 18 years, 43% women in the non-OH group), particularly in those admitted due to neurological conditions (4%), spinal cord dysfunction (11%), orthopedic disorders (4%) and stroke (3%). On admission, OH patients had a longer predicted length of rehabilitation hospitalization stay (LOS; 18 ± 6 vs. non-OH 16 ± 5 days; P \ 0.01) and lower functional independence measure (FIM, 49 ± 19 vs. non-OH 55 ± 19; P \ 0.01), reflecting greater medical complexity. At discharge, however, OH patients had longer than predicted LOS (actual-predicted LOS [DLOS], 1 ± 11 vs. non-OH -2 ± 8 days; P \ 0.01) and lower FIM efficiency ([discharge-admission FIM]/LOS, 2.5 ± 1.6 vs. non-OH 3.1 ± 1.9; P \ 0.01), suggesting that OH may be an independent factor for worse rehabilitation outcomes. To test this hypothesis, we conducted univariate and multivariate regression analyses in the adult patients (n = 8146) of this cohort. OH and other potential factors affecting DLOS and FIM efficiency including, age, sex, diagnosis of admission and comorbidities (grouped into 22 categories by organ systems) were assessed. We found that OH was independently associated with a longer than predicted LOS (i.e., greater DLOS) and lower FIM efficiency (regression coefficient 2.2 ± 0.5 and -0.4 ± 0.1, respectively; P \ 0.01). These associations remained significant after adjusting for predicted LOS and FIM on admission, suggesting that the effects of OH were not accounted for in these metrics. Other factors significantly associated with greater DLOS and lower FIM efficiency were comorbidities associated with the urinary tract, gastrointestinal and peripheral nervous systems, infections, electrolyte imbalance and pressure ulcers. In conclusion, OH has a major independent, negative effect on rehabilitation outcomes, and is associated with longer than predicted inpatient rehabilitation LOS and lower functional gain. We suggest that the presence of OH should be taken into account when setting up the rehabilitation plan, to include management of OH.

Blunting initial orthostatic hypotension: mechanistic roles of muscle contraction vs. sympathetic activation Background: Initial orthostatic hypotension (IOH) is a form of orthostatic intolerance defined by a large, transient drop in systolic blood pressure (SBP) within 15 s of standing that is associated with symptoms of transient cerebral hypoperfusion. IOH typically presents after active standing, but not after a passive tilt. Lower body muscle pre-contraction before standing can blunt the IOH response, which may be related to muscle activation of lower body or increased vasomotor tone (i.e., sympathetic activation). The relative influence of these factors in IOH is not well understood. We hypothesized that muscle contractions prior to standing would significantly reduce the drop in SBP seen in IOH, while increasing sympathetic activity would not. Methods: Participants performed four sit-to-stand maneuvers following serial 7 (Mental), cold pressor (Cold), and functional electrical stimulation (Electrical) stressors, as well as no intervention (Control). Continuous heart rate (HR) and beat to beat SBP were measured. Cardiac output (CO) and systemic vascular resistance (SVR) were estimated from waveform data. Data are presented as mean ± SD. Stressor groups were compared to Control using paired t-tests, adjusting for multiple comparisons. Results: A total of 23 female IOH participants (31 ± 8 years) completed the study. The drops in SBP following Mental (-26 ± 12 mmHg; p = 0.004), Cold (-20 ± 15 mmHg; p \ 0.001), and Electrical (-28 ± 12 mmHg; p = 0.01) stressors were significantly reduced versus Control (-34 ± 11 mmHg). Significant drops in SVR with Mental (-391 ± 206 dyne*s/cm 5 ; p = 0.006) and Cold (-386 ± 179 dyne*s/cm 5 ; p = 0.011), but not with Electrical (-456 ± 165 dyne*s/cm 5 ; p = 0.388) stressors, were observed versus Control (-488 ± 173 dyne*s/cm 5 ). CO was significantly increased upon standing (7 ± 2 L/min) versus sitting (6 ± 1 L/min; p \ 0.001) for the Electrical Stressor. Conclusion: Both sympathetic activation and isolated muscle contraction can mitigate the drop in blood pressure seen in IOH. Active muscle contractions may induce both of these mechanisms of action in their pre-treatment of IOH. 

The patient experience with initial orthostatic hypotension: a qualitative study lead to a faint. Symptoms may occur multiple times a day. Despite the severity and frequency of symptoms, there was little known about the patient experience regarding IOH. Aim: To explore the patient's day-to-day experience of living with IOH, specifically, the (a) social, (b) emotional, and (c) financial implications of IOH on daily living. Patient priorities for strategies to assist them in living with IOH were identified. Methods: Sixteen patients with IOH (31 ± 9 years; 14 female) were interviewed, using an inductive approach, through semi-structured qualitative interviews. The interviews were recorded and transcribed verbatim and analyzed using qualitative thematic analysis. Results: Three underlying thematic categories were identified: (1) daily negative impact on patient life; (2) overlooked obstacles of coping with an invisible disorder; and (3) barriers while attempting to seek help. The main finding was that IOH affects many aspects of the patients' lives including social, financial, and emotional well-being, at times contributing to feelings of anxiety and depression. IOH patients also perceive their condition as an 'invisible illness', making it difficult for them to initiate conversations with medical professionals and with personal communities about their symptoms and their need for support. Patient priorities focused on increasing awareness of IOH to overcome these barriers to receiving care and support to ameliorate the impacts of the condition on daily living. Patients also highlighted the importance of increasing awareness of IOH to aid in receiving an official diagnosis, increasing patient information with increasing acceptance of this condition, and linking this acceptance to their own help-seeking and self-management behaviour. Conclusion: These data illustrate the importance of creating more awareness of IOH. Patients consider receiving a diagnosis to be an important part of allowing them to move forward from ''struggling with IOH'' to ''living with IOH''. Treatment and self-management strategies to mitigate the daily impact of living with IOH should also be part of a care plan. Case: A 61-year-old woman presented for evaluation of orthostatic hypotension (OH) and syncope. Her first syncopal episode was one year prior; since that time, she had progressive worsening of orthostatic symptoms, to the point that she was falling two or three times per day due to presyncope. She denied a history of chest pain. She had a history of type 2 diabetes (for 13 years, insulin dependent, poorly controlled until recently, complicated by neuropathy), superior mesenteric artery thrombosis, hypertension, and lifelong sleepwalking. She was taking amitriptyline for abdominal discomfort after her episode of mesenteric ischemia. Evaluation: She presented to the autonomic lab for testing. Postganglionic sudomotor function was moderately impaired, and cardiovagal function was normal. Blood pressure response to Valsalva showed absent phase IIL and phase IV, with prolonged pressure recovery time of 7.9 s. On tilt table testing, supine blood pressure was 149/64, and fell to 76/47 at 3 min of head up tilt. In addition to her typical lightheadedness, patient developed the acute onset of substernal, pressure-like chest pain. The tilt test was aborted, with rapid recovery of blood pressure, but chest pain persisted for about 15 min.

She was sent to the emergency department for concern for cardiac ischemia. Cardiac enzymes were negative. Cardiac CT showed vulnerable plaque with 70% stenosis in the distal left anterior descending artery (LAD). She was taken for cardiac catheterization which revealed 90% LAD stenosis, successfully treated with stenting. Discussion: Chest pain has been reported as a symptom of severe OH in patients with normal coronary vasculature. However, hypotension could also cause further reduced blood flow through a stenotic vessel, thus provoking symptoms. Orthostatic chest pain may need further evaluation before being attributed solely to OH, particularly in the setting of vascular risk factors.

Employment implications and workplace accommodation of chronic syncope in Canada Background: Chronic syncope affects 13.5% of Canadians and may significantly impact daily living. Syncope may present as an ''invisible disability'': until the patient faints or becomes faint, there are few outward manifestations of the condition. Syncope can also be categorized as a ''transient disability'': a patient may experience one or several faints unpredictability over any period of time. Little is known about the impact on employment or workplace accommodations required by chronic syncope patients. Aim: To explore the impact of chronic syncope on patients' employment and workplace accommodation-seeking experiences. Methods: Study 1: Ten focus groups (n = 91) and 62 semi-structured interviews were conducted with Canadian patients diagnosed with cardiac arrhythmias. 22 identified syncope as their diagnosis and another 56 identified syncope as a ''troubling symptom''. Patients described the impact of their diagnosis and symptoms on daily living, including employment. Study 2: 15 semi-structured interviews focused on employment and workplace accommodations. Interviews were recorded and transcribed verbatim and analyzed using qualitative thematic analysis. Results: Patients chose to disclose their syncope to their employer when they: (a) were having, or at risk of having, an episode at work; or (b) needed time off for medical appointments and procedures. Those who had chosen not to disclose their arrhythmia stated either the syncope did not impact their work or were concerned their supervisor would not be supportive. Patients reported they would disclose their symptoms if they ever felt that their safety, or their coworker's safety, was at risk. Patients who reported frequent and unpredictable symptoms were more likely to request accommodation. Reluctance by employer to provide accommodations led patients to seek other employment, move to self-employment, or retire. Conclusion: In Canada, legislation requires employers to address employee disability concerns in the workplace within the limits of undue hardship. Supervisor acceptance of disability accommodation requests are impacted by the visibility of the disability and the degree to which the nature of accommodation required is unambiguous. Chronic syncope patients experience barriers to workplace accommodation due to the invisibility of their condition. Background: Both gender identity (internalized and personal experience of gender) and gender roles (externally imposed expectations based on perceived gender) impact health care experiences and outcomes. Certain behaviours, values or characteristics can be gendered as ''masculine'' or ''feminine'', with more positive traits often ascribed to masculinity. This qualitative study explores patient perception of syncope as gendered and how this gendering influences treatmentseeking behavior. Methods: Study 1: Syncope patients (n = 25) were interviewed regarding their decision-making process in accessing emergency services after a syncopal event. Cardiac arrhythmia patients were interviewed in focus groups (n = 91) and 62 semi-structured interviews (n = 62) to explore the patient experience of living with arrhythmia. Syncope was identified as their diagnosis in 22 patients, and as a ''troubling symptom'' in 56 patients. Semi-structured interviews were transcribed and thematically analyzed. Patients did not self-identify outside of the binary categories of sex. Recruitment is ongoing to more broadly sample across genders. Results: ''Female'' patients reported experiences or concerns that their symptoms would be dismissed as being a ''women's issue'' (e.g., menopause or menstruation) without appropriate investigation. Syncope was described by both groups as ''girly'' or ''dramatic'' and linked to ''swooning'' or ''something from a romance novel.'' Female patients explicitly linked this gendering to their decision not to access care. They felt that such a feminine symptom did not merit attention: ''It would be silly to go to the ER.'' Male patients preamble their explanation of care-seeking with stereotypical masculine descriptions of their syncopal event: they were ''working too hard'' or ''working out hard.'' Conclusion: Syncope affects both men and women but stereotypes persist that the symptom is ''feminine'' and reflective of weakness or dramatization. Patients link a perceived need to justify accessing care of treatment to this gendering. Men and women seeing the ''feminine'' nature of syncope as a reason to not access care may reinforce differential access to care for both women and men. Men are less likely than women to access emergency care for syncope, and the gendering of syncope may affect this decision. Background: Frequent syncope and presyncope symptoms can be disruptive to a child's lifestyle, causing embarrassment, anxiety, and injury. Slow Sodium tablets have been used in children attending our local syncope clinic for several years. Objectives: We wanted to systematically assess the long-term outcomes for our patients on Slow Sodium. Methods: We undertook retrospective analysis of consecutive patients at our centre from October 2014 through September 2019. Patients dispensed Slow Sodium aged less than 18 years, for vasovagal syncope and/or pre-syncope symptoms, or orthostatic intolerance were included. Patients concurrently taking fludrocortisone, using Slow Sodium for another indication, or who had no follow-up appointment 1 year or more after starting were excluded. Data was collected from the hospital's digital health records pre-treatment and 1-year posttreatment, including indication (symptoms and diagnosis), frequency of symptoms, and adverse effects. Where possible, an ordinal scale which categorized frequency of symptoms per day, week, month, or year was used. In all cases a Clinical Global Impression (CGI) scale rated the change in symptoms as 'significantly worse', 'no clinically significant change' and 'significant improvement'. Results: The median age was 14 years , 54/81 (67%) were female. 77/81 (95%) were treated for pre-syncopal and/or orthostatic symptoms, and 43/81 (53%) for syncope. Most were dispensed a maintenance dose of 5 tablets = 50 mmol sodium (3 g NaCl) twice a day, with a median daily dose of 1.62 mmol/kg . The CGI scale demonstrated improvement in frequency of orthostatic/pre-syncopal symptoms in 63/77 (82%), and in syncope in 40/43 (93%) at 1 year or more follow-up. The ordinal scale demonstrated improvement in frequency of orthostatic/presyncopal symptoms in 44/46 (96%), and improvement in frequency of syncope in 21/21 (100%) evaluable patients at 1 year or more followup. 4/81 (5%) experienced nausea, and there were no other possibly attributable adverse effects. Conclusions: Slow Sodium appeared to be beneficial in reducing frequency of symptoms in the vast majority, with only 5% reporting adverse effects. However, a randomized double-blind placebo-controlled trial is required to prove efficacy by controlling for life-style advice, increased fluids, and the passage of time.

Funding: This was a registered clinical audit of the Nottingham University Hospitals NHS Trust, undertaken as a medical student project, with no external funding.

Video-EEG-head-up tilt testing in children: useful in selected cases Aims: To review the conduct, case mix, and results of our HUTTs. Methods: Data on the first 100 consecutive 45 min 60°HUTTs performed with video-EEG were extracted from the clinical charts. Cases were referred from tertiary syncope clinics where there was diagnostic uncertainty, accounting for 17% of patients seen. Clinical audit of process assessed the procedures and reporting. Clinical audit of outcome evaluated the results of the tests using current standard thresholds. Simple descriptive statistics were used. Results: Patients were aged 2 years to 18 years (median 14), 63/100 were female. Continuous video scalp EEG and ECG was recorded in all. Beat-to-beat finger BP and interval right brachial artery BP were recorded in 98/100. End-tidal CO 2 was recorded in 66/100. Reports by a pediatrician with expertise in cardiology or pediatric neurologist were found for 94/100 HUTTs. The HUTTs demonstrated diagnostic abnormalities in BP and/or HR in 31/100, including 2 who were asymptomatic, with excessive postural tachycardia. The 29 with positive symptomatic results included 21 with vasodepressor or mixed and 4 with cardioinhibitory syncope or pre-syncope, and 4 with excessive postural tachycardia. A further 9/100 demonstrated reproduction of symptoms but with normal BP and HR changes, including 6 with dissociative states, clearly evident on video-EEG. In addition one, who was negative asymptomatic from a heart rate and blood pressure point of view, showed EEG features of juvenile absence epilepsy, and 8 which were negative asymptomatic yielded positive results on external ocular compression, performed immediately after the negative asymptomatic HUTT. The 29 positive symptomatic events occurred at 1-45 min (median 23; IQR 10-45), including 7 at 31-45 min. Conclusions: Useful information was obtained from 40% of HUTTs, and in 49% of children when inter-ictal EEG data and post-HUTT ocular compression are considered. Patients with dissociative states were clearly distinguished. A longer HUTT of 50 min at 60°may yield more positive responses. There is little data on evaluation of Holter monitors in patients with vasovagal pre-syncope, syncope or postural tachycardia syndrome (POTS). We have identified more repolarization abnormalities on Holter monitors in these patients (syncope group) than expected. Methods: We performed a retrospective review of patients presenting to the Pediatric Syncope Clinic over a three year period (2016-2019) who had Holter monitors, compared to patients with palpitations and no subsequent arrhythmia diagnosis. Repolarization patterns were assessed in all patients and described as normal or abnormal (flattened ST-T wave or T wave slurring). We used t-test and chi-square test to compare characteristics between the two groups, and performed logistic regression models to predict abnormal repolarization on the Holter. Results: There were 64 patients in the syncope group and 40 patients in the palpitation group. The syncope patients were more likely to have abnormal repolarization on the Holter (34.5% vs. 10%, p = 0.005). After adjusting for age, gender, average heart rate, and medications that affect heart rate, the syncope group remained more likely to have abnormal repolarization (odds ratio 4.44, 95% CI 1.32-14.9). No life-threatening events or significant structural heart defects were identified in either group. One patient in the syncope group was later diagnosed with cardioinhibitory syncope and received a pacemaker for a prolonged asystolic pause seen on subsequent monitoring. No other clinically significant arrhythmias were seen on Holter monitoring.

Discussion: Abnormal repolarization on Holter monitoring was common in patients referred for pre-syncope, syncope or POTS, although these abnormalities did not correlate to clinically significant conditions. The abnormal repolarization in the syncope group may reflect a unique phenotype in this population. Conclusion: Pediatric patients with pre-syncope, syncope, or POTS may have different Holter phenotypes than other pediatric patients, even in the absence of other clinically relevant findings.

Postural tachycardia syndrome (POTS) and neurocardiogenic syncope (NCS) in the young population: are they different physiology?

M.T. Numan 1 , H.K. Varner 3 , J.E. Lankford 2 , I.J. Butler 2 1 Pediatric Cardiology, 2 Pediatric Neurology, 3 Department of Neurology and Neurological Sciences, University of Texas, Houston, TX, USA Introduction: Recently, Heart Rhythm Society and ACC published clinical guidelines to differentiate POTS from NCS by using heart rate (HR) and blood pressure (BP) criteria, where POTS patients will have 30 ([ 18 years age) or 40 beats (\ 18 years age) increase of HR from supine to upright position with no significant decrease of BP. NCS patients will manifest decrease in systolic BP C 20 mmHg and no significant increase of HR. We hypothesized that there is a physiological overlap between these two diseases' physiology. Methods: Retrospectively we reviewed the head up tilt table (HUTT) data from our center between 2013 till 2019, then we specifically looked at the patients who developed NCS during HUTT. We obtained their demographics, physiological parameters of HR, SBP, bilateral cerebral perfusion depicted by near-infrared regional spectroscopy and cardiac stroke volume (SV). We divided these patients into two groups: NCS with no significant increase of HR (NCS-NPOTS) while second group of NCS patients with HR C 30 (patients C 18 years) or HR C 40 (B 18 years) in the first 10 min of HUTT (NCS-POTS group). We noted their time of syncope (from the start of HUTT), presence of convulsions (due to brain anoxia), change in SV and presence of significant cardiac asystole (C 3 s) during the syncopal episode. We excluded all patients above 21 years of age as well as those with incomplete or corrupted digital files. Results: During the study period there were 875 HUTT procedures, of those 245 patients developed syncope during the tests. We excluded 55 patients (above 21 years old) and 5 patients had incomplete (corrupted) files. Of 185 syncopal patients, 100 had met POTS HR threshold according to the guidelines (NCS-POTS group) and 85 patients had no significant increase of HR (NCS-NPOTS). Comparing the two groups, there was no significant difference in the time of syncopal episode, development of convulsions, the cerebral perfusion changes or SV difference. We noted a higher incidence of cardiac asystole in the NCS-NPOTS group compared to NCS-POTS group. Conclusion: The precision of the HR as a criterion to differentiate POTS from NCS patients is not adequate. The overlap of physiological parameters between NCS and POTS is significantly high and indicates common pathological root-cause for both with a need to redefine the two terms or their nomenclatures.

Peripheral skin temperature gradients as a potential biomarker of autonomic dysregulation in congenital central hypoventilation syndrome (CCHS) vs. controls Background: Congenital central hypoventilation syndrome (CCHS) is a rare pediatric neurocristopathy characterized by impaired control of breathing and autonomic regulation, indicated in part by reduced core temperatures and cool extremities. Peripheral skin temperature (PST) offers objective measures of vasomotor tone and may be a biomarker of autonomic function. We hypothesized that patients with CCHS will have different PST gradients than controls and an altered PST gradient by age. If confirmed, PST measurement may have clinical utility regarding disease development or progression in children with autonomic dysregulation. Methods: 349 PST observations were collected among 215 controls and 44 CCHS patients (0-22 years). Measurements on all four extremities were collected at 3 different anatomic sites (dorsal center, tip of 3 rd digit, ventral center) using a handheld infrared device (Exergen DT 1001, Watertown, MA, USA). PST gradients (delta from center to tip of extremity) are the basis for all comparisons. Gradients for left-right paired extremities did not differ significantly so were combined for analysis. Differences were determined and regression analyses were conducted (linear mixed-effect models in R). Results: A 'cohort by gradient' interaction was observed for handsfeet. Specifically, a significant difference (ps \ 0.001) between cohorts was observed in the dorsal gradients (Hands: CCHS x = 1.49, SD = 2.98; controls x = 3.23, SD = 2.51; Feet: CCHS x = 4.30, SD = 2.59; controls x = 6.85, SD = 2.12) with a lesser difference in the ventral gradients (Feet: CCHS x = 3.39, SD = 2.11; controls x = 4.51, SD = 2.12; no difference in hands CCHS x = 3.72, SD = 1.91; controls x = 4.22, SD = 2.15). Both dorsal and ventral gradients in hands-feet increase linearly with age (ps B 0.05). An 'age by cohort' interaction was observed in the foot dorsal gradient that increased linearly with age in CCHS but not controls (p = 0.0002). No sex differences or 'cohort by sex' interactions were observed (ps [ 0.05). Conclusions: These results support our hypothesis that CCHS patients have different PST gradients than controls. However, the relationship between age and PST gradients in CCHS is similar to controls in all except the dorsal foot gradient. The dorsal vs. ventral PST gradient disparity may serve as a biomarker of autonomic dysregulation that can be followed longitudinally and for intervention trials in CCHS and other disorders with autonomic dysregulation. Background: Congenital central hypoventilation syndrome (CCHS) is a rare neurocristopathy causing a wide array of cardiac autonomic nervous system (ANS) abnormalities including abnormal heart rate (HR) regulation, decreased HR variability (HRV), and prolonged sinus pauses. PHOX2B is the disease-defining gene for CCHS. Different types and locations of PHOX2B mutations have been associated with different levels of CCHS cardiac phenotype severity. We hypothesized that among individuals with CCHS HRV will be influenced by age and PHOX2B genotype. Methods: Data from PHOX2B mutation-confirmed CCHS patients followed longitudinally with serial Holter monitoring from our Center were included. HRV measures were extracted from Holter monitoring reports and analyzed using linear mixed-effect models. Evaluation of variables that might predict sinus pauses and cardiac pacemaker implantation were analyzed using linear and logistic regression. Only data preceding implantation of a cardiac pacemaker were included in analysis. Results: 965 Holter recordings from 97 CCHS patients (0-18 years old) were analyzed. PHOX2B genotypes/mutations included the following: 20/25 genotype (n = 21), 20/26 genotype (n = 21), 20/27 genotype (n = 26), genotypes ranging from 20/28-20/33 (n = 7), and with non-polyalanine repeat expansion mutations (NPARMs) (n = 22). HRV metrics included in analysis were min-and max-HR, longest-RR, SDNN, ASDNN5, SDANN5, and RMSDD. Significant differences were observed between PHOX2B genotypes for min-HR and longest-RR (ps \ 0.05). Age by genotype interactions identified that certain HRV metrics had different developmental trajectories (ps \ 0.05). Min-HR and longest-RR predicted eventual cardiac pacemaker implantation (AUCs [ 0.78). Different HRV metrics emerged as predictors of sinus pauses across PHOX2B genotypes suggesting their potential utility to anticipate future need for cardiac pacemaker implantation. Conclusion: HRV in CCHS patients is age-dependent and PHOX2B genotype-dependent, with significant differences in HRV metrics between patients with PHOX2B genotypes 20/25, 20/26, and 20/27 and the patients with 20/28-20/33 genotypes as well as those with NPARMs. Consistent with treatment guidelines, min-HR and longest-RR were predictive of eventual cardiac pacemaker implantation. Differences in HRV metrics that predict sinus pauses and overall group differences may improve anticipatory management by earlier identification of CCHS patients at-risk for prolonged sinus pauses.

Autonomic nervous system dysfunction is associated with rehospitalization in pediatric sepsis survivors Introduction: Patients with symptoms of orthostatic intolerance (OI) are often referred for diagnostic head-up tilt (HUT) testing. While HUT is accepted as a sensitive test of dysfunction in autonomic responses leading to OI, it is cumbersome, expensive, and not widely available. Pupillometry in the context of the pupillary light response (PLR) to a fixed light stimulus offers an objective, accurate, and non-invasive tool to assess sympathetic and parasympathetic tone. PLR has potential to serve as a biomarker in this population to measure response to intervention, track disease progression, or as a diagnostic alternative to HUT. We hypothesized that pupillometry measures would be abnormal in patients referred for OI when compared to healthy controls. Methods: Pupillometry (Neuroptics, Irvine, CA) was performed using a published protocol in 74 adolescents ages 12-18 years (81% female; 89% Caucasian) referred to Lurie Children's Hospital with symptoms of OI. Standard pupillometry measures from the OI cohort were compared to normal ranges (mean ± 2 SD) established in published controls matched for age and sex. Medications that might affect the pupillary light reflex (PLR) were held for at least five half-lives before pupillometry testing. Results: 21/60 girls (35%) and 4/14 boys (29%) had C 2 PLR measures outside of 2 SDs from the normative cohort values. There was not an identifiable pattern of abnormalities within or between subjects to consistently identify a sequence of altered sympathetic or parasympathetic function in this cross-sectional study. Conclusions: Results suggest that a subset of adolescents referred for OI have altered pupillary response to light, reflecting autonomic dysfunction present in this population. With the newly approved CPT code for pupillometry we expect this test will be more widely used in adults and children. Longitudinal pupillometry and HUT testing with correlation of findings will be necessary to determine if pupillometry may serve as a proxy for HUT, as an early indicator of autonomic dysfunction, as a discriminator of patient subsets requiring specific therapy, or as a measure of response to treatment intervention.

Poster #112

Report on the progress of the iSTAND study, a randomized controlled trial of intravenous immunoglobulin for autoimmune neuropathic postural tachycardia syndrome Background: Postural tachycardia syndrome (POTS) is a heterogeneous syndrome; a minority of patients have some evidence of underlying autoimmunity and or small fiber neuropathy. Retrospective case series suggest benefit of treatment with intravenous immunoglobulin (IVIG); however, controlled trials are needed to control for placebo and volume expansion effects. Methods: iSTAND is a double-blind, controlled trial to evaluate safety and efficacy of IVIG compared to intravenous albumin in a two-phase cross-over design. Each study phase consists of four weekly infusions followed by four alternate week infusions with sixweek washout between treatment phases. Primary outcome is autonomic symptom severity evaluated by COMPASS-31. Secondary outcomes are also assessed. Recruitment goal is 20 participants completing the first phase of randomized treatment. Data from all participants who begin treatment will be analyzed in an intention-totreat analysis. Eligible participants are adults who have POTS by heart rate criteria who have moderate to severe symptom burden (COMPASS-31 C 40) who also have evidence suggesting an autoimmune neuropathic etiology. The latter requires 3 of the following 5 criteria: (1) clear history of subacute onset, (2) confirmed personal or family history of defined autoimmune disorder, (3) severe gastrointestinal dysmotility, (4) one of more serum autoantibody or immune markers, (5) evidence of small fiber neuropathy by skin biopsy or QSART. Results: Despite strong interest from the POTS community, recruitment was hampered by the COVID-19 pandemic. Other barriers to participation included distance from the study site, time required for weekly infusions and inclusion criteria for autoimmunity. As of May 2021, 15 participants (all women) have been enrolled and started treatment; mean age 33 (18-55) ; initial COMPASS31 score 58 . Three participants discontinued during first treatment phase (two due to medical events and one who started IVIG elsewhere); one discontinued during second treatment phase with infusion-related headache. Some participants have reported improvements in orthostatic tolerance, although the allocation of these participants is unknown as the study remains blinded. Conclusions: Recruitment continues. Longer term controlled randomized immunotherapy trials in POTS are challenging but important to provide high quality evidence for therapeutics. Funding: Funded by Dysautonomia International, Grifols and UT Southwestern.

Toward a more accurate estimate of the prevalence of postural tachycardia syndrome S. Vernino Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA Background: Although postural tachycardia syndrome (POTS) represents one of the most common forms of orthostatic intolerance, its exact prevalence is unknown. Estimates of POTS prevalence have relied on experience from autonomic centers. Challenges in determining prevalence include physician differences in applying consensus diagnostic criteria and lack of a specific ICD10 diagnosis code for POTS. Analysis tools in modern electronic medical records systems and billing databases can be leveraged to better estimate prevalence. Methods: As a first step toward creating a population model for prevalence of POTS, we used data (since 2018) from electronic medical record systems (EPIC) at our three affiliated health systems, Children's Health, Parkland, and UT Southwestern. We examined the distribution of demographics and utilization of ICD10 diagnosis codes in patients with POTS as a recorded diagnosis. Results: As expected, a recorded POTS diagnosis was strongly associated with female sex (89% of patients), non-Hispanic white race and younger age (less than 50). Among all patients with an outpatient visit at UTSW during the time frame studied, 0.21% had a diagnosis of POTS. The frequency was 0.68% for patients 21-30 years old, and 0.94% for women in this age group. Prevalence of POTS diagnosis was similar at the Children's hospital but five times lower at the county safety net hospital. ICD10 symptom codes most commonly associated with a POTS diagnosis were dizziness (R42), syncope (R55), and tachycardia (R00). White females, age 21-30 with one of these ICD10 symptom codes, accounted for 25% of all POTS diagnoses. Commonly associated ICD10 disease codes were ''unspecified disorder of autonomic nervous system'' (G90.8 and G90.9), orthostatic hypotension (I95.1), other arrhythmia (I49.8) and hypermobile EDS (Q79.62). Conclusions: In certain demographics (young white women), the prevalence of POTS approaches 1%. However, this estimate is based on patients who interacted with the academic health system (a minority of the US population each year). This analysis is further limited by uncertainty about the recorded diagnosis of POTS and the lack of a specific ICD10 code. However, based on this data, a model can be developed to more accurately predict overall POTS prevalence using national health care registries.

Lumping and splitting heart rates in evaluating orthostatic intolerance W.P. Cheshire 1 , D.V. Dudenkov 2 Departments of 1 Neurology and 2 Internal Medicine, Mayo Clinic, Jacksonville, FL, USA Purpose: Symptoms of both postural tachycardia syndrome (POTS) and vasovagal syncope (VVS) typically occur in the upright posture, although they differ in that POTS is ongoing whereas VVS is an episodic phenomenon. The coexistence of both syndromes in some patients and the increase in heart rate (HR) that may precede a vasodepressor response suggest a partly shared physiology. This investigation compared HR changes during head-up tilt in both conditions. Methods: Data from patients referred for autonomic testing over the previous two years were screened retrospectively for HR changes during 10 min of 70-degree head-up tilt. POTS was defined as a sustained increase in HR of [ 30 ([ 40 if under age 20) beats/min above baseline. VVS was defined as the delayed development of decreased systolic blood pressure (BP) to \ 30 mmHg of baseline. We examined differences of baseline HR and BP, HR change during active standing, and HR changes and rates of change (prior to cardioinhibitory response) during head-up tilt at 20 s, 1 min, 5 min, and 10 min. We also compared symptoms, BP change during tilt, BP oscillations, HR variability during deep breathing, Valsalva ratio, and baroreflex sensitivity. Values were compared by t-test with significance defined as p \ 0.05. Results: Of 2257 patients referred for autonomic testing, 226 met HR criteria for POTS, and a vasodepressor response occurred in 29, 17 of which also qualified as POTS. The mean time-averaged HR increases from baseline for POTS were 36.1 ± 8.5 and VVS 38.5 ± 15.7 (P = 0.4) with no significant difference found at any time point. HR temporal profiles comparing POTS without vs. with a prior history of VVS were also indistinguishable at all time points, regardless of the frequency of syncope, with average increases of 36.4 ± 8.9 vs. 35.6 ± 7.7, respectively (P = 0.5). Apart from the magnitude of HR change, no other variable distinguished VVS with vs. without POTS. Presyncopal patients with VVS were, however, more likely to report symptoms during tilt (93% vs. 60%, p \ 0.001). Conclusion: Vasovagal syncope appears to represent an episodic form of orthostatic intolerance with HR changes along a physiologic spectrum with POTS. Objective: This systematic review aims to aggregate and summarize evidence for nutrient and vitamin deficiencies in patients with postural tachycardia syndrome (POTS) as well as outcomes after supplementation of subsequent deficiencies. Sources: Electronic databases and subsequent reference lists of studies published January 1, 1980 -May 15, 2021 Selection criteria: Case-studies/series, retrospective reviews and clinical studies investigating nutrient and vitamin deficiencies and supplementation in POTS. Data extraction: English language publications reporting supplementation and deficiencies were stratified based on substrate. The positive and negative results were counted within substrate supplemented or deficiency associated with POTS. Results: PubMed and Google Scholar were searched for ''postural tachycardia syndrome'' AND ''salt, vitamin, mineral supplementation'' with associated MeSh terms, returning 211 records, of which 98 were duplicates. One hundred-six records were screened, 73 were deemed irrelevant, and 33 were comprehensively reviewed. Six were primarily summaries and 7 included nonspecific POTS patients, totaling 18 records for inclusion. The 18 included studies contained much heterogeneity, representing 822 POTS patients (73% female) with a mean age of 19 years. Across 8 studies, 255 POTS patients with deficiencies received salt/electrolyte supplementation. Across 12 studies, 567 POTS patients with vitamin deficiencies received supplementation. The most common deficiencies across all 18 studies were sodium chloride, vitamins B1, B3, B12, D, and iron. The electrolyte supplementation response rate was 71%. The vitamin/ mineral supplementation response rate was 52%. The rate of POTSassociated vitamin or mineral insufficiency was 47%. Conclusion: POTS is a debilitating and heterogenous condition often associated with various electrolyte, vitamin, or mineral deficiencies. This review demonstrates how the burdensome array of POTS symptoms may potentially improve with personalized supplementation to address deficiencies. Further POTS research must properly measure vitamin and nutrient deficiencies, precisely evaluate regimens for restoring suboptimal levels, and systematically assess clinical and physiological improvements after supplementation. Objective: To report a case series of patients with neuropathic POTS and cutaneous phosphorylated alpha-synuclein (P-SYN) deposition on skin biopsy and compare these to neuropathic POTS patients without P-SYN deposition. Methods: The medical history, physical examination findings, autonomic function testing, and skin biopsy neuropathology of patients under the age of 50 with a postural tachycardia and a diagnosis of POTS were retrospectively reviewed. Included patients completed the composite autonomic severity score (COMPASS 31), the Wood Mental Fatigue Inventory, the Epworth Sleepiness scale, the REM Behavior Disorder Questionnaire, the Patient-Reported Outcomes Measurement Information System (PROMIS-10), and the Gastroparesis Cardinal Symptom Index. Results: Of 296 patients seen with POTS, 22 patients with suspected neuropathic POTS had skin biopsies performed during their evaluation. Seven of 22 patients had P-SYN present on skin biopsy, while 15 individuals did not. Those with P-SYN on biopsy: (1) were more likely to be male; (2) had features of REM sleep behavioral disorder;

(3) reported less sleepiness and cognitive impairment; and (4) noted greater symptoms of gastroparesis. On autonomic testing, the group with P-SYN deposition was more likely to have a hypertensive response to tilt-table testing and abnormal QSART responses.

Interpretation: Phosphorylated alpha-synuclein deposition is present in some postural tachycardia patients with neuropathic features. Individuals with a postural tachycardia and cutaneous phosphorylated alpha-synuclein deposition may be distinguished from other patients with neuropathic POTS. Objective: We sought to demonstrate the effect of LVM on cardiac function in pediatric POTS patients. Methods: This study was approved by the Nemours IRB. After informed consent, 18 new POTS patients and 9 control patients, all under the age of 18 years, received formal echocardiogram studies in supine. LVM and indices of cardiac filling were collected. POTS diagnosis was confirmed according to the established criteria for children. Results: Eighteen POTS (14 female, age 15.4 years ± 1.4) and 9 control patients (6 female, age 15.0 years ± 1.3; p = 0.44) were enrolled. Body mass index in the control group was slightly higher (22.1 ± 4.3 kg/m 2 vs. 19.4 ± 2.3 kg/m 2 , p = 0.041). LVM (103.3 ± 26.7 g vs. 93.1 ± 22.0 g, p = 0.308) and LVM index (63.0 ± 12.6 g/m 2 vs. 56.7 ± 8.7 g/m 2 , p = 0.150) were similar in both groups. Indices of cardiac filling and output were lower in POTS: left ventricular end-diastolic volume index (50.1 ± 8.3 ml/m 2 vs. 62.4 ± 8.5 ml/m 2 , p = 0.001), stroke index (30.9 ± 5.7 ml/m 2 vs. 37.8 ± 4.7 ml/m 2 , p = 0.004). The velocity time integral of the inferior vena cava flow in supine position was similar between groups (30.3 ± 9.5 cm vs. 38.9 ± 16.7 cm, p = 0.1). While cardiac index was similar between groups (2.55 ± 0.55 l/min/m 2 vs. 2.54 ± 0.53 l/ min/m 2 , p = 0.987), heart rate was higher in POTS (78 ± 13 bpm vs. 65 ± 9 bpm, p = 0.018). Discussion: Left ventricular mass and its index value were similar at baseline in POTS and control group. Indices of cardiac filling and output were lower in POTS patients. Higher heart rate in POTS patients compensated their lower stroke index and equalized cardiac output between groups. These findings may explain lower exercise capacity in POTS patients.

Echocardiographic evidence of exercise intolerance in children with POTS: a prospective controlled study: effect of cardiac filling during exercise B. Kakavand, T.M. Maul, P.C. Madueme, J. Cibiras, G. Dadlani Department of Pediatric Cardiology, Nemours Children's Hospital, Orlando, FL, USA Background: Exercise intolerance is a known problem in pediatric and adult POTS (postural tachycardia syndrome) patients. Its etiology remains unclear especially in children. Objective: We sought to examine cardiac filling indices during exercise testing and their relationship to exercise intolerance in POTS patients.

Methods: This study was approved by the Nemours Institutional Review Board. After informed consent, 18 new POTS patients and 9 control patients, all under the age of 18 years, underwent echocardiogram and cardiopulmonary exercise testing. POTS was diagnosed using standard criteria. During the exercise test, echocardiographic images were obtained at baseline, every 2 min of exercise, and 2 min into recovery. Cardiac filling and function indices were measured. Results: Most POTS patients, unlike control group, did not reach 8and 10-min mark. As a result, exercise time was higher in control group (11.4 ± 2.7 min vs. 9.2 ± 2.1 min, p = 0.024). Heart rate was significantly higher in POTS patients at all time points. Velocity time interval of inferior vena cava (IVC) was lower in POTS at 4 min (21.3 ± 1.7 cm, p = 0.018) and 6 min (22.7 ± 1.8 cm, p = 0.05). Left ventricular end-diastolic dimension was smaller in POTS vs. control at 6 min (3.8 ± 0.1 cm vs. 4.3 ± 0.1 cm, p = 0.03). Left ventricular end-diastolic volume was smaller POTS vs. control (68 ± 3.6 ml vs. 90.2 ± 5.5 ml, p = 0.004). Stroke index was also smaller in POTS vs. control (28.6 ± 1.4 ml vs. 34.3 ± 2.1 ml, p = 0.03). With peak heart rate being significantly higher in POTS (161 ± 5 BPM vs. 138 ± 6 bpm, p = 0.006), cardiac index was similar in both groups (POTS 4.2 ± 0.4 ml/kg/min vs. control 3.8 ± 0.7, p = 0.59). Discussion: POTS patients have lower cardiac diastolic filling based on lower blood flow in the IVC and lower left ventricular diastolic dimension and volume and lower stroke index. Higher heart rate in POTS patients resulted in similar cardiac output. Lower filling indices and reaching peak heart rate early seem to be the limiting factors for lower exercise capacity in children with POTS.

Mycoplasma pneumoniae infection associated with autoimmune small fiber neuropathy and postural tachycardia syndrome (POTS)

A. Sandefer 1 , K.R. Che´mali 2 . 1 Department of PM&R, Eastern Virginia Medical School, Norfolk, VA, USA; 2 Department of Neurology, Eastern Virginia Medical School and Sentara Neuromuscular and Autonomic Center, Norfolk, VA, USA Background: Mycoplasma pneumoniae (MP) is a common bacterial pathogen often eliciting mild respiratory symptoms. Prevalence within the community ranges from 2 to 35% and individuals are often asymptomatic. Though rare, MP has been linked to immune-mediated Guillain-Barré syndrome through proposed molecular mimicry. Along the same line, we propose a relationship between MP and other autoimmune disorders resulting in POTS and/or small fiber neuropathy (SFN). Methods: This is a retrospective cohort study of patients presenting to our autonomic center between 2018 and 2021 with symptoms suggestive of an autonomic nervous system dysfunction, who underwent etiological investigation. We analyzed those patients on whom we reached a diagnosis of autoimmune disorder including Hashimoto Thyroiditis, Sjögren's syndrome, or other autoimmune disorders, for the presence or absence of MP infection. MP IgG [ 320 units/ml is defined as definite infection while values between 100 and 320 units/ ml are defined as likely or remote infection. Secondarily, we analyzed the proportion of MP infection in patients who were found to have POTS or SFN. Results: MP serologic testing results were analyzed on 51 patients with one or more of the above-mentioned autoimmune disorders. MP IgG [ 320, [ 100, and \ 100 units/ml were found in 30 (59%), 43 (84%), and 8 (16%) of all patients, respectively. Thirty-six patients were diagnosed with SFN (71%), of which 30 (83%) had IgG [ 100 and 20 (56%) had IgG [ 320. Twenty patients were diagnosed with Background: Postural tachycardia syndrome (POTS) is a disorder of orthostatic intolerance defined by orthostatic symptoms and an increase in heart rate (C 40 bpm in youth 12-18 yrs) within 10 min of upright posture, in the absence of orthostatic hypotension (C 20/ 10 mmHg). The aim of this study was to characterize POTS in patients under age 18. Methods: Data was collected using the ''Diagnosis and Impact of POTS'' survey:an IRB-approved, community-based survey conducted between 2015 and 2021. This international survey explored demographics, symptoms, co-morbidities and other topics. Parents were invited to complete the survey for children under age 18. Summary statistics are reported as number and percentage. Continuous results are reported as median (IQR) . Background: Sympathetic nervous system (SNS) dysfunction following spinal cord injury (SCI) is a life-threatening condition that leads to blood pressure (BP) instability. The lack of descending supraspinal control results in over-excitation in response to nociceptive or non-nociceptive input caudal to the lesion which is termed ''autonomic dysreflexia (AD)''. AD is characterized by acute elevations in systolic BP up to 300 mmHg, leading to cerebral and cardiovascular disease. We harnessed the rehabilitative epidural electrical stimulation paradigm to promote spinal cord plasticity of the sympathetic circuits. We hypothesized that long-term stimulation of sympathetic circuits would prevent aberrant sympathetic connectome, and mitigate the occurrence of AD. Methods: Three groups of Lewis rats were used in this experiment: spinal cord injured rats that underwent 60 min of epidural stimulation 5x/week for 7 weeks, spinal cord injured rats and uninjured controls. Colorectal distension was used to assess the severity of AD using a balloon-tipped catheter inflated in the colon while monitoring beatby-beat blood pressure using a wireless telemetry device. The functional assessments (i.e., baseline hemodynamics and AD) were performed once a week for 7 weeks. To understand how specific neuronal populations (i.e., excitatory, inhibitory and sympathetic preganglionic neurons) are involved in the development of AD, we performed a preliminary chemogenetic experiment wherein we injected inhibitory Designer Receptors Exclusively Activated by Designer Drugs (i.e., AAV5-hSyn-DIO-hm4d-mCherry) into the lower thoracic segments in Vglut2-IRES-Cre, Vgat-IRES-Cre and Chat-IRES-Cre mice. Results: We showed a reduction in AD severity (i.e., no increase of blood pressure) following 7 weeks of epidural stimulation rehabilitation compared with the injured group without rehabilitation. Moreover, to understand how specific neuronal populations are involved in the development of AD, we performed a silencing chemogenetic experiment targeting the lower thoracic segments in Vglut2-IRES-Cre, Vgat-IRES-Cre and Chat-IRES-Cre mice. Preliminary data indicate that the reduction in AD severity is, at least in part, due to inhibition of excitatory interneuronal connections to sympathetic preganglionic neurons. This project has the potential to provide direction for basic and clinical research to develop treatments for SNS dysfunction after SCI, and thereby improve cardiovascular health and patient quality of life over the long term. Funding: RESTORE.network, Wings for Life Foundation, Compute Canada, Natural Sciences and Engineering Research Council, the Canadian Institutes of Health Research, Alberta Innovates Health Solutions, Brain Canada, Campus Alberta Neuroscience, the Libin Cardiovascular Institute, the Hotchkiss Brain Institute, and PRAXIS.

Spinal cord injury necessitates controlled breathing to index cardiac vagal modulation from respiratory sinus arrhythmia J.A. Taylor, G. Schleifer, R. Solinsky Cardiovascular Research Laboratory, Spaulding Research Institute, Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA Almost half a century ago, Angelone and Coulter described respiratory sinus arrhythmia (RSA) as frequency dependent with amplitude that varies almost tenfold as breathing frequency changes. However, it is common to find published data on RSA (or high-frequency variability) without controlling or otherwise accounting for breathing. This might be most important in populations with compromised respiratory and cardiac autonomic function in whom inferences on cardiac autonomic modulation from RSA could be seriously confounded. Spinal cord injuries have wide ranging effects on both respiratory and cardiac autonomic function, depending on the characteristics of the injury. Hence, studies in individuals with spinal cord injuries require assiduous attention to the effects of breathing on RSA. We assessed RSA in 59 supine individuals under the age of 40 and with a spinal cord injury during semi-supine rest with uncontrolled and controlled (0.25 Hz) breathing. Although average RSA did not differ between breathing conditions, lack of agreement resulted in widening disparity as RSA increased within individuals. For example, at the mean value for this group, uncontrolled breathing induces a ninefold over/under-estimation of RSA. We further examined the effect of uncontrolled versus controlled breathing on cross-spectral relations between RR-interval and systolic pressure at the breathing frequencies. The slowest breathing frequency observed ranged from 0.02 to 0.33 Hz during uncontrolled breathing, compared with [ 0.21 Hz in 57 of 59 subjects during paced breathing (p \ 0.001). Coherence was adequate in all subjects ([ 0.50) for both breathing conditions (0.74 vs. 0.84, p \ 0.001), yet phase was shifted from negative to positive (p \ 0.05) between uncontrolled and controlled breathing, corresponding to delays of -406 to 125 ms. Hence, despite only slightly different gains (18 vs. 16, p = 0.02), these reflected different feedforward and feedback RSA mechanisms. Indeed, given that the sympathetic role is most pronounced at slower breathing frequencies, RSA during uncontrolled breathing in those with SCI likely reflects a baroreflex-mediated, mixed autonomic response to blood pressure fluctuations. Therefore, given the impact of SCI on respiratory function and the effect of altering breathing pattern on cardiorespiratory interactions, controlled breathing is necessary in SCI to index cardiac vagal modulation. Funding: NHLBI R01 HL117037, NIDILRR 90SI5021-01-00.

Transplanting embryonic Raphe nuclei-derived neural stem cells into the injured spinal cord to improve cardiac function S. Fernandes, E. Oatman, S. Hou Marion Murray Spinal Cord Research Center, Department of Neurobiology & Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA High-level spinal cord injury (SCI) often interrupts supraspinal regulation of sympathetic activity to the heart. The loss of balance between autonomic components renders the exposure of cardioelectric disorders like arrhythmias eventually leading to heart failure. Even though, immense clinical data is available explaining cardiac dysfunction following SCI, few animal experiments have successfully been investigated to model the disease for potential therapeutic interventions. We are currently using an upper thoracic crush SCI model which interrupts supraspinal fibers thereby inducing cardiac dysfunction. Subsequently, we propose to utilize cell transplantation as a treatment strategy for the inferred cardiac abnormalities. In our study, we will employ a complete spinal cord crush injury, which is an ideal lesion for further cell transplantation, at the T2/3 level to induce cardiac dysfunction. Using a radio-telemeter to record electrocardiogram (ECG) and blood pressure (BP), we will analyze a battery of parameters to deduce the cardiac performance of the animal following the injury. Since, brainstem derived supraspinal projections

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of The University of Texas Southwestern Medical Center and the American Autonomic Society. The University of Texas Southwestern Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credit(s) TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Autonomic Society would like to thank the following for their support of this meeting: 

Division of Autonomic Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago

Department of Cardiothoracic, Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato

Of the 7820 participants who disclosed their age and reported being diagnosed with POTS by a physician, 891 (11.4%) were under 18 years old. Among these pediatric patients, the majority were female (85.6%) and Caucasian (92.3%) with a median age of symptom onset of 13.0 (10.8-14) years. Almost all participants reported symptoms of lightheadedness (98.8%), pre-syncope (93.6%), tachycardia (96.5%), headaches (96.1%), nausea (91.4%), and difficulty concentrating (93.5%)

Postural tachycardia syndrome (POTS) is a disorder of orthostatic intolerance that primarily affects female patients. It has been suggested that autoimmunity plays a role in POTS. This study sought to compare adrenergic receptor autoantibody concentrations in POTS patients and healthy controls to elucidate the role of autoantibodies in POTS. Methods: Serum samples from POTS patients (n = 116) and healthy controls (n = 81) from Calgary, Canada and Malmö, Sweden were evaluated for adrenergic antibody concentrations using a commercially available ELISA assay conducted by CellTrend GmbH

The majority of POTS patients (98.3%) and all controls (100%) had Alpha-1 adrenergic receptor antibody (A1AR-Ab) levels above the cut-off value of 7 U/mL (p = 0.2). A1AR-Ab concentration was not different between POTS and controls

For beta-1 adrenergic receptor antibodies (B1AR-Ab), 9.5% of POTS patients and 8.6% of controls were positive (cutoff 15 U/mL)

Likewise, for beta-2 adrenergic receptor antibodies (B2AR-Ab), 7.8% of POTS patients and 6.2% of controls were above the 14 U/mL cut-off

Conclusion: Both POTS patients and healthy controls have adrenergic receptor antibody titres above the cut-off concentration determined by CellTrend. These findings suggest that there are no significant differences in alpha-and beta-adrenergic receptor autoantibody concentrations between POTS patients and controls. While adrenergic receptor autoantibodies may play a role in the pathophysiology of POTS, their increased concentration are not diagnostic of POTS

Conclusions: The majority of adolescents with OI demonstrated consistency in bedtimes and risetimes with delayed sleep phase tendencies and borderline sufficient sleep. There was significant variability in all parameters measured. They report frequent tiredness and unrefreshing sleep. Funding: Dysautonomia Youth Network of America

Raj Department of Cardiac Sciences

Methods: POTS patients (n = 29) completed 2 9 10 min head up tilt tests (HUT) with full lower body compression (FULL) or no compression (NONE), in a random order. Continuous ECG and blood pressure were recorded, with advanced hemodynamics from Modelflow. Oscillation magnitude was defined by systolic blood pressure [SBP] range (SPR; Max-Min SBP) within 5 min windows. Low frequency mean arterial pressure (LF-MAP) power was calculated using spectral analysis (for baseline and last 5 min HUT). Data are presented as mean ± SEM. Results: Baseline SBP was higher in FULL than NONE (121 ± 3 mmHg vs. 116 ± 2 mmHg

but HUT SPR was lower with FULL than NONE (36 ± 2 mmHg vs. 45 ± 3 mmHg; p = 0.008). Baseline LF-MAP was not different between FULL and NONE

There was a positive correlation between SPR and LF-MAP during baseline (r = 0.63; p \ 0.001) and HUT (r = 0.60; p \ 0.001)

HUT SV fell less, and was higher, in FULL than NONE (78 ± 3 mL vs. 65 ± 3 mL; p \ 0.001)

These findings suggest that increased SBP oscillations may be driven by lower stroke volume, leading to increased sympathetic vascular tone. interrelationships of secondary consequences of SCI are complex and need further exploration. Funding: ZonMw Rehabilitation Program and Fonds NutsOhra

Heart rate (R-R interval [RRI]) and known electrocardiographic markers of atrial and ventricular arrhythmia were evaluated before, 1-week and 5-weeks post-SCI at baseline and during DOB infusion (30 lg/kg/min). Both time (standard deviation of normal-to-normal beats [SDNN]) and frequency (power in low frequency [LF] and high frequency [HF] ranges, total power, and LF-to-HF ratio) domain metrics of heart rate variability (HRV) were also assessed. Results: Baseline markers of atrial and ventricular arrhythmia risk were increased in both T2 and T10 animals (p \ 0.05). DOB decreased RRI (p \ 0.001) and increased LF-to-HF ratio (p = 0.004), with an overall reduction in total HRV (p \ 0.001). DOB also further increased markers of risk for ventricular arrhythmia

SCI; we insinuate the use of Raphe nucleusderived stem cells (RN-NSC) to re-establish regulation of autonomic control to the heart and study the specific role of RN-NSCs in enhancing cardiac function. The experiments will investigate if RN-NSCs are necessary for re-establishing supraspinal regulation to the sympathetic pre-ganglionic cells (SPNs) and promote cardiac recovery by decreasing the number of arrhythmias improving overall cardiac health. Ultimately, these findings will help understand cardioelectric control by the spinal cord and will propose a treatment strategy for promoting cardiac function

Objective: Re-hospitalization after sepsis can lead to impaired quality of life in survivors. Predictors of re-hospitalization could help identify survivors at high risk for re-hospitalization who may benefit from targeted interventions. Our goal was to determine whether low heart rate variability (HRV), a measure of autonomic nervous system dysfunction, is associated with re-hospitalization in survivors of pediatric septic shock. Methods: This was a retrospective, observational cohort study from 7/2012-10/2020 at a single institution. Patients admitted to the pediatric intensive care unit (PICU) with septic shock who had continuous heart rate data available from the bedside monitors were included. HRV was measured using the z-scores of the integer HRV (HRVi), which is the standard deviation of the heart rate sampled every 1 s over 5 consecutive minutes and normalized for age. The median HRVi in 24 h was assessed on two different days during the PICU admission: the last 24 h (''last HRVi'') and the 24-h period with the lowest median HRVi (''lowest HRVi''). The change between the lowest and the last HRVi was termed ''delta HRVi.'' The primary outcome was re-hospitalization to the same institution within 365 days, including both emergency department encounters and hospital readmission. Results: Of the 463 patients who met inclusion criteria, 306 (66%) were re-hospitalized, including 270 readmissions (58%). The median last HRVi was significantly lower among re-hospitalized patients compared to those who were not (-0.35, interquartile range [IQR] -0.63-0.01 vs. -0.22, IQR -0.52 to -0.06, p = 0.016). There was no difference in the lowest HRVi, but re-hospitalized patients showed a smaller improvement in their delta HRVi compared to those who were not re-hospitalized (0.44, IQR 0.13-0.84 vs. 0.58, IQR 0.22-1.03, p = 0.024). This association remained significant after adjusting for potential confounders including age, severity of illness, immunocompromised state, and technology dependence. Conclusions: Lower HRV at PICU discharge and a smaller improvement in HRV during PICU admission are significantly associated with re-hospitalization within a year of discharge in survivors of pediatric septic shock. This continuous physiologic measure could potentially be used as a predictor of patients at risk for re-hospitalization and lower health-related quality of life.

Evaluation of pupillometry as a measure of autonomic dysfunction in adolescents referred for orthostatic intolerance J.R. Boris 1 , N. Krishnamurthi 2 , C.M. Rand 2 , R. Gonik 3 , M. Winston 2,4 , T.M. Stewart 2 , L. Kitsis 2 , C.D. Brogadir 2 , I. Khaytin 2,5 , S.M. Slattery 2,5 , D.E. Weese-Mayer 2,5 POTS (39%) out of whom 17 (85%) had IgG [ 100 and 14 (70%) had IgG [ 320. Conclusions: We have demonstrated highly elevated MP titers in a large majority of patients with autoimmune disorders as well as cooccurring SFN or POTS, as compared to their published prevalence in the general population. Further research is needed to determine whether this is a causative link or a pure association due to molecular mimicry.

Respiratory patterns in postural tachycardia syndrome B.P. Goodman 1 , J.A. Khoury 1 , J. Hemp 2 , L.A. Pace 2 1 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA; 2 Metrodora Institute, Salt Lake City, UT, USA Introduction: Dyspnea is a common, at times disabling symptom, frequently reported by individuals with postural tachycardia syndrome (POTS). In the absence of a significant comorbid pulmonary disorder, this symptom may not otherwise be addressed or may be attributed to hyperventilation, dysfunctional breathing, or central sensitization. Purpose: We sought to describe the respiratory pattern, rate, presence of apnea, sighing, and respiratory symptoms during autonomic testing in 50 individuals with well-characterized POTS. Methods: Demographic features, autonomic testing findings, including postganglionic sympathetic sudomotor, cardiovagal, and cardiovascular adrenergic results were recorded in 50 POTS patients. Respiratory plethysmography was performed and analyzed while supine and with head-up tilt (HUT), using chest and abdominal recordings, and symptoms during HUT were recorded. Tachypnea was defined as a respiratory rate exceeding 20 breaths per minute (bpm); postural tachypnea as a doubling of respiratory rate with HUT relative to supine. Results: Autonomic testing and respiratory plethysmography was performed in 50 patients, showing postganglionic sympathetic sudomotor impairment in 10 patients (20%); 26 patients (52%) had hyperadrenergic features with either or both postural hypertension or abnormal standing norepinephrine. The mean respiratory rate was 14.2 bpm while supine, and 16.4 breaths per minute with HUT. Respiratory rate and pattern was classified as normal in 23 patients, ataxic in 11 patients, non-positional tachypnea in 5 patients, postural tachypnea in 8 patients, and dyscoordination between chest and abdominal respiration in 3 patients. A respiratory rate of 7 or less was seen in 2 patients. Postural tachypnea significantly correlated with hyperadrenergic features. 23 patients (46%) reported respiratory symptoms during HUT. Conclusion: Respiratory symptoms were reported by nearly half of the patients during HUT in this cohort, and abnormal respiratory rate and/or rhythm was seen in 54% of patients. Patients with hyperadrenergic features may be more likely to demonstrate postural tachypnea.

Symptoms and autonomic changes induced by chronic transcutaneous vagus nerve stimulation in hyperadrenergic postural tachycardia syndrome D. Shiffer 1,2 , F. Barbic 1,2 , S. Rigo 1 , M. Minonzio 2 , A.R. Zamuner 3 , B. Cairo 4,5 , A. Porta 4,5 , E. Tobaldini 6 , L. Furlan 6 , N. Montano 6 , V. Ulrechie 7 , I. Biaggioni 7 , A. Diedrich 7 , R. Furlan 1, 2 Background: Sympathetic over-activity and reduced cardiac vagal modulation underlie most of the symptoms in postural tachycardia syndrome (POTS) hyperadrenergic phenotypes. Transcutaneous vagus nerve electrical stimulation (tVNS) might improve symptoms by potentially rebalancing such an altered cardiovascular autonomic profile. Aims: To evaluate the effects of chronic tVNS on cardiac autonomic profile, post-ganglionic sympathetic activity and overall dysautonomia symptoms in POTS. Methods: Twenty-three hyperadrenergic POTS patients (high frequency power of heart rate variability HF RR \ 200 ms 2 ), upright plasma norepinephrine [ 600 pg/ml; age 40 ± 12 yrs; 21 F) were studied before (baseline) and after tVNS for 4 h a day for 14 days ECG, blood pressure, respiratory activity, and muscle sympathetic nerve activity (MSNA) were continuously recorded while supine and during a 15°stepwise increased head-up Tilt, till 75°(TILT). COMPASS-31 questionnaire (range 0-100) was collected before and after tVNS. Autoregressive spectral analysis of heart period variability provided the marker of cardiac vagal modulation (high frequency oscillatory component, HF RR , & 0.25 Hz). Hospital Internal Review Board (#2459/2020) approved the investigation. All participants signed a written consent. Results: Heart rate was only slightly reduced after tVNS while supine (79 ± 2 b/min) and during tilt (118 ± 4 b/min), compared to baseline (83 ± 3 and 124 ± 4 b/min, respectively). While supine, HF RR was greater after tVNS (156.0 ± 20.6 ms 2 ) compared to baseline (102.5 ± 12.6 ms 2 ; p \ 0.05). Blood pressure was unchanged after tVNS both while supine and during TILT. After tVNS, MSNA burst rate and incidence were reduced both while supine (20 ± 2 burst/min and 24 ± 2 burst/100 beats, respectively) and during TILT (25 ± 2 burst/min and 22 ± 2 burst/100 beats, respectively) compared to baseline (supine: 35 ± 3 burst/min and 42 ± 4 burst/100 beats, respectively; TILT 45 ± 4 burst/min and 36 ± 3 burst/100 beats, p \ 0.05). Symptoms intensity (COMPASS-31 Total score) decreased after tVNS (34.3 ± 3.4) compared to baseline (54.4 ± 3.3 p \ 0.05). Conclusion: Chronic tVNS induced an enhancement of cardiac vagal modulation and a reduction of the sympathetic discharge activity to vessels. A concomitant improvement of overall symptoms was also observed. Thus, chronic tVNS seemed to have a symptomatic effect in hyperadrenergic POTS patients. Funding: Funded by Dysautonomia International Grant (IRB-ID 986).

The POTS patient experience in Canada versus the United States Background: Postural tachycardia syndrome (POTS) is a form of orthostatic intolerance characterized by orthostatic symptoms and excessive tachycardia in the absence of hypotension. While POTS poses a significant burden on people worldwide, the illness experience may vary between countries. This study aims to compare this experience between the USA and Canada. Methods: Data were collected using the IRB-approved, patient community-based ''Diagnosis and Impact of POTS'' online survey (RedCap) between July 2015-April 2021. Answers related to diagnosis and process of care were compared between Canadian and American patient populations. Continuous results are reported as mean ± SEM and categorical results are reported as percentage. Statistical analyses were conducted using Mann-Whitney U and Chisquare tests for continuous and categorical data, respectively. Results: Among respondents who indicated their geographical location (n = 5,733), 221 were located in Canada and 5,512 were in the USA. The majority of respondents were females (94%) and over 18 years old (89%). Diagnostic delay in the Canadian population was significantly longer than in the USA (5.4 ± 0.5 yrs vs. 4.3 ± 0.1 yrs; p \ 0.001). Similarly, Canadian respondents saw more doctors for their POTS symptoms before being diagnosed than did respondents in the USA (8.0 ± 0.5 vs. 6.9 ± 0.1; p \ 0.001). Canadians were also more likely than Americans to report having suggested to their doctor that they had POTS before having it suggested to them by their doctor (43% vs. 34%, p = 0.011). Even after diagnosis, more Canadians than Americans (78.1% vs. 67.3%, p \ 0.001) were seen by a doctor who had never heard of POTS. Canadian respondents more commonly had doctors suggest their symptoms were the result of a psychological illness rather than a physical illness prior to their POTS diagnosis (86% vs. 78%; p = 0.005). Following POTS diagnosis, more Americans than Canadians (38% vs. 29%, p = 0.006) were being treated for a psychiatric problem. Conclusion: Canadian POTS patients experience more challenges with diagnosis than POTS patients in the USA. The diagnostic delay, need to visit more doctors prior to diagnosis, and lack of doctor familiarity with POTS, suggest that Canada may benefit from additional awareness about POTS and its clinical care. Further studies are needed to determine why these differences exist.

Estimation of sleep timing and duration using actigraphy in patients with orthostatic intolerance Background: Lack of adequate quality and quantity of sleep impacts neurocognition, mood, immunity and cardiometabolic functioning. Patients with orthostatic intolerance (OI) frequently report problems with sleep and fatigue. A study of adult postural tachycardia syndrome (POTS) patients reported more subjective complaints of daytime sleepiness, fatigue, worse sleep, and health related quality of life compared to controls. To our knowledge, there are no studies looking at objective measures of sleep timing and duration in adolescents with OI. The goal of this study is to gain a better understanding of sleep and fatigue complaints in adolescents with OI by objectively measuring sleep duration and timing with actigraphy and subjectively measuring sleep complaints by survey. Methods: Patients aged 12-18 years old presenting for first-time comprehensive OI evaluations at the Mayo Clinic Pediatric Diagnostic and Referral clinic were asked to participate. Patients were mailed an actigraph to wear for 1 week prior to travel for their initial visit. A brief survey to assess perceived sleep quality was completed upon device return. Additional information was gathered from chart review after the clinical evaluation which included autonomic reflex screen results, presence/absence of final diagnosis of OI, and, for some individuals, polysomnogram data. Actigraphy data assessed bedtime, risetime, sleep efficiency, number of awakenings, and total sleep time. Results: Data collection was completed on 54 subjects, with 43 of those having confirmed diagnoses of OI. In these 43, consistency in bedtimes and risetimes (within 1 h of their average) was noted in 74.4% and 65.1%, respectively. Mean bedtime was 23:53 (20:28-3:03), and mean rise time was 8:58 ( We have previously shown a significant suppression of vagal function and an increase in inflammatory markers in patients with postural tachycardia syndrome (POTS). Vagal nerve stimulation (VNS) has been proposed to lower cytokines, including tumor necrosis factor (TNF), through enhancing the effects of acetylcholine on nicotinic receptors. This has led to interest in VNS as a therapy for POTS, a syndrome characterized by a 30 bpm increase in heart rate upon standing accompanied by orthostatic symptoms in the absence of orthostatic hypotension. We hypothesized that, by slowing the breakdown of acetylcholine, the central-acting drug galantamine (GAL) or the peripheral-acting drug pyridostigmine (PYR) would enhance the effects of acetylcholine released by VNS to reduce TNF levels. We enrolled 11 females with POTS in a double-blind randomized crossover trial over 3 days. Participants took a study medication (GAL, PYR or placebo) in the morning. Next, they completed real (STIM, 50 Hz at max tolerable level) or sham (SHAM, 50 Hz at 0.01 mA) vagal stimulation sessions each in randomized order. After the 30-min stimulation blood for TNF was drawn. TNF samples were processed using Luminex's Milliplex Assay. A two-way repeated measures ANOVA with post-hoc paired t-tests was done to look at the effect of drug, stimulation and the interaction of drug and stimulation on TNF levels. In our ANOVA model, the interaction of stimulation and drug had a significant effect on TNF levels (p = 0.03) with post-hoc analysis showing that the combination of STIM and PYR decreased TNF (PRY and SHAM: 16 ± 2.6 pg/mL vs. PYR and STIM: 14 ± 2.1, pg/mL, MEAN ± SD, p = 0.049). Our results suggest that a combination of PYR and vagal stimulation might be beneficial in POTS by reducing TNF levels. Background: Postural tachycardia syndrome is a chronic, disabling condition with a wide range of systemic symptoms and a complex and still not fully understood etiology. In recent years, the gut microbiota and fermentative metabolites like short-chain fatty acids (SCFAs) have been associated with the pathogenesis of conditions ranging from obesity to chronic fatigue syndrome. The primary goal of this study was to determine differences in the fecal SCFAs and gut microbiota between POTS patients and healthy controls (HC). Methods: We enrolled a total of 48 subjects, 25 had postural tachycardia syndrome, and 23 were healthy volunteers. During the twoweek run-in period prior to the stool collection. They were required not to change their usual diet and to record their dietary intake using an online food track diary. Subjects were excluded if they reported acute illness or use of antibiotics. Healthy controls (HC) were enrolled from the Nashville community, and they were excluded if they were a member of the household of an enrolled POTS patient. We used 16S rRNA gene sequencing analyses and Shotgun metagenomic sequencing to determine gut microbiome. SCFAs were measured using liquid chromatography-mass spectrometry. Results: There were no differences in age (33 ± 11.0 vs. 35 ± 9.0, p = 0.603) or BMI (24 ± 3.5 vs. 26 ± 6.1 kg/m 2 , p = 0.124) between POTS and HC. Dietary consumption of fat, carbohydrates and proteins were similar between groups. Gut microbiome was similar in alpha diversity by Shannon index (p = 0.520) and beta diversity by Bray-Curtis index were similar between groups (p = 0.377). Linear discriminant analysis effect size analysis revealed no differentially abundant features between groups. We also observed no differences in neither relative Proteobacteria abundance (POTS, 0.02 ± 0.004 vs. HC, 0.03 ± 0.014, p = 0.530) nor Firmicutes to Bacteroidetes ratio (POTS n = 21, 0.49 ± 0.075 vs. HC n = 21, 0.61 ± 0.09, p = 0.326). Comparing the control and POTS groups, the data did not show any significant differences in SCFAs in t-test analysis: Acetate, p = 0.06; Propionate, p = 0.334; Butyrate, p = 0.208; Valerate, p = 780; Caproate, p = 0.599; Heptanoate, p = 0.5659; Caprylate, p = 6016; Caprate, p = 0.934; Laurate, p = 0.253. Conclusions: In this well-controlled study, POTS patients did not have gut dysbiosis or differences in fecal SCFA compared with controls. Funding: Dysautonomia International.

Body compression reduces upright blood pressure oscillations in patients with postural tachycardia syndrome Background: There is a high prevalence of neuropathic pain (NP) and decreased mental health (MH-) following spinal cord injury (SCI). NP and MH-are reported to be associated with increased odds of a cardiovascular event. In addition, NP and cardiovascular disease (CVD) risk are reported to be associated with the extent of autonomic impairment after SCI. We aimed to investigate if NP and MH-contribute to CVD risk, and to further explore the relationships between CVD risk, autonomic function, NP, and MH-following SCI. Methods: We performed a multicentre cross-sectional study of individuals with chronic, traumatic SCI (n = 257, 61 females, aged 47 ± 9 years, duration of injury 23 ± 9 years). CVD risk was calculated using the 10-year Framingham risk score; cardiovascular autonomic function was determined from peak heart rate during maximal exercise (HR peak ); NP was inferred using the DN4 (n = 257); MH-was assessed using the MHI-5 questionnaire (n = 240). Results: There was a high prevalence for both NP (33%) and MH-(42.5%) in individuals with chronic SCI, with 15% experiencing both conditions. An adverse CVD risk profile was present in 38% of individuals and was correlated with MH-(r = 0.14; p = 0.04), with a threefold increase in the odds of adverse CVD risk when MH-is present (OR = 3.07, CI 1.73-5.47; p \ 0.001). Females (r = 0.13; p = 0.03) and those with a higher HR peak (r = -0.13; p = 0.09) were more likely to have NP; NP was not associated with age at injury or duration of injury. Multiple logistic regression revealed that MH-(b = 0.77; p = 0.04), but not NP or HR peak , was a significant predictor of adverse 10-year CVD risk. Conclusion: This study confirms that MH-is an independent risk factor for CVD, increasing the odds of an adverse risk profile more than threefold following SCI. The presence or severity of NP was not correlated with CVD risk. However, more preserved cardiovascular autonomic function tended to be associated with NP, suggesting a link between preservation of spinal autonomic pathways and NP. The Background: Improvement to autonomic functions including bladder, bowel, and sexual function are prioritized by individuals with spinal cord injury (SCI). Bowel care is often associated with high levels of dissatisfaction, decreased quality of life, and acts as a potent trigger for cardiovascular complications in high-level (T6 or higher) SCI such as autonomic dysreflexia (paroxysmal hypertension in response to sensory stimuli). Despite dissatisfaction, 71% of individuals report using the same bowel care routine for at least the past five years, highlighting a disconnect between bowel care dissatisfaction and changing care routines to optimise bowel care. Methods: Using an integrated knowledge translation approach, we aimed to investigate the barriers and facilitators to making changes to bowel care in individuals with SCI, guided by the Behaviour Change Wheel and using the Theoretical Domains Framework (TDF). Semistructured interviews were conducted with individuals living with SCI (n = 13, mean age 48.6 ± 13.1 years) and transcribed verbatim (interview duration 31.9 ± 7.1 min). Barriers and facilitators were extracted, deductively coded using TDF domains, and inductively analyzed for themes within each domain. Results: Changing bowel care after SCI was heavily influenced by four TDF domains, in which specific themes emerged: environmental context and resources (23%; workplace flexibility, opportunity or circumstance to change bowel care, and access to support and resources); beliefs about consequences (21%; bowel care outcomes and expectations); social influences (11%; perceived support and peer mentorship); and knowledge (6%; awareness of bowel care options and support). Linking the TDF to the BCW showed that all intervention functions and policy categories can be considered as viable intervention options. Human (61%) and digital platforms (33%) of delivery were identified as preferred methods for intervention delivery. Conclusion: Modifying bowel care is a multi-factorial behaviour. These findings will inform individuals with SCI in making changes to their bowel care with the goal of improving quality of life and mitigating the cardiovascular consequences of bowel care. In keeping with an integrated knowledge translation approach, these findings will enable the systematic co-development, adoption, and implementation of relevant and feasible interventions aimed at supporting individuals with SCI in making changes to improve their bowel care.